US8071740B2 - Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis - Google Patents

Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis Download PDF

Info

Publication number
US8071740B2
US8071740B2 US10/988,487 US98848704A US8071740B2 US 8071740 B2 US8071740 B2 US 8071740B2 US 98848704 A US98848704 A US 98848704A US 8071740 B2 US8071740 B2 US 8071740B2
Authority
US
United States
Prior art keywords
cells
promoter
expression
ppe
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/988,487
Other languages
English (en)
Other versions
US20050186179A1 (en
Inventor
Dror Harats
Shoshana Greenberger
Eyal Breitbart
Livnat Bangio
Michael Peled
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Notable Labs Ltd
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2001/001059 external-priority patent/WO2002040629A2/en
Priority claimed from US10/135,447 external-priority patent/US7067649B2/en
Priority claimed from PCT/IL2002/000339 external-priority patent/WO2003033514A1/en
Priority to US10/988,487 priority Critical patent/US8071740B2/en
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Assigned to VASCULAR BIOGENICS LTD. reassignment VASCULAR BIOGENICS LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GREENBERGER, SHOSHANA, HARATS, DROR
Publication of US20050186179A1 publication Critical patent/US20050186179A1/en
Priority to JP2007540833A priority patent/JP2008519596A/ja
Priority to AT09168899T priority patent/ATE531392T1/de
Priority to EP10184033.8A priority patent/EP2301585B1/en
Priority to PCT/IL2005/001195 priority patent/WO2006051545A2/en
Priority to CA2913047A priority patent/CA2913047A1/en
Priority to EP09168899A priority patent/EP2174668B1/en
Priority to CNA2005800464128A priority patent/CN101098882A/zh
Priority to NZ580289A priority patent/NZ580289A/en
Priority to NZ555612A priority patent/NZ555612A/en
Priority to AU2005303385A priority patent/AU2005303385B2/en
Priority to EP05806361A priority patent/EP1814897A4/en
Priority to CA2587469A priority patent/CA2587469C/en
Priority to KR1020137013132A priority patent/KR101396454B1/ko
Priority to KR1020137031896A priority patent/KR101522309B1/ko
Priority to SG201102612-7A priority patent/SG171581A1/en
Priority to CN201210086460.1A priority patent/CN102698287B/zh
Priority to EP10185195A priority patent/EP2301586B1/en
Priority to MX2007005783A priority patent/MX2007005783A/es
Priority to KR1020077013464A priority patent/KR101313257B1/ko
Priority to US11/359,513 priority patent/US8039261B2/en
Priority to US12/224,178 priority patent/US20100282634A1/en
Priority to US11/790,992 priority patent/US20070286845A1/en
Priority to IL183187A priority patent/IL183187A/en
Priority to ZA200704687A priority patent/ZA200704687B/xx
Assigned to VASCULAR BIOGENICS LTD. reassignment VASCULAR BIOGENICS LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BANGIO, LIVNAT, BREITBART, EYAL
Priority to US12/591,252 priority patent/US20100081193A1/en
Priority to HK10109638.7A priority patent/HK1143078B/en
Priority to IL209034A priority patent/IL209034A/en
Priority to US13/018,447 priority patent/US8206743B2/en
Assigned to VASCULAR BIOGENICS LTD. reassignment VASCULAR BIOGENICS LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PELED, MICHAEL
Priority to IL211489A priority patent/IL211489A/en
Priority to US13/098,512 priority patent/US20110207985A1/en
Priority to JP2011191492A priority patent/JP5728337B2/ja
Publication of US8071740B2 publication Critical patent/US8071740B2/en
Application granted granted Critical
Priority to US13/549,355 priority patent/US8835398B2/en
Priority to US14/059,426 priority patent/US20140155467A1/en
Priority to JP2014205463A priority patent/JP2015057057A/ja
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Definitions

  • the present invention relates to nucleic acid constructs, pharmaceutical compositions and methods which can be used to regulate angiogenesis in specific tissue regions of a subject. More particularly, the present invention relates to isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, and methods of use thereof and, yet more particularly, to a modified-preproendothelin-1 (PPE-1) promoter which exhibits increased activity and specificity in endothelial cells, and nucleic acid constructs, which can be used to either activate cytotoxicity in specific cell subsets, thus, enabling treatment of diseases characterized by aberrant neovasculariza tion or cell growth or induce the growth of new blood vessels, thus, enabling treatment of ischemic diseases.
  • the invention further relates to modifications of the PPE promoter, which enhance its expression in response to physiological conditions including hypoxia and angiogenesis, and novel angiogenic endothelial-specific combined therapies.
  • Angiogenesis is the growth of new blood vessels, a process that depends mainly on locomotion, proliferation, and tube formation by capillary endothelial cells. During angiogenesis, endothelial cells emerge from their quiescent state and proliferate rapidly. Although the molecular mechanisms responsible for transition of a cell to angiogenic phenotype are not known, the sequence of events leading to the formation of new vessels has been well documented [Hanahan, D., Science 277, 48-50, (1997)]. The vascular growth entails either endothelial sprouting [Risau, W., Nature 386, 671-674, (1997)] or intussusceptions [Patan, S., et al; Microvasc. Res.
  • Angiogenesis occurs under conditions of low oxygen concentration (ischemia and tumor metastases etc.) and thus may be an important environmental factor in neovascularization.
  • the expression of several genes including erythropoietin, transferrin and its receptor, most of glucose transport and glycolytic pathway genes, LDH, PDGF-BB, endothelin-1 (ET-1), VEGF and VEGF receptors is induced under hypoxic conditions by the specific binding of the Hypoxia Inducible Factor (HIF-1) to the Hypoxic Response Element (HRE) regulating the transcription of these genes. Expression of these genes in response to hypoxic conditions enables the cell to function under low oxygen conditions.
  • HIF-1 Hypoxia Inducible Factor
  • HRE Hypoxic Response Element
  • regulating or modifying the angiogenic process can have an important therapeutic role in limiting the contributions of this process to pathological progression of an underlying disease state as well as providing a valuable means of studying their etiology.
  • proangiogenic therapy is directed not only to restoring required angiogenic factors, but to reestablishing the proper balance between them (Dor, et al, Ann N Y Acad Sci 2003; 995:208-16)(for an extensive review of pro- and antiangiogenic therapies see Zhang et al Acta Bioch and Biophys Cinica, 2003: 35:873-880, and Mariani et al. Med Gen Med 2003, 5:22; and Folkman, Semin. Onc 2002, 29:15-18).
  • tumor angiogenesis a process known as tumor angiogenesis.
  • Tumor growth and metastasis are angiogenesis-dependent.
  • a tumor must continuously stimulate the growth of new capillary blood vessels to deliver nutrients and oxygen for the tumor itself to grow. Therefore, either prevention of tumor angiogenesis or selective destruction of tumor's existing blood vessels (vascular targeting therapy) underlies anti-angiogenic tumor therapy.
  • An angiogenic switch may occur via several mechanisms:
  • the relative balance between activators and inhibitors of angiogenesis is important for maintaining tumors in a quiescent state. Reducing inhibitors or increasing activator levels alters the balance and leads to tumor angiogenesis and tumor growth.
  • Oxygen diffusion to neoplastic tissue is inadequate when tumor tissue thickness exceeds 150-200 ⁇ m from the nearest vessel. So, by definition, all tumors that exceed these dimensions are already angiogenically switched-on.
  • the tumor cell proliferation rate is independent of the vascular supply. However, as soon as the angiogenic switch occurs, the rate of apoptosis decreases by 3-4 fold (24). Furthermore, nutrient supply and catabolite release are not the only contribution of angiogenic vessels to the decline in tumor apoptosis.
  • Microvasculature endothelial cells also secrete anti-apoptotic factors, mitogens and survival factors such as b-FGF, HB-EGF, IL-6, G-CSF, IGF-1 and PDGF that further suppress tumor cell apoptosis.
  • mitogens and survival factors such as b-FGF, HB-EGF, IL-6, G-CSF, IGF-1 and PDGF that further suppress tumor cell apoptosis.
  • tissue-specific promoters conjugated to cytotoxic genes For example, endothelial cell targeting of a cytotoxic gene, expressed under the control endothelial-specific promoters has been described by Jagger et al who used the KDR or E-selectin promoter to express TNF ⁇ specifically in endothelial cells [Jaggar RT. Et al. Hum Gene Ther (1997) 8(18):2239-47].
  • Ozaki et al used the von-Willebrand factor (vWF) promoter to deliver herpes simplex virus thymidine kinase (HSV-tk) to HUVEC [Hum Gene Ther (1996) 7(13):1483-90].
  • vWF von-Willebrand factor
  • Bu et al. identified a complex regulatory region in the murine PPE-1 promoter (mET-1) that appears to confer endothelial cell specific transcriptional activity and to bind proteins or protein complexes that are restricted to the endothelial cell.
  • This region designated endothelial specific positive transcription element, is composed of at least three functional elements, positioned between the ⁇ 364 bp and ⁇ 320 bp of the murine PPE-1 promoter. All three elements are required for full activity. When one or three copies are constructed into a minimal mET-1 promoter, reporter gene expression in endothelial cells in vitro increased 2-10 times, compared to a minimal promoter with no element.
  • HSV-TK/GCV system was first described by Kraiselburd et al. in 1976. Cells transfected with an HSV-TK containing plasmid or transduced with an HSV-TK containing vector, are becoming sensitive for a super family of drugs including aciclovir, ganciclovir (GCV), valciclovir and famciclovir.
  • the guanosine analog GCV is the most active drug in the setup of gene therapy.
  • HSV-TK positive cells produce a viral TK, which is three orders of magnitude more efficient in phosphorylating GCV into GCV monophosphate (GCV-MP) than the human TK. GCV-MP is subsequently phosphorylated by the native thymidine kinase into GCV diphosphate and finally to GCV triphosphate (GCV-TP).
  • Recent studies have characterized the HSV-TK/GCV cell cytotoxicity mechanism. They revealed cell cycle arrest in the late S or G2 phase due to activation of the G2-M DNA damage checkpoint. These events were found to lead to irreversible cell death as well as a bystander effect related to cell death. Profound cell enlargement is a well-known morphological change in cells administered with the HSV-TK/GCV system. These morphological changes are due to specific cytoskeleton rearrangement. Stress actin fibers and a net of thick intermediate filaments appear following cell cycle arrest.
  • the HSV-TK/GCV system utilizes an amplification potential designated as the “bystander effect”.
  • the bystander effect stands for the phenomenon by which HSV-TK positive cells induce the killing of HSV-TK negative cells.
  • Culver et al. were the first to demonstrate a bystander effect in an in vivo model. They demonstrated tumor regression when implanted with HSV-TK positive tumor cells in different ratios. Unlike in vitro models, cell-cell contact was not found to be essential for the bystander effect in vivo. Kianmanesh et al. demonstrated a distant bystander effect by implanting tumor cells in different liver lobes, where only some were HSV-TK positive. Both HSV-TK positive and negative foci regressed. A bystander effect was also demonstrated in vivo between cells from different origins. All in all, HSV-TK and its bystander effect facilitate an effective means for tumor suppression when implemented in gene delivery systems. However, to date, clinical studies have demonstrated only limited results.
  • an isolated polynucleotide comprising a cis regulatory element including at least a portion of the sequence set forth in SEQ ID NO:15 covalently linked to at least a portion of the sequence set forth in SEQ ID NO:16, the isolated polynucleotide being capable of directing transcription of a polynucleotide sequence transcriptionally linked thereto in eukaryotic cells.
  • nucleic acid constructs comprising the isolated polynucleotide, cells comprising the nucleic acid constructs of the invention, and scaffolds seeded with the cells.
  • nucleic acid constructs further comprising a nucleic acid sequence positioned under the regulatory control of the cis regulatory element.
  • the nucleic sequence can further encode an angiogenesis regulator.
  • the nucleic acid sequence is selected from the group consisting of VEGF, p55, angiopoietin-1, bFGF and PDGF-BB.
  • the scaffold is composed of a synthetic polymer, a cell adhesion molecule, or an extracellular matrix protein.
  • the extracellular matrix protein is selected from the group consisting of fibrinogen, Collagen, fibronectin, vimentin, microtubule-associated protein 1D, Neurite outgrowth factor (NOF), bacterial cellulose (BC), laminin and gelatin.
  • a method of expressing a nucleic acid sequence of interest in eukaryotic cells the method effected by administering to a subject a nucleic acid construct including the nucleic acid sequence of interest positioned under transcriptional control of a cis regulatory element including at least a portion of the sequence set forth in SEQ ID NO:15 covalently linked to at least a portion of the sequence set forth in SEQ ID NO:16.
  • a method of regulating angiogenesis in a tissue the method effected by expressing in the tissue a nucleic acid construct including a nucleic acid sequence encoding an angiogenesis regulator, the nucleic acid sequence being under regulatory control of a cis regulatory element including at least a portion of the sequence set forth in SEQ ID NO:15 covalently linked to at least a portion of the sequence set forth in SEQ ID NO:16, thereby regulating angiogenesis in the tissue.
  • administering is effected by a method selected from the group consisting of, systemic in-vivo administration, ex-vivo administration to cells removed from a body of a subject and subsequent reintroduction of the cells into the body of the subject; and local in-vivo administration.
  • the tissue is a natural or an engineered tissue.
  • nucleic acid sequence encodes an inhibitor of angiogenesis and regulating angiogenesis is downregulating angiogenesis.
  • a nucleic acid construct comprising: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of a cytotoxic molecule; and (b) a second polynucleotide region encoding a cis regulatory element being capable of directing expression of said chimeric polypeptide in a specific tissue or cell.
  • the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, and binding of said ligand to the ligand binding domain activates the effector domain of the cytotoxic molecule.
  • eukaryotic cells transformed with the nucleic acid construct of the invention.
  • the cis regulatory element is an endothelial cell-specific or periendothelial cell-specific promoter selected from the group consisting of the PPE-1 promoter, the PPE-1-3x promoter, the TIE-1 promoter, the TIE-2 promoter, the Endoglin promoter, the von Willerband promoter, the KDR/flk-1 promoter, The FLT-1 promoter, the Egr-1 promoter, the ICAM-1 promoter, the VCAM-1 promoter, the PECAM-1 promoter and the aortic carboxypeptidase-like protein (ACLP) promoter.
  • the PPE-1 promoter the PPE-1-3x promoter
  • the TIE-1 promoter the TIE-2 promoter
  • Endoglin promoter the von Willerband promoter
  • the KDR/flk-1 promoter the KDR/flk-1 promoter
  • the FLT-1 promoter the Egr-1 promoter
  • the ICAM-1 promoter the VCAM-1 promoter
  • the PECAM-1 promoter
  • the ligand binding domain is a ligand-binding domain of a cell-surface receptor.
  • the cell-surface receptor can be selected from the group consisting of a receptor tyrosine kinase, a receptor serine kinase, a receptor threonine kinase, a cell adhesion molecule and a phosphatase receptor.
  • the cytotoxic molecule is selected from the group consisting of Fas, TNFR, and TRAIL.
  • the ligand binding domain is selected such that it is capable of binding a ligand present in, or provided to, the sub-population of angiogenic cells, and binding of the ligand to the ligand binding domain activates the effector domain of said cytotoxic molecule, thereby down-regulating angiogenesis in the tissue.
  • a method of down-regulating angiogenesis in a tissue of a subject the method effected by: (a) expressing in the tissue of the subject a nucleic acid construct designed and configured for generating cytotoxicity in a sub-population of angiogenic cells, the nucleic acid construct including: (i) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of a cytotoxic molecule, wherein the effector domain is selected such that it is activated following binding of a ligand to the ligand binding domain; and (ii) a second polynucleotide region encoding a cis acting regulatory element for directing expression of the chimeric polypeptide in the sub-population of angiogenic cells; and (b) administering to the subject the ligand, thereby down-regulating angiogenesis in the tissue.
  • a pharmaceutical composition for down regulating angiogenesis in a tissue of a subject including, as an active ingredient, a nucleic acid construct designed and configured for generating cytotoxicity in a subpopulation of angiogenic cells and a pharmaceutical acceptable carrier.
  • a method of down-regulating angiogenesis in a tissue of a subject the method effected by: (a) expressing in the tissue a nucleic acid construct designed and configured for cytotoxicity in angiogenic cells, the nucleic acid construct including: (i) a first polynucleotide region encoding a suicide gene and (ii) a second polynucleotide region encoding a cis acting regulatory element capable of directing expression of the suicide gene in the angiogenic cells; and (b) administering to the subject a therapeutic amount of a prodrug sufficient to cause apoptosis of the tissue when the prodrug is converted to a toxic compound by the suicide gene, thereby down-regulating angiogenesis in the tissue.
  • a nucleic acid construct including: (a) a first polynucleotide region encoding a suicide gene, the suicide gene being capable of converting a prodrug to a toxic compound, and (b) a second polynucleotide region encoding a cis regulatory element capable of directing expression of the suicide gene in angiogenic cells. Also provided are eukaryotic cells transformed with the nucleic acid construct of the invention.
  • a method of treating a tumor in a subject the method effected by administering a therapeutically effective amount of a nucleic acid construct designed and configured for generating cytotoxicity in cells of the tumor, the nucleic acid construct including: (i) a first polynucleotide region encoding a suicide gene; and (ii) a second polynucleotide region encoding a cis acting regulatory element capable of directing expression of the suicide gene in the cells of the tumor, where the suicide gene is selected capable of converting a prodrug to a toxic compound capable of causing cytotoxicity in the cells of the tumor.
  • the suicide gene is thymidine kinase of herpes simplex virus and the prodrug is ganciclovir, acyclovir, FIAU or their derivatives.
  • the suicide gene is varicella zoster virus thymidine kinase and said prodrug is 6-methoxypurine arabinoside or its derivatives.
  • the nucleic acid sequence includes an isolated polynucleotide comprising a cis regulatory element including at least a portion of the sequence set forth in SEQ ID NO:15 covalently linked to at least a portion of the sequence set forth in SEQ ID NO:16, the isolated polynucleotide being capable of directing transcription of a polynucleotide sequence transcriptionally linked thereto in eukaryotic cells.
  • the at least a portion of the sequence set forth in SEQ ID NO:15 can be positioned upstream of the at least a portion of the sequence set forth in SEQ ID NO:16 in said cis regulatory element, or the least a portion of the sequence set forth in SEQ ID NO:16 can be positioned upstream of said at least a portion of the sequence set forth in SEQ ID NO:15.
  • the cis regulatory element further includes at least one copy of the sequence set forth in SEQ ID NO: 6, or at least two copies of SEQ ID NO:6.
  • the at least two copies of SEQ ID NO:6 can be contiguous.
  • the at least a portion of the sequence set forth in SEQ ID NO:15 is covalently linked to the at least a portion of the sequence set forth in SEQ ID NO:16 via a linker polynucleotide sequence.
  • the linker polynulceotide sequence can be a promoter and/or an enhancer element.
  • the isolated polynucleotide further includes a hypoxia response element, the hypoxia response element preferably including at least one copy of the sequence set forth in SEQ ID NO: 5.
  • the cis regulatory element is as set forth in SEQ ID NO: 7.
  • nucleic acid construct further includes a conditionally replicating adenovirus.
  • the cis regulatory element is an endothelial cell-specific or periendothelial cell-specific promoter selected from the group consisting of the PPE-1 promoter, the PPE-1-3x promoter, the TIE-1 promoter, the TIE-2 promoter, the Endoglin promoter, the von Willerband promoter, the KDR/flk-1 promoter, The FLT-1 promoter, the Egr-1 promoter, the ICAM-1 promoter, the VCAM-1 promoter, the PECAM-1 promoter and the aortic carboxypeptidase-like protein (ACLP) promoter.
  • the PPE-1 promoter the PPE-1-3x promoter
  • the TIE-1 promoter the TIE-2 promoter
  • Endoglin promoter the von Willerband promoter
  • the KDR/flk-1 promoter the KDR/flk-1 promoter
  • the FLT-1 promoter the Egr-1 promoter
  • the ICAM-1 promoter the VCAM-1 promoter
  • the PECAM-1 promoter
  • the present invention successfully addresses the shortcomings of the presently known configurations by providing isolated polynucleotide sequences comprising cis regulating elements with novel enhancer elements, and methods of use thereof.
  • the novel enhancer elements can be used to make nucleic acid constructs and pharmaceutical compositions for tissue-specific regulation of transgene expression, and for treating a variety of disorders, diseases and conditions by gene therapy.
  • the cis regulatory elements, isolated polynucleotides and pharmaceutical compositions of the present invention can be used, along with selected transgenes, to specifically upregulate and/or downregulate angiogenesis in endothelial cells, thus treating tumors, metastatic disease, and ischemic disease.
  • FIGS. 1 a - b are schematic illustrations of Fas chimera gene constructed from the extracellular region of TNFR1 and the trans-membrane and intracellular regions of Fas and cloned into pcDNA3 plasmid (a) or into adenoviral vectors (b).
  • FIGS. 2 a - b illustrate apoptotic activity of the pro-apoptotic genes, Fas chimera and TNFR1.
  • FIG. 2 a Illustrates Bovine Aortic Endothelial Cells (BAEC) transfected with either pcDNA-3-TNFR1 (lower panel) or control empty vector (upper panel) and an expression plasmid encoding GFP.
  • FIG. 2 b Illustrates 293 Cells transfected with either pcDNA-3-Fas-c (lower panel) or control empty vector (upper panel) and an expression plasmid encoding GFP. Transfected cells were visualized using fluorescence microscopy and apoptotic activity was morphologically determined.
  • FIGS. 3 a - f are electron microscopy images of BAEC cells transfected with pro-apoptotic genes. 24 hours post transfection, BAEC cells were fixed in 2.5% glutaraldehyde and processed. Presented are cells in successive stages of the apoptotic process.
  • FIG. 4 are histograms quantifying apoptotic activity of the indicated pro-apoptotic genes in transfected BAEC and 293 cells.
  • FIG. 5 a represents a PCR analysis of AdPPE-Fas-c.
  • Lanes 1-2 PCR products obtained using primers encompassing the PPE-1 promoter and Fas-c gene.
  • Lanes 3-4 PCR products obtained using Fas-c primers.
  • Lanes 5-6 PCR products obtained in the absence of template DNA.
  • FIG. 5 b is a western blot analysis of AdPPE-Fas-c transfected BAEC cells. Protein samples were resolved by SDS-PAGE, transferred to nitrocellulose membrane and probed with a polyclonal antibody directed against the extracellular portion of TNFR1. Lane 1-2—pcDNA3-Fas-c BAEC transfected cells (positive control). Lane 3-4—BAEC cells transfected with the indicated MOI of AdPPE-Fas-c viruses. Lane 5—non-transfected cells. Lane 6-7—BAEC cells transfected with the indicated MOI of AdPPE-Luc.
  • FIGS. 6 a - d are photomicrographs illustrating the effect of Fas-chimera over-expression on apoptosis of endothelial cells.
  • BAEC cells were infected with: Ad-PPE-1-3x-Fas-chimera ( FIG. 6 a ); Ad-PPE-1-3x-luciferase ( FIG. 6 b ); Ad-PPE-1-3x-Fas-chimera and Ad-PPE1-3x-GFP ( FIG. 6 c ); Ad-PPE-1-3x-luciferase and Ad-PPE-1-3x-GFP; each at MOI 1000 ( FIG. 6 d ). Photomicrographs were taken 72 h post infection at ⁇ 10 magnification.
  • FIG. 7 is a histogram illustrating apoptotic specific effect of Ad-PPE-1-3x-Fas-chimera on endothelial cells. Viability of endothelial (BAEC, HUVEC) and non-endothelial (Normal skin fibroblasts-NSF) cells was quantified by crystal violet staining 72 h post infection with either Ad-PPE-1-3x-Fas-chimera or control (luciferase) virus.
  • FIG. 8 shows a dose response effect of TNF ⁇ administration on Fas-chimera mediated apoptosis.
  • BAEC were infected with Ad-PPE-1-3x-Fas-c. 48 h post infection TNF was added to the growth medium (at the indicated dose). Viability was determined by the crystal violet assay 24 h thereafter.
  • FIGS. 9 a - e are photomicrographs illustrating an endothelial cell-specific apoptosis mediated by the cooperative action of TNF ⁇ ligand and Fas-c receptor.
  • the indicated cells were incubated in the presence or absence of TNF ⁇ (10 ng/ml) 48 h following infection with Ad-PPE-1-3x-Fas-c; crystal violet staining was effected 72 h post infection.
  • FIG. 10 a is a dose response curve illustrating the TNF ⁇ -dependent apoptotic effect of Ad-CMV-Fas-c on endothelial cells. Viability of BAEC cells infected with the indicated MOI of Ad-CMV-Fas-chimera was determined following incubation with TNF ⁇ .
  • FIGS. 10 b - d illustrate the apoptotic effect of TNF ⁇ ligand and Ad-CMV-Fas-chimera on the non-endothelial cells NSF.
  • FIG. 10 b NSF infected with a control virus.
  • FIG. 10 c NSF infected with Ad-CMV-Fas-chimera.
  • FIG. 10 d NSF infected with Ad-CMV-Fas-chimera and incubated with TNF (10 ng/ml).
  • FIGS. 11 a - c illustrate the In-vivo anti-tumoral effect of Ad-PPE-1-3x-Fas-c.
  • Mice inoculated with B16 melanoma cells were injected intravenously with Ad-PPE-1-3x-Fas-c, Ad-CMV-Fas-chimera, control virus or saline when tumor was palpable.
  • FIG. 11 a tumor areas, measured during treatment period.
  • FIG. 11 b tumor weights at end of treatment period.
  • FIG. 11 c an image representing the state of the tumor in the Ad-PPE-1-3x-Fas-c treated mouse and the control mouse.
  • FIG. 12 is a histogram illustrating the effect of the enhancer element of the present invention on Luciferase expression in both bovine and human endothelial cell lines using the B2B cell line (bronchial cell line that expresses endothelin) as a control.
  • FIG. 13 is a histogram illustrating endothelial specificity of a promoter of the present invention in an adenoviral vector on Luciferase expression in various cell lines.
  • FIGS. 14A-B are photomicrographs illustrating GFP expression under the control of Ad5PPE-1-3X of the present invention ( 14 A) and an Ad5CMV ( 14 B) control construct in the BAEC cell line.
  • FIG. 15 is histogram of % apoptosis induced by pACPPE-1-3Xp55, pACPPE-1-3XLuciferase and pCCMVp55 in endothelial and non-endothelial cells.
  • FIG. 16 is a histogram illustrating the effect of introducing an enhancer element according to the present invention into a promoter construct on hypoxia response.
  • FIG. 17 is a histogram illustrating the effect of introducing an enhancer element according to the present invention into a promoter of an adenovector construct on hypoxia response.
  • FIG. 18 is a histogram illustrating the effect of introducing an enhancer element according to the present invention into a promoter on levels of expression in bovine and human endothelial, endothelin expressing cell lines.
  • FIG. 19 is a histogram illustrating levels of expression of a reporter gene observed in various organs following injection of an adenoviral construct containing either an endothelial promoter (PPE-1) or a control (CMV) promoter;
  • PPE-1 endothelial promoter
  • CMV control
  • FIGS. 20A-B are two photomicrographs illustrating cellular expression of an Ad5CMVGFP construct ( FIG. 20A ) and an Ad5PPE-1-GFP construct ( FIG. 20B ) in liver tissue of mice injected with the constructs.
  • FIG. 21 is a histogram illustrating the effect of introducing an enhancer element according to the present invention into a promoter on levels of expression in endothelial and non-endothelial cell lines.
  • FIG. 22 is a histogram illustrating the effect of introducing an enhancer element according to the present invention into a promoter on levels of expression in endothelial and non-endothelial cell lines.
  • FIGS. 23A-C are photomicrographs illustrating GFP expression in Ad5PPE-1-3XGFP transduced cells, Ad5PPE-1 GFP transduced cells and Ad 5CMVGFP transduced cells respectively.
  • FIGS. 24A-B illustrate GFP expression in SMC transduced by moi-1 of Ad5PPE-1-3XGFP and Ad5CMVGFP respectively.
  • FIGS. 25A-B show results of an experiment similar to that of FIGS. 24A-B conducted in HeLa cells.
  • FIGS. 26A-B show results of an experiment similar to that of FIGS. 24A-B conducted in HepG2 cells.
  • FIGS. 27A-B show results of an experiment similar to that of FIGS. 24A-B conducted in NSF cells.
  • FIGS. 28A-B are photomicrographs illustrating GFP expression in endothelial cells lining a blood vessel of mice injected with the Ad5PPE-1GFP and the Ad5PPE-1-3XGFP constructs respectively.
  • FIGS. 30A-C illustrate experiments similar to those depicted in FIGS. 29A-C , conducted on sections of spleen tissue.
  • FIGS. 31A-D illustrate GFP expression in metastatic lungs of control mice injected with Saline ( FIG. 31A ), mice injected with Ad5CMVGFP ( FIG. 31B ), mice injected with Ad5PPE-1GFP ( FIG. 31C ) and mice injected with Ad5PPE-1-3XGFP ( FIG. 31D ).
  • Anti Cd31 immunostaining (FIGS. 31 C′ to 31 D′) confirm the co-localization of the GFP expression and CD31 expression in each metastatic tissue.
  • FIG. 33 is a histogram as in FIG. 32 , except that Ad5PPE-1Luc and Ad5CMVLuc were employed.
  • FIG. 34 is a histogram as in FIG. 33 showing the effects of hypoxia in different cell lines.
  • FIG. 35 is a histogram illustrating the effect of the 3X sequence of the present invention on the PPE-1 hypoxia response in BAEC cells. Cells were transduced by Ad5PPE-1Luc and Ad5PPE-1-3XLuc.
  • FIG. 36 is a histogram showing levels of Luciferase expression in various tissues of PPE-1-Luc transgenic mice following femoral artery ligation.
  • FIGS. 37A-B are plasmid maps of constructs employed in conjunction with the present invention.
  • FIGS. 38A-F illustrate the effects of Ad5PPE-1-3XVEGF and Ad5CMVVEGF on blood perfusion and angiogenesis in mouse ischemic limbs.
  • FIGS. 38A-D are representative ultrasonic (US) angiographic images of perfusion in the ischemic limb of mice from the various treatment groups captured 21 days following ligation. Yellow signal represents intense perfusion. The right side of the image represents the distal end of the limb.
  • FIG. 38 A Ad5PPE-1-3XVEGF treated mouse
  • FIG. 38 B Ad5CMVVEGF treated mouse
  • FIG. 38 C control, saline treated mouse
  • FIG. 38 D control, normal limb.
  • FIGS. 38E-F are histograms illustrating: mean intensity of signal in the US images of the various treatment groups ( FIG. 38E ); mean capillary density, measured as the number of CD31+ cells/mm 2 in the various treatment groups ( FIG. 38F ).
  • FIG. 39 is a histogram illustrating Luciferase activity in proliferating and quiescent Bovine Aortic Endothelial Cells (BAEC) transduced with Ad5PPE-1Luc (open bars) and Ad5CMVLuc (black bars).
  • BAEC Bovine Aortic Endothelial Cells
  • FIG. 40 is a histogram illustrating Luciferase activity in BAEC transduced with Ad5PPE-1Luc. during normal proliferation, a quiescent state and rapid proliferation following addition of VEGF.
  • FIG. 43 is a prior art image depicting an aorta dissected from ApoE deficient mice colored by Sudan-IV.
  • the thoracic aorta contains less red stained atherosclerotic lesion while the abdominal region includes many red stained atherosclerotic lesions.
  • FIG. 45 is a histogram illustrating absolute Luciferase activity (light units/ ⁇ g protein) 5 days post systemic injections of Ad5PPE-1Luc (black bars) or Ad5CMVLuc (open bars) to healing wound C57BL/6 induced mice.
  • FIG. 46 is a histogram illustrating Luciferase activity in normal lung, metastatic lung and primary tumor of Lewis lung carcinoma-induced mice.
  • FIGS. 47A-D are photomicrographs illustrating GFP expression and tissue morphology in lungs and tumors of LLC bearing mice following intra-tumoral injection of Ad5PPE-1GFP. Tissue was frozen in OCT and sectioned to 10 ⁇ m by cryostat. All pictures were taken in magnification of 25 ⁇ .
  • FIG. 47 A GFP in angiogenic blood vessels of lung metastases
  • FIG. 47 B CD31 antibody immunostaining of the section pictured in FIG. 47A
  • FIG. 47 C GFP expression in blood vessels of primary tumor
  • FIG. 47 D phase contrast of the section of C illustrating blood vessels.
  • FIG. 49 is a histogram illustrating Luciferase activity as percentage of liver activity (where the liver is 100%), in normal lung and lung metastasis of Lewis lung carcinoma-induced mice injected with Ad5CMV, Ad5PPE-1Luc and Ad5PPE-1(3X).
  • FIGS. 50A-B are photomicrographs illustrating co-localization of GFP expression ( FIG. 50A ) and CD31 immunostaining ( FIG. 50B ) in mice with LLC lung metastases injected with Ad5PPE-1-3X-GFP.
  • FIG. 53 is a histogram illustrating Luciferase activity, (light units/ ⁇ g protein detected in the livers, lungs and primary tumors of LLC mice injected in primary tumors with Ad5CMVLuc (black bars) or Ad5PPE-1Luc (open bars).
  • FIGS. 54A-H are in-situ hybridization images illustrating tissue distribution of tissue-specific or constitutive expression of various transgenes.
  • FIGS. 54A-C illustrate in-situ hybridization with a VEGF specific antisense probe on representative ischemic muscles from: A, Ad5PPE-1-3XVEGF treated mouse; B, Ad5CMVVEGF treated mouse; C, saline treated mouse; D, liver section from Ad5CMVVEGF treated mouse. An arrow indicates positively stained cells.
  • 54E-G illustrate in-situ hybridization with a PDGF-B specific antisense probe of representative ischemic muscles from: E, Ad5PPE-1-3XPDGF-B treated mouse; F, Ad5CMVPDGF-B treated mouse; G, saline treated mouse; H, liver section from Ad5CMVPDGF-B treated mouse.
  • FIGS. 55A-B are histograms illustrating a long-term effect of Ad5PPE-1-3XVEGF or Ad5CMWEGF on blood perfusion and angiogenesis in mouse ischemic limb.
  • A mean intensity of signal in the US images of the various treatment groups, 50 days following femoral artery ligation.
  • B mean capillary density, measured as number of CD31+ cells/mm 2 in the various treatment groups, 70 days following femoral artery ligation.
  • FIGS. 56A-D are histograms showing early and long term effects of Ad5PPE-1-3XPDGF-B on neovascularization in mouse ischemic limb.
  • FIGS. 56 A-B mean perfusion intensity measured by US imaging ( 56 A, 30 days following femoral artery ligation; 56 B, 80 days following femoral artery ligation).
  • FIGS. 56 C-D mean capillary density, measured as number of CD31+ cells/mm 2 in the various treatment groups ( 56 C, 35 days following femoral artery ligation; 56 D, 90 days following femoral artery ligation).
  • FIGS. 57A-G illustrate long term effects of angiogenic therapy using PDGF-B and VEGF alone or in combination under regulation of an endothelial specific or a constitutive promoter on neovascularization and blood flow in mouse ischemic limb.
  • A mean intensity of signal in the US images of the various treatment groups, 80 days following femoral artery ligation.
  • B mean capillary density, measured as number of CD31+cells/mm 2 in the various treatment groups, 90 days following femoral artery ligation.
  • FIGS. 57 C-G smooth muscle cells recruitment to mature vessels in ischemic limb muscles, 90 days following femoral artery ligation.
  • Smooth muscle cells are immunostained with anti- ⁇ -SMactin antibodies (in red, X20).
  • FIG. 59 is a schematic representation of the basic principles of gene-directed enzyme prodrug therapy (GDEPT).
  • FIGS. 60A-B are a schematic map representing the construction of the plasmid pEL8(3x)-TK.
  • FIG. 60A is a schematic map representing the construction of the plasmid pEL8(3x)-TK.
  • FIG. 60B is a map of plasmid pACPPE-1(3x)-TK.
  • FIG. 61 is an agarose gel separation of PCR products of the AdPPE-1(3x)-TK vector, visualized by UV fluorescence.
  • Two primers were used: the forward primer 5′-ctcttgattcttgaactct-3′ (455-474 bp in the pre-proendothelin promoter sequence) (SEQ ID NO:9) and the reverse primer 5′-taaggcatgcccattgttat-3′ (1065-1084 bp in the HSV-TK gene sequence)(SEQ ID NO:10).
  • Primers specific for other vectors gave no PCR products.
  • Lane 1 100 bp size marker ladder.
  • Lane 2 pACPPE-1(3x)-TK plasmid.
  • Lane 3 AdPPE-1(3x)-TK virus.
  • FIGS. 62A-C show linear, schematic maps of the vectors AdPPE-1(3x)-TK FIG. 62 a ).
  • AdPPE-1(3x)-Luc FIG. 62 b
  • AdCMV-TK FIG. 62 c ).
  • FIG. 65 is a series of photomicrographs illustrating the superior synergy of endothelial cell cytotoxicity of TK under control of the PPE-1 (3x) promoter and ganciclovir administration.
  • Bovine aorta endothelial cells (BAECs) were transduced with AdPPE-1(3x)-TK, AdCMV-TK and AdPPE-1(3x)-Luc, as described hereinabove, at multiplicity of infection (m.o.i.) of 10, and exposed to increasing concentrations of GCV (0.001-10 ⁇ g/ml, as indicated), added four hours post-transduction. Controls were cells transduced with the vectors without GCV, or GCV without vectors.
  • FIG. 66 is a graph representing synergy of endothelial cell cytotoxicity of TK under control of the PPE-1 (3x) promoter and ganciclovir administration.
  • BAECs were prepared in 96-well plates and transduced as in FIG. 65 , followed by the addition of increasing concentrations (0.0001-10 ⁇ g/ml) GCV four hours post-transduction. 10 days post vector addition, cell viability was determined using crystal violet staining. Note the superior cytotoxicity of AdPPE-1 (3x)+GCV at GCV concentrations greater than 0.01 ⁇ g/ml, compared with the strong constitutive TK expression of AdCMV-TK.
  • FIG. 67 is a series of photomicrographs illustrating the specific, synergic endothelial cytotoxicity of TK under control of the PPE-1 (3x) promoter and ganciclovir administration.
  • Endothelial Bovine aortic endothelial cells (BAEC), Human umbilical vein endothelial cells (HUVEC)] and non-endothelial [Human hepatoma cells (HepG-2), Human normal skin fibroblasts (NSF)] cells were transduced with ADPPE-1(3x)-TK, ADPPE-1(3x)-Luc or AdCMV-TK at m.o.i. of 10, followed by the administration of 1 ⁇ g/ml GCV four hours post-transduction.
  • BAEC Bovine aortic endothelial cells
  • HUVEC Human umbilical vein endothelial cells
  • NSF Human normal skin fibroblasts
  • FIG. 68 is a histogram representing the specific, synergic endothelial cell cytotoxicity of TK under control of the PPE-1 (3x) promoter and ganciclovir administration.
  • Endothelial (BAEC and HUVEC) and non-endothelial (HepG-2 and NSF) cells were prepared in 96-well plates and transduced as in FIG. 67 , followed by the addition of increasing concentrations (1 ⁇ g/ml) GCV four hours post-transduction. 10 days post vector addition, cell viability was determined using crystal violet staining. Note the superior, endothelial specific cytotoxicity of AdPPE-1 (3x)+GCV, compared with the non-specific cytotoxicity of AdCMV-TK+GCV.
  • FIG. 69 is a series of photomicrographs illustrating the endothelial selective cytotoxicity of TK under control of the PPE-1 (3x) promoter and ganciclovir administration at extreme multiplicity of infection.
  • NSF Non-endothelial
  • Non-endothelial (NSF) cells were transduced with AdPPE-1(3x)-TK, AdPPE-1(3x)-Luc or AdCMV-TK as in FIG. 66 , at the higher m.o.i. of 100, followed by the administration of 1 ⁇ g/ml GCV four hours post-transduction.
  • the experiment was performed twice, in 96-well plates, 12 wells for every group. Cytotoxicity and cell morphological changes were detected microscopically four days post-transduction. Note the lack of effect on NSF cell morphology with AdPPE-1(3x)-TK+GCV, compared to the non-specific cytotoxicity of AdCMV-TK+GCV.
  • FIG. 70 is a series of photographs illustrating synergic suppression of metastatic growth by in vivo expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration.
  • FIG. 71 is a histogram illustrating synergic suppression of metastatic growth by in vivo expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration.
  • Lung metastases were induced in C57BL/6 mice, and the mice treated with 10 11 PFUs of the adenoviral vectors [AdPPE-1(3x)-TK+GCV; AdCMV-TK+GCV; AdPPE-1(3x)-TK without GCV] and GCV (100 mg/kg) as described hereinabove.
  • the mice were sacrificed on the 24 th day post vector injection, and lungs removed for assessment of the lung metastases. Control mice received saline and GCV.
  • FIGS. 72 a and 72 b were sectioned and stained with hematoxylin and eosin. Note the massive central necrosis and numerous clusters of mononuclear infiltrates in metastases from lungs with AdPPE-1 (3x)+GCV administration ( FIGS. 72 a and 72 b ).
  • FIGS. 74 a and 74 b are representative histopathology sections of induced LLC lung metastases stained with TUNEL and anti-caspase-3 of lung metastases, illustrating the endothelial-specific, synergic enhancement of tumor apoptosis by in vivo expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration. Sections from LLC lung metastases, induced and prepared as described in FIGS.
  • 73 a - 73 b were fixed and embedded in paraffin, and assayed for indicators of apoptosis by the deoxynucleotide transferase-mediated dUTP-nick end-labeling (TUNEL) assay using the Klenow-FragE1 (Oncogene, Cambridge, Mass.) ( FIG. 74 a ) and anti-caspase-3-specific immunohistopathology ( 74 b ).
  • Black arrows indicate erythrocytes, red arrows apoptotic endothelial cells, and white arrows apoptotic tumor cells. Note the enhanced apoptosis in the vascular (endothelial) regions of the lung metastases from the mice treated with intravenous AdPPE-1 (3x)-TK+GCV.
  • FIGS. 75 a - 75 d are representative immunohistopathology sections of tissue from murine lung carcinoma, illustrating the endothelial-specific, synergic inhibition of angiogenesis by in vivo expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration.
  • Sections from LLC lung metastases ( FIG. 75 a ) livers ( FIG. 75 c ) and normal lung tissue ( FIG. 75 b ) induced and prepared as described in FIGS. 73 a - 73 b were fixed and embedded in paraffin, and assayed for indicators of angiogenesis by anti-CD-31 immunofluorescence.
  • FIG. 75 d is a histogram showing a computer-based vascular density assessment (Image Pro-Plus, Media Cyberneticks Incorporated) of the lung metastases vascularization (angiogenesis). Left bar: AdPPE-1(3x)TK+GCV; right bar: ADPPE-1(3x)TK no GCV.
  • FIG. 76 is a representative histopathology section of tissue from murine liver, illustrating the absence of hepatotoxicity in in-vivo expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration.
  • Sections from livers of mice bearing LLC lung metastases induced and prepared as described in FIGS. 73 a - 73 b were fixed and embedded in paraffin, and stained with hematoxylin and eosin. Note the absence of cytotoxic indicators in livers from mice treated with AdPPE-1-TK+GCV (3x) (left panel), compared to the profound cytotoxicity in the livers from mice treated with the constitutively expressed AdCMV-TK+GCV(right panel)
  • FIG. 77 depicts a RT-PCR analysis illustrating the organ-specific expression of the expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration. LLC lung metastases were induced and prepared in nine 15 week-old C57BL/6 male mice as described in FIGS. 73 a - 73 b . Adenovirus vectors [AdPPE-1 (3x)-TK and AdCMV-TK], and saline control were delivered intravenously 14 days post primary tumor removal. The mice were sacrificed 6 days post vector injection, and organs harvested.
  • AdPPE-1 (3x)-TK and AdCMV-TK AdCMV-TK
  • RNA of different organs was extracted, as described hereinbelow, and PPE-1 (3x) and HSV-TK transcripts amplified by RT-PCR PCR with PPE-1(3x) promoter and HSV-TK gene primers. Note the endothelial-specific expression of TK under control of the PPE-1 (3x) promoter (center, bottom panel).
  • FIGS. 78 a and 78 b are graphs illustrating a range of sub-therapeutic and non-toxic irradiation in Balb/c murine colon carcinoma tumor model.
  • the 5 Gy dose induced only a partial, non-statistically significant delay in tumor progression ( FIG. 78 a ), and no significant weight loss ( FIG. 78 b ).
  • FIGS. 79 a - 79 g illustrate synergistic suppression of tumor growth in murine colon carcinoma with combined sub-therapeutic radiotherapy and expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration.
  • 100 male Balb/C mice aged 8 weeks were inoculated with CT-26 colon carcinoma tumor cells.
  • 10 11 PFUs of the viral vectors [AdPPE-1 (3x)-TK or AdCMV-TK] were injected intravenously into the tail vein followed by 14 days of daily intraperitoneal GCV injection (100 mg/kg body weight), where indicated. 3 days post vector administration, the mice were irradiated with a local 5 Gy dose.
  • FIG. 79 a shows mean tumor volume ⁇ S.E. on day 14 post vector injection.
  • FIG. 79 b shows mean tumor volume progression over time, in groups treated with radiotherapy.
  • FIG. 79 c shows mean tumor volume progression over time, in AdPPE-1(3x)-TK+GCV treated mice.
  • FIG. 79 d shows mean tumor volume progression over time, in AdCMV-TK+GCV treated mice.
  • FIG. 79 e shows mean tumor volume progression over time, in control saline+GCV treated mice.
  • FIG. 79 f shows mean tumor volume progression over time, in AdPPE-1(3x)-TK treated mice without GCV.
  • FIGS. 80 a - 80 b are representative histopathology sections of primary CT-26 tumor showing synergistic induction of tumor necrosis in murine colon carcinoma with combined sub-therapeutic radiotherapy and expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration. Sections from CT-26 colon carcinoma tumors induced and prepared as described in FIGS. 79 a - 79 g were fixed and embedded in paraffin, and stained with hematoxylin and eosin. Note the areas of necrosis ( FIG. 80 a ) and granulation tissue ( FIG. 80 b ) with combined AdPPE-1 (3x)+GCV+low dose radiotherapy.
  • FIGS. 81 a - 81 b are representative histopathology sections of induced primary colon carcinoma tumors stained with TUNEL and anti-caspase-3, illustrating synergic enhancement of endothelial cell and tumor apoptosis by combined radiotherapy and in vivo expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration. Sections from CT-26 primary colon carcinoma tumors, induced and prepared as described in FIGS.
  • FIG. 82 is representative histopathology sections of induced primary colon carcinoma tumors stained with anti-caspase-3, illustrating synergic enhancement of endothelial cell and tumor apoptosis by combined radiotherapy and in vivo expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration.
  • Sections from CT-26 primary colon carcinoma tumors, induced and prepared as described in FIGS. 79 a - 79 g were fixed and embedded in paraffin, and assayed for indicators of apoptosis by anti-caspase-3-specific immunohistopathology.
  • Black arrow indicates erythrocytes; red arrow indicates apoptotic endothelial cell, and white arrow indicates apoptotic tumor cell. Note the GCV-dependent apoptotic effect.
  • FIGS. 83 a and 83 b are representative histopathology sections of liver tissue and induced primary colon carcinoma tumors stained with anti-CD-31, illustrating synergic enhancement of inhibition of tumor vascularization by combined radiotherapy and in vivo expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration.
  • Sections from liver tissue( 83 b ) and CT-26 primary colon carcinoma tumors ( 83 a ), induced and prepared as described in FIGS. 79 a - 79 g were fixed and embedded in paraffin, and reacted with endothelial-specific anti-CD-31 for immunohistopathology.
  • Black arrow indicates erythrocytes; red arrow indicates apoptotic endothelial cell, and white arrow indicates apoptotic tumor cell. Note the extensive vascular disruption in the tumors from the mice treated with combined radiotherapy and intravenous AdPPE-1 (3x)-TK+GCV ( 83 a ) compared with the normal vasculature in the liver cells ( 83 b ).
  • FIG. 84 is representative histopathology sections of mouse liver tissue showing tissue-specific cytotoxicity of radiotherapy and TK expression under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration. Sections from mouse livers exposed to a vectors (AdPPE-1 (3x)-TK and AdCMV-TK) and GCV, alone and in combination, were fixed and embedded in paraffin, and stained with hematoxylin and eosin. Note the typical mild hepatotoxicity with AdCMV-TK and ganciclovir (left panel), and the absence of vascular abnormalities in the AdPPE-1 (3x)-TK treated liver (right panel).
  • FIGS. 85 a and 85 b are graphs illustrating a range of sub-therapeutic and non-toxic irradiation in C57Bl/6 lung carcinoma metastatic model.
  • 35 C57Bl/6 male mice aged 8 weeks were inoculated with Lewis Lung Carcinoma (LLC) cells into the left footpad and received irradiation into the chest wall with 0, 5, 10, or 15 Gy under general anesthesia, 8 days following removal of the primary tumor. Mice were sacrificed 28 days post tumor removal. Weight loss indicated metastatic disease.
  • the 5 Gy dose was neither therapeutic ( FIG. 85 a ) nor toxic ( FIG. 85 b ).
  • FIGS. 86 a - 86 d illustrate synergistic suppression of metastatic disease in murine lung carcinoma with combined sub-therapeutic radiotherapy and expression of TK under control of the PPE-1 (3x) promoter and ganciclovir (GCV) administration.
  • 180 male Balb/C mice aged 8 weeks were inoculated with LLC cells into the left footpad. The foot was amputated under general anesthesia as soon as the primary tumor developed.
  • 5 days post amputation 10 10 PFUs of vector [AdPPE-1(3x)-TK or AdCMV-TK] were injected into the tail vein, followed by 14 days of daily intraperitoneal injections of GCV (100 mg/kg).
  • FIG. 86 a shows survival of irradiated, non-vector treated mice over 55 days.
  • FIG. 86 b shows survival of AdPPE-1(3x)-TK treated mice.
  • FIG. 86 c shows survival of AdCMV-TK treated mice.
  • FIG. 86 d shows survival of saline treated control mice. Note that radiotherapy significantly potentiated only the angiogenic endothelial cell transcription-targeted vector, AdPPE-1(3x)-TK, compared to the non-targeted vector, AdCMV-TK ( FIG. 86 b - 86 d ). Treatment regimens with all virus vectors were ineffective without radiotherapy.
  • FIGS. 87 a - 87 c are a series of histograms showing endothelial cell cytotoxicity of Fas-c under control of CMV promoter.
  • Bovine aortic endothelial cells (BAEC) were stained with crystal violet 72 hours after transduction with 100 (left), 1000 (right) and 10000 (left bottom) moi's of CMV-FAS (dark) or CMV-LUC (gray, negative control), and 24 hours after the addition of human TNF- ⁇ ligand, in different concentrations. Note the reduced viability of BAE cells at high moi and TNF- ⁇ concentrations.
  • FIG. 88 is a graph of plaque development showing enhanced spread of viral replication in 293 cells with CMV-FAS (blue diamonds) compared to CMV-LUC (red squares). Titers of CsCl-banded stocks of CMV-FAS and CMV-LUC were determined by PFU assay, as described hereinbelow. Data is plotted as number of plaques seen on every 2-3 days of the plaque assay in log-scale.
  • FIGS. 89 a and 89 b is a series of photographs of 293 cell cultures illustrating the higher rate of cell-to-cell spread of virus infection (plaquing) with CMV-Fas-c as compared with CMV-luciferase. 4 days after infection, photographs of plaques from CMV-FAS (left) and CMV-LUC (right) with identical dilution, were taken. Plaques from CMV-FAS are clearly larger than those of CMV-LUC, indicating a higher rate of cell to cell spread, probably induced by apoptosis.
  • FIG. 90 is a histogram illustrating the specific, synergic endothelial cytotoxicity of Fas-c under control of the PPE-1 (3x) promoter and doxorubicin administration.
  • BAEcells were exposed to 100 nM of Doxorubicin 48 hours after vector (PPE-1 (3x)-FAS) transduction (10 3 moi).
  • Cells were stained with crystal violet 96 hours after vector transduction, and cell viability was assessed microscopically. Note the significant synergy in endothelial cytotoxicity between AdPPE-1 (3x)-Fas-c and doxorubicin.
  • FIGS. 91 a - 91 b are a graphic representation illustrating superior induction of angiogenesis in engineered tissue constructs by VEGF under the control of the endothelin (PPE-1 3X).
  • Tissue engineered constructs (undisclosed procedure) were grown with or without VEGF supplementation to the medium (50 ng/ml).
  • Parallel constructs were infected with Ad5PPEC-1-3x VEGF viruses or control Ad5PPEC-1-3x GFP adenoviruses (control virus) (for 4 hours). Following 2 weeks in culture the constructs were fixed, embedded, sectioned and stained. Vascularization was expressed as the number of vessels per mm 2 , and the percentage of area of sections that was vascularized.
  • FIG. 91 a shows that infection of the cells with Ad5PPEC-1-3x VEGF has an inductive effect on number and size of vessels-like structures formed in the engineered constructs. Note the dramatic increase (4-5 ⁇ ) in both parameters of vascularization in the Ad5PPEC-1-3x VEGF-transduced tissue constructs (VEGF virus), compared to constructs exposed to VEGF to the medium (VEGF medium).
  • FIG. 91 b is a histogram of LUC luminescence intensity, illustrating the superior survival and vascularization of implanted tissue constructs grown with cells infected with Ad5PPEC-1-3x VEGF, compared with Ad5PPEC-1-3x GFP controls.
  • FIG. 92 is the wild-type murine PPE-1 promoter DNA sequence (SEQ ID NO: 1).
  • the promoter contains the endogenous endothelial specific positive transcriptional element (black italics), the NF-1 response element (pink italics), the GATA-2 element (red italics), the HIF-1 responsive element (blue italics), the AP-1 site (green italics), the CAAT signal (orange italics) and the TATA box (purple italics).
  • FIG. 93 is the sequence of the 3 x fragment of the modified murine pre-proendothelin-1 promoter (SEQ ID NO: 7).
  • the fragment contains 2 complete endothelial cell specific positive transcription elements (red) and two portions that are located as inverted halves of the original sequence (blue): SEQ ID NO:15 (nucleotides from the 3′ portion of the transcription elements SEQ ID NO: 6), and SEQ ID NO:16 (nucleotides from the 5′ portion of the transcription elements SEQ ID NO: 6).
  • FIG. 94 is a histogram illustrating the tissue specific, Bosentan-induced enhancement of expression of the LUC gene under control of the PPE-1 (3x) promoter in transgenic mice.
  • FIGS. 95 a and 95 b are histograms illustrating the lack of host immune response to transgenes expressed under control of the PPE-1(3x) promoter, measured by ELISA. Note the nonspecific anti-adenovector response ( FIG. 95 a ), compared with the minimal anti TNF-R1 response evoked in the PPE-1(3x) Fas-c treated mice ( FIG. 95 b ).
  • the present invention is of polynucleotide sequences exhibiting endothelial cell specific promoter activity, and methods of use thereof. More particularly, the present invention relates to a modified-preproendothelin-1 (PPE-1) promoter which exhibits increased activity and specificity in endothelial cells, and nucleic acid constructs, which can be used to activate apoptosis in specific cell subsets, thus, enabling treatment of diseases characterized by aberrant neovascularization or cell growth. The invention further relates to modifications of the PPE promoter, which enhance its expression in response to physiological conditions including hypoxia and angiogenesis, and novel angiogenic endothelial-specific combined therapies.
  • PPE-1 modified-preproendothelin-1
  • Unbalanced angiogenesis typifies various pathological conditions and often sustains progression of the pathological state.
  • vascular endothelial cells divide about 35 times more rapidly than those in normal tissues (Denekamp and Hobson, 1982 Br. J. Cancer 46:711-20).
  • Such abnormal proliferation is necessary for tumor growth and metastasis (Folkman, 1986 Cancer Res. 46:467-73).
  • Vascular endothelial cell proliferation is also important in chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and synovitis, where these cells proliferate in response to growth factors released within the inflammatory site (Brown & Weiss, 1988, Ann. Rheum. Dis. 47:881-5).
  • regulating or modifying the angiogenic process can have an important therapeutic role in limiting the contributions of this process to pathological progression of an underlying disease state, as well as providing a valuable means of studying the etiology of such diseases.
  • endothelial regulating agents whether designed to be inhibitory or stimulatory, has been made (for a recent review, see Mariani et al Gen Med Gen 2003, 5:22).
  • endothelial regulating agents for pro angiogenic applications and mass formation of long lasting functional blood vessel there is a need for repeated or long term delivery of the above described protein factors, thus limiting their use in clinical settings.
  • efficient delivery of these factors requires the use of catheters to be placed in the coronary arteries, which further increases the expense and difficulty of treatment.
  • endothelial-specific targeting of therapeutic agents is essential to pro- and anti-angiogenic therapies.
  • Endothelial specific promoters have been described in the art, examples include flk-1, Flt-1 Tie-2 VW factor, and endothelin-1 (see U.S. Pat. No. 6,200,751 to Gu et al; U.S. Pat. No. 5,916,763 to Williams et al, and U.S. Pat. No. 5,747,340 to Harats et al, all of which are incorporated by reference herein).
  • Endothelial cell targeting of a therapeutic gene, expressed under the control endothelial-specific promoters has also been described in the art.
  • Jagger et al used the KDR or E-selectin promoter to express TNF ⁇ specifically in endothelial cells [Jaggar R T. Et al. Hum Gene Ther (1997) 8(18):2239-47] while Ozaki et al used the von-Willebrand factor (vWF) promoter to deliver herpes simplex virus thymidine kinase (HSV-tk) to HUVEC [Hum Gene Ther (1996) 7(13):1483-90].
  • vWF von-Willebrand factor
  • Enhancer elements specific to endothelial cells have previously been described, for example, by Bu et al. (J. Biol Chem. (1997) 272(19): 32613-32622) who demonstrated that three copies of the enhancer element of PPE-1 (containing elements ETE-C, ETE-D, and ETE-E) endows promoter sequences with endothelial cell specificity in-vitro. However, no in-vivo utility of the enhancer element could be demonstrated.
  • the present inventors have proven the enhancer element to be suitable for use in in-vivo therapeutic applications.
  • a unique, modified, thrice-repeated (3x) enhancer element SEQ ID NO: 7
  • the present inventors have further constructed a highly active enhancer element comprising portions of the 3x enhancer element sequence in a novel, rearranged orientation.
  • This modified enhancer element exhibits enhanced specificity to proliferating endothelial cells participating in angiogenesis, and negligible activity in normal endothelial cells in-vivo.
  • the present inventors have, for the first time, identified portions of the enhancer element which, when reconfigured, impart superior activity to nearby promoter sequences.
  • an isolated polypeptide comprising a cis regulatory element capable of directing transcription of a polynucleotide sequence transcriptionally linked hereto in eukaryotic cells.
  • the isolated polynucleotide includes at least a portion of the sequence set forth in SEQ ID NO:15, covalently linked to at least a portion of the sequence as set forth in SEQ ID NO:16.
  • the at least a portion of the sequence set forth in SEQ ID NO:15 is positioned upstream of the at least a portion of the sequence set forth in SEQ ID NO:16 in the cis regulatory element.
  • the at least a portion of the sequence set forth in SEQ ID NO:16 is positioned upstream of the at least a portion of the sequence set forth in SEQ ID NO:15 in the cis regulatory element.
  • SEQ ID NO:15 is a polynucleotide sequence representing nucleotide coordinates 27 to 44 of the murine endothelial specific enhancer element (SEQ ID NO:6), with an additional guanyl nucleotide linked at the 3′ terminus
  • SEQ ID NO:16 is a polynucleotide sequence representing nucleotide coordinates 1 to 19 of the murine endothelial specific enhancer element (SEQ ID NO:6).
  • tissue specific enhancer refers to an enhancer which increases the transcriptional activity of a promoter in a tissue-or context-dependent manner. It will be appreciated that such a “tissue specific enhancer” reduces, inhibits or even silences the transcriptional activity of a promoter in non-compatible tissue or environment.
  • the isolated polynucleotide includes contiguous copies of at least a portion of SEQ ID Nos: 15 and 16. Such sequences are preferably positioned in a head-to tail orientation, although other orientations well known in the art can be constructed, such as inverted orientation (tail to tail, or head to head), complementary orientation (replacing “a” with “t”, “t” with “a”, “g” with “c”, and “c” with “g”), inverted complementary orientation, and the like.
  • linker polynucleotide refers to a polynucleotide sequence which is linked between two or more flanking polynucleotides (e.g. SEQ ID Nos: 15 and 16).
  • linker sequence is the trinucleotide sequence “cca”, for example, which is the linker sequence as set forth in nucleotides in positions 55-57 of SEQ ID NO:7.
  • linker sequences can include entire additional enhancer elements, native or artificial, for example, multiple copies of SEQ ID NO.15, SEQ ID NO:16, the 1 ⁇ enhancer element of PPE-1, additional entire promoters, hypoxia response element (such as SEQ ID NO: 5), and the like.
  • the phrase “a portion of the sequence as set forth in SEQ ID NO:15 . . . ” or ““a portion of the sequence as set forth in SEQ ID NO:16 . . . ” is defined as a sequence representing at least 8 contiguous nucleotides of the 5′ terminus, 3′ terminus or any sequence therebetween, of the indicated sequence.
  • nucleotide coordinates 1-17 of SEQ ID NO:15 in increments of 1 nucleotide up to nucleotide coordinates 1-17 of SEQ ID NO:15 all constitute a portion of SEQ ID NO:15 according to the present invention, as do all the sequences representing nucleotide coordinates 2-9, 2-10, 2-11, . . . to 2-17 of SEQ ID NO:15, as do all the sequences representing nucleotide coordinates 3-10, 3-11, 3-12, . . . to 3-17 of SEQ ID NO:15, inclusive up to sequences representing nucleotide coordinates 10-17 of SEQ ID NO:15.
  • nucleotide coordinates 1-19 of SEQ ID NO:16 in increments of 1 nucleotide up to nucleotide coordinates 1-19 of SEQ ID NO:16 all constitute a portion of SEQ ID NO:16 according to the present invention, as do the sequences representing nucleotide coordinates 2-9, 2-10, . . . , as described hereinabove.
  • the modified enhancer PPE-1(3x) includes a sequence as set forth in SEQ ID NO:15 linked to a sequence as set forth in SEQ ID NO:16, flanked Immediately upstream and immediately downstream by a copy of the murine endothelial specific enhancer element (1x) (see SEQ ID NO:7).
  • the cis regulatory element of the present invention further includes at least one copy of the sequence as set forth in SEQ ID NO:6.
  • the cis regulatory element includes at least two copies of the sequence as set forth in SEQ ID NO:6.
  • the cis regulatory element of the present invention is as set forth in SEQ ID NO:7.
  • the isolated polynucleotide further includes an endothelial cell-specific promoter sequence element.
  • promoter refers to any polynucleotide sequence capable of mediating RNA transcription of a downstream sequence of interest.
  • the endothelial specific promoter element may include, for example, at least one copy of the PPE-1 promoter.
  • suitable promoters/enhancers which can be utilized by the nucleic acid construct of the present invention include the endothelial-specific promoters: preproendothelin-1, PPE-1 promoter (Harats D, J Clin Invest.
  • PECAM-1 [AJ313330 X96849; CD31, Newman P J, Science 1990 Mar. 9;247(4947):1219-22], the vascular smooth-muscle-specific elements: CArG box X53154 and aortic carboxypeptidase-like protein (ACLP) promoter [AF332596;Layne M D, Cire Res. 2002; 90: 728-736] and Aortic Preferentially Expressed Gene-1 [Yen-Hsu Chen J. Biol. Chem., Vol. 276, Issue 50, 47658-47663, Dec. 14, 2001].
  • ACLP carboxypeptidase-like protein
  • endothelial specific promoters are well known in the art, such as, for example, the EPCR promoter (U.S. Pat. No. 6,200,751 to Gu et al) and the VEGF promoter (U.S. Pat. No. 5,916,763 to Williams et al).
  • non-endothelial promoters can also be incorporated into the isolated polynucleotide described above, in order to direct expression of desired nucleic acid sequences in a variety of tissue. Promoters suitable for use with the construct of the present invention are well known in the art.
  • viral promoters e.g., retroviral ITRs, LTRs, immediate early viral promoters (IEp) (such as herpesvirus IEp (e.g., ICP4-IEp and ICP0-IEp) and cytomegalovirus (CMV) IEp), and other viral promoters (e.g., late viral promoters, latency-active promoters (LAPs), Rous Sarcoma Virus (RSV) promoters, and Murine Leukemia Virus (MLV) promoters)).
  • IEp immediate early viral promoters
  • IEp such as herpesvirus IEp (e.g., ICP4-IEp and ICP0-IEp) and cytomegalovirus (CMV) IEp
  • CMV cytomegalovirus
  • viral promoters e.g., retroviral ITRs, LTRs, immediate early viral promoters (IEp) (such as herpesvirus IEp (e.g.,
  • promoters are eukaryotic promoters which contain enhancer sequences (e.g., the rabbit.beta.-globin regulatory elements), constitutively active promoters (e.g., the .beta.-actin promoter, etc.), signal and/or tissue specific promoters (e.g., inducible and/or repressible promoters, such as a promoter responsive to TNF or RU486, the metallothionine promoter, PSA promoter, etc.), and tumor-specific promoters such as the telomerase, plastin and hexokinase promoters.
  • enhancer sequences e.g., the rabbit.beta.-globin regulatory elements
  • constitutively active promoters e.g., the .beta.-actin promoter, etc.
  • signal and/or tissue specific promoters e.g., inducible and/or repressible promoters, such as a promoter responsive to TNF
  • the isolated polynucleotide further includes a hypoxia response element, for example at least one copy of the sequence set forth in SEQ ID NO: 5.
  • the isolated nucleic acid sequence of the present invention can be used to regulate gene expression in eukaryotic tissue, and in particular, in proliferating endothelial cells, for example endothelial cells involved in angiogenesis, or for silencing (inhibiting) gene expression in resting endothelial cells.
  • the isolated polynucleotide sequence of the present invention may be provided, in some cases, as part of a nucleic acid construct further including a nucleic acid sequence positioned under the regulatory control of the isolated polynucleotide of the present invention.
  • the nucleic acid construct of the present invention can further include additional polynucleotide sequences such as for example, sequences encoding selection markers or reporter polypeptides, sequences encoding origin of replication in bacteria, sequences that allow for translation of several proteins from a single mRNA (IRES), sequences for genomic integration of the promoter-chimeric polypeptide encoding region and/or sequences generally included in mammalian expression vector such as pcDNA3, pcDNA3.1(+/ ⁇ ), pZeoSV2(+/ ⁇ ), pSecTag2, pDisplay, pEF/myc/cyto, pCMV/myc/cyto, pCR3.1, which are available from Invitrogen, pCI which is available from Promega, pBK-RSV and pBK-CMV which are available from Stratagene, pTRES which is available from Clontech, and their derivatives.
  • Such a nucleic acid construct is preferably configured for mammalian cell expression and can
  • nucleic acid sequences which may be used by the construct according to the present invention are, for example, positive and negative regulators of angiogenesis such as VEGF, FGF-1, FGF-2, PDGF, angiopoietin-1 and angiopoietin-2, TGF- ⁇ , IL-8 (for an extensive list of regulators of angiogenesis, see Table 1 hereinabove), cytotoxic drugs, reporter genes and the like.
  • the nucleic acid sequence is selected from the angiogenesis regulators VEGF, p55, angiopoietin-1, bFGF and PDGF-BB. Additional transcribable nucleic acid sequences suitable for control by the cis regulatory element of the present invention are provided hereinbelow and in the Examples section which follows.
  • Examples presented hereinbelow illustrate that the novel cis regulatory elements of the present invention can reliably direct expression of a reporter gene (GFP and LUC) to endothelial tissue following systemic in-vivo administration, in a preferential manner in ischemic and/or angiogenic (proliferating) endothelial tissue. More significantly, the examples further show, that the isolated polynucleotide of the present invention can be used to preferentially express therapeutic genes in tumors, metastases, ischemic and/or angiogenic tissue, thus providing direct evidence as to the importance of the cis regulatory element of the present invention, and its derivatives, in therapeutic applications.
  • a reporter gene GFP and LUC
  • the nucleic acid construct of the present invention is used in upregulating angiogenesis in a tissue, and treating or preventing a disease or condition associated with ischemia.
  • a disease or condition associated with ischemia are well known in the art, for example—wound healing, ischemic stroke, ischemic heart disease and gastrointestinal lesions.
  • the phrase “down-regulating angiogenesis” refers to either slowing down or stopping the angiogenic process, which lead to formation of new blood vessels.
  • the phrase “upregulating angiogenesis” refers to enhancing the expression of a dormant or minimally-functioning endothelial cell angiogenesis activator.
  • ex vivo and (2) in vivo gene therapy Two basic approaches to gene therapy have evolved: (1) ex vivo and (2) in vivo gene therapy.
  • ex vivo gene therapy cells are removed from a patient, and while being cultured are treated in vitro.
  • a functional replacement gene is introduced into the cell via an appropriate gene delivery vehicle/method (transfection, transduction, homologous recombination, etc.) and an expression system as needed and then the modified cells are expanded in culture and returned to the host/patient.
  • These genetically reimplanted cells have been shown to express the transfected, genetic material in situ.
  • target cells are not removed from the subject rather the genetic material to be transferred is introduced into the cells of the recipient organism in situ, that is within the recipient.
  • the host gene if the host gene is defective, the gene is repaired in situ (Culver, 1998. (Abstract) Antisense DNA & RNA based therapeutics, February 1998, Coronado, Calif.).
  • the gene expression vehicle is capable of delivery/transfer of heterologous nucleic acid into a host cell.
  • the expression vehicle may include elements to control targeting, expression and transcription of the nucleic acid in a cell selective manner as is known in the art. It should be noted that often the 5′UTR and/or 3′UTR of the gene may be replaced by the 5′UTR and/or 3′UTR of the expression vehicle. Therefore, as used herein the expression vehicle may, as needed, not include the 5′UTR and/or 3′UTR of the actual gene to be transferred and only include the specific amino acid coding region.
  • the expression vehicle can include a promoter for controlling transcription of the heterologous material and can be either a constitutive or inducible promoter to allow selective transcription. Enhancers that may be required to obtain necessary transcription levels can optionally be included. Enhancers are generally any nontranslated DNA sequence which works contiguously with the coding sequence (in cis) to change the basal transcription level dictated by the promoter.
  • the expression vehicle can also include a selection gene as described herein below.
  • DNA viral vector introducing and expressing recombination sequences is the adenovirus-derived vector Adenop53TK.
  • This vector expresses a herpes virus thymidine kinase (TK) gene for either positive or negative selection and an expression cassette for desired recombinant sequences.
  • TK herpes virus thymidine kinase
  • This vector can be used to infect cells that have an adenovirus receptor which includes most cancers of epithelial origin as well as others.
  • This vector as well as others that exhibit similar desired functions can be used to treat a mixed population of cells and can include, for example, an in vitro or ex vivo culture of cells, a tissue or a human subject.
  • features that limit expression to particular cell types can also be included. Such features include, for example, promoter and regulatory elements that are specific for the desired cell type.
  • recombinant viral vectors are useful for in vivo expression of a desired nucleic acid because they offer advantages such as lateral infection and targeting specificity.
  • Lateral infection is inherent in the life cycle of, for example, retrovirus and is the process by which a single infected cell produces many progeny virions that bud off and infect neighboring cells. The result is that a large area becomes rapidly infected, most of which was not initially infected by the original viral particles. This is in contrast to vertical-type of infection in which the infectious agent spreads only through daughter progeny.
  • Viral vectors can also be produced that are unable to spread laterally. This characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.
  • viruses are very specialized infectious agents that have evolved, in may cases, to elude host defense mechanisms.
  • viruses infect and propagate in specific cell types.
  • the targeting specificity of viral utilizes its natural specificity of viral vectors utilizes its natural specificity to specifically target predetermined cell types and thereby introduce a recombinant gene into the infected cell.
  • the vector to be used in the methods of the invention will depend on desired cell type to be targeted and will be known to those skilled in the art. For example, if breast cancer is to be treated then a vector specific for such epithelial cells would be used. Likewise, if diseases or pathological conditions of the hematopoietic system are to be treated, then a viral vector that is specific for blood cells and their precursors, preferably for the specific type of hematopoietic cell, would be used.
  • Retroviral vectors can be constructed to function either as infectious particles or to undergo only a single initial round of infection.
  • the genome of the virus is modified so that it maintains all the necessary genes, regulatory sequences and packaging signals to synthesize new viral proteins and RNA. Once these molecules are synthesized, the host cell packages the RNA into new viral particles which are capable of undergoing further rounds of infection.
  • the vector's genome is also engineered to encode and express the desired recombinant gene.
  • the vector genome is usually mutated to destroy the viral packaging signal that is required to encapsulate the RNA into viral particles. Without such a signal, any particles that are formed will not contain a genome and therefore cannot proceed through subsequent rounds of infection.
  • the specific type of vector will depend upon the intended application.
  • the actual vectors are also known and readily available within the art or can be constructed by one skilled in the art using well-known methodology.
  • the recombinant vector can be administered in several ways. If viral vectors are used, for example, the procedure can take advantage of their target specificity and consequently, do not have to be administered locally at the diseased site. However, local administration can provide a quicker and more effective treatment, administration can also be performed by, for example, intravenous or subcutaneous injection into the subject. Injection of the viral vectors into a spinal fluid can also be used as a mode of administration, especially in the case of neuro-degenerative diseases. Following injection, the viral vectors will circulate until they recognize host cells with appropriate target specificity for infection.
  • Such therapeutic applications include both the enhancement, and inhibition of angiogenesis in the target tissue.
  • proliferation of endothelial cells, leading to enhanced angiogenesis, or inhibition of endothelial cell proliferation, leading to reduced angiogenesis and ischemia can result.
  • nucleic acid sequence the expression of which is cytotoxic in the nucleic acid construct of the invention provides a method of targeting cell death to rapidly proliferating endothelial cells in angiogenic vessels of, for example, tumors. Because such a vector may be administered systemically, it can be employed to effectively induce cell death in developing metastatic foci, in advance of any presently available ability to identify and locate such foci of metastatic spread.
  • Such therapeutic nucleic acid sequences that can be used with the constructs of the present invention for cancer gene therapy are often classified as either corrective gene therapy, aimed at restoring mutant gene activity and control, immuno-modulatory gene therapy, aimed at sensitizing the immune system against cancer cells, and cytoreductive gene therapy, aimed at killing cancer cells by a prodrug or toxic agent (suicide gene therapy), pro-apoptotic gene, anti-angiogenic genes or enhancement of chemotherapy or radiotherapy.
  • Nucleic acid sequences suited for corrective gene therapy with the cis regulatory element of the present invention include, but are not limited to, the p53 gene (GenBank Access. No.
  • BC018819 an anti-neoplastic, DNA-stabilizing gene whose expression is suppressed in cancer cells; Cip/Kip (p21, GenBank Acces. No. NM000389; and p27, GenBank Accesss. No. NM004064) and Ink4 (p14, GenBank Access. No. NM058197), cyclin-dependent kinase inhibitors.
  • Nucleic acid sequences suited for suppression of oncogene function with the cis regulatory element of the present invention include, but are not limited to, antisense oligonucleotides that interfere with the transcription and translation of oncogenes such as ras, myc, erbB2 and bcl-2, and catalytic ribozymes that interfere with their translation.
  • antisense oligonucleotides that interfere with the transcription and translation of oncogenes such as ras, myc, erbB2 and bcl-2
  • catalytic ribozymes that interfere with their translation.
  • the nucleic acid sequence expressed under control of the cis regulatory element of the present invention is directed to immunomodulation gene therapy, designed to prevent avoidance of immune surveillance by tumor and metastatic cells.
  • Nucleic acid sequences encoding immunomodulatory factors suitable for use with the cis regulatory element of the present invention are cytokine genes, intracellular molecule genes for augmenting cytotoxic T cell recognition of Tumor Antigen and exogenous foreign immunogens (in order to induce a non-specific local immune reaction).
  • sequences of human .beta.-interferon, human GM-CSF, human TNF and human lymphotoxin are known and are available.
  • sequence of human gamma.-interferon is known (Fiers et al. (1982) Philos. Trans. R. Soc. Lond., B, Biol. Sci. 299:29-38) and has been deposited with GenBank under Accession No. M25460.
  • the sequence of human GM-CSF is known (Wong et al. (1985) Science 228:810-815) and has been deposited with GenBank under Accession No. M10663.
  • sequence of human TNF has been described (Wang et al.
  • the nucleic acid sequence expressed under control of the cis regulatory element of the present invention can be directed to genetic radioisotopic therapy: Uptake of the radio-labeled catecholamine I131-metaiodobenzyl-guanidine into cells which express the noradrenaline receptor (NAT) is an established treatment modality for pheochromocytoma, neuroblastoma, carcinoid tumor and medullary thyroid carcinoma. Alternatively, sodium iodine symporter (NIS) mediates the uptake of iodine into normal and malignant thyroid cells. The NIS gene, as a transgene, has been reported to suppress prostate cancer in in vitro and in vivo models.
  • NAT noradrenaline receptor
  • AdPPE-1-3X-GF where GF is a growth factor (e.g., cytokine) or modificants thereof (e.g., AdPPE-1-SEQ ID NO:7-GF), can be employed.
  • GF is a growth factor (e.g., cytokine) or modificants thereof (e.g., AdPPE-1-SEQ ID NO:7-GF)
  • Suitable growth factors for use in this context include, but are not limited to, VEGF (GenBank accession M95200) and rat PDGF-BB (GenBank accession; 99% identity to mus-AF162784) and EGR-1 (GenBank accession M22326) FGFs (including, but not limited to, GenBank accession XM 003306) and combinations thereof.
  • a hypoxia response element e.g. SEQ ID NO: 5
  • a hypoxia response element within the promoter sequence of the present invention
  • the hypoxia response element ceases to be induced, GF levels decline and the neo-vascularization process is halted.
  • the cis regulatory element comprising the novel enhancer element of the present invention [for example, PPE-1 (3x)] directs increased expression of recombinant genes specifically in tissues undergoing vascular proliferation, while preventing recombinant gene expression in other, non-angiogenic tissues (see Examples 12, 14, 16, 19, 20, 23, 27, 29, 34 and 35).
  • a construct including the cis regulatory element of the present invention in a gene therapy context can be expected to maximize delivery to tumors while minimizing toxic effects on surrounding normal tissue.
  • the surrounding tissue contains an endothelial component, as illustrated in the Examples section that follows. This is because, as demonstrated in Example 16, the cis regulatory element of the present invention greatly increases the level of expression in rapidly proliferating endothelial tissue, even in the context of the PPE-1 promoter.
  • enhancer elements related to those of the present invention for example, enhancers including SEQ ID Nos. 15 and 16, or SEQ ID NO: 6 may be used with constitutive promoters, for example the SV-40 promoter.
  • constructs containing, methods employing and isolated polynucleotides including a eukaryotic promoter modified to include the enhancer sequence of the present invention are well within the scope of the claimed invention.
  • an enhancer element is an isolated polynucleotide including at least a portion of the sequence set forth in SEQ ID NO:15 covalently linked to at least a portion of the sequence set forth in SEQ ID NO:16.
  • This enhancer is anticipated to function with a wide variety of promoters, including but not limited to endothelial specific promoters (e.g. PPE-1; SEQ ID NO.: 1) and constitutive promoters, for example viral promoters such as those derived from CMV and SV-40.
  • This enhancer should be capable of imparting endothelial specificity to a wide variety of promoters.
  • the enhancer element may be augmented, for example by addition of one or more copies of the sequence set forth in SEQ ID NO:6. These additional sequences may be added contiguously or non-contiguously to the sequence of SEQ ID NO.: 8.
  • the present invention further includes a method of expressing a nucleic acid sequence of interest in endothelial cells employing a construct which relies upon an enhancer element including at least at least a portion of the sequence set forth in SEQ ID NO:15 covalently linked to at least a portion of the sequence set forth in SEQ ID NO:16 and a promoter to direct high level expression of the sequence of interest specifically to endothelial cells.
  • a human polypeptide (TNF-R1) expressed as a portion of the Ad5PPE-1(3x) nucleic acid construct (Example 41, FIG. 95 b ) lacks antigenicity in mice, and does not induce a significant immunological response in the host, despite the clear anti-TNF-R1 response to administration of the Fas-c chimera gene under control of the CMV promoter ( FIG. 95 ).
  • the isolated polypeptide of the present invention can be used for reducing or eliminating a host immune response to an endogenously expressed recombinant transgene product or products, effected by expressing within a cell the recombinant transgene (or genes), under transcriptional control of the cis regulatory element of the present invention.
  • the cis regulatory element is the PPE-1 (3x) promoter.
  • a construct including the cis regulatory element of the present invention is administered in combination with an adjunct anti-angiogenic therapy, the anti-angiogenic therapy selected capable of inducing an endogenous enhancer of endothelial-specific promoter activity.
  • Anti-angiogenic therapy well known in the art includes, but is not limited to endothelin receptor antagonists such as Bosentan, VEGF-receptor antagonists, angiostatin and endostatin, and antiangiogenic antibodies such as Bevacizumab and Novast.
  • VEGF and PDGF are commonly used to induce vascularization, however methods of administration of these factors in an effective way are still not optimal.
  • the growth factors are added in the growth medium. In this method relatively high concentration are needed.
  • engineered tissue constructs need to be vascularized rapidly and to induce angiogenesis to the site of implantation.
  • the cis regulatory elements and nucleic acid constructs of the present invention can be used for neovascularization of tissue in vivo and ex-vivo, for example, for use in tissue engineering, treatment of wound healing, and the like.
  • Infection of the cells with Ad5PPEC-1-3x VEGF has an inductive effect on number and size of vessels-like structures formed in the engineered constructs, resulting in a 4-5 fold increase in the number of vessels and percentages of vessel area in the samples treated with Ad5PPEC-1-3x VEGF virus comparing to addition of VEGF to the medium ( FIG. 91 a ).
  • survival, differentiation, integration and vascularization of implanted scaffold-based tissue constructs were analyzed. Constructs infected with Ad5PPEC-1-3x VEGF virus show an increase in vessel structures compared to control constructs.
  • the nucleic acid construct of the present invention is used to regulate angiogenesis in a tissue, the tissue being a natural or an engineered tissue.
  • a cell comprising the nucleic acid construct of the present invention.
  • these cells are used to seed a scaffold to be used, for example, for tissue engineering.
  • Methods for tissue engineering using scaffolds are well known in the art (see, for example, U.S. Pat. Nos. 6,753,181; 6,652,583; 6,497,725; 6,479,064; 6,438,802; 6,376,244; 6,206,917, 6,783,776; 6,576,265; 6,521,750; 6,444,803; 6,300,127; 6,183,737; 6,110,480; 6,027,743; and 5,906,827, and U.S.
  • Suitable scaffolds can be composed of synthetic polymer, a cell adhesion molecule or an extracellular matrix protein.
  • the cell adhesion/ECM protein used by the present invention can be any cell adhesion and/or extracellular matrix protein, including, but not limited to, fibrinogen, Collagen, integrin (Stefanidakis M, et al., 2003; J Biol Chem. 278: 34674-84), intercellular adhesion molecule (ICAM) 1 (van de Stolpe A and van der Saag P T. 1996; J. Mol. Med. 74: 13-33), tenascin, fibrinectin (Joshi P, et al., 1993; J. Cell Sci. 106: 389-400); vimentin, microtubule-associated protein 1D (Theodosis D T.
  • the synthetic polymer used by the present invention can be polyethylene glycol (PEG), Hydroxyapatite (HA), polyglycolic acid (PGA) (Freed L E, Biotechnology (N Y). 1994 July;12(7):689-93.), epsilon-caprolactone and 1-lactic acid reinforced with a poly-1-lactide knitted [KN-PCLA] (Ozawa T et al., 2002; J. Thorac. Cardiovasc. Surg.
  • a method of down-regulating angiogenesis in a tissue of a subject refers to either slowing down or stopping the angiogenic process, which lead to formation of new blood vessels.
  • angiogenic cells refers to any cells, which participate or contribute to the process of angiogenesis.
  • angiogenic cells include but are not limited to, endothelial cells, smooth muscle cells.
  • cytotoxicity refers to the ability of a compound or process to disrupt the normal metabolism, function and/or structure of a cell, in a potentially irreversible manner, most often leading to cell death.
  • a “cytotoxic molecule” is herein defined as a molecule having, under defined conditions, the capability of generating cytotoxicity, or inducing a cytotoxic process or pathway within a cell.
  • cytotoxic molecules include cytotoxic drugs such as, but not limited to antimetabolites such as methotrexate, nucleoside analogues, nitrogen mustard compounds, anthracyclines, inducers of apoptosis such as caspase, as well as genes encoding cytotoxic drugs and other inducers of cytotoxic processes, such as the Fas-c chimera gene.
  • cytotoxic drugs and molecules may be absolutely cytotoxic, independent of other factors, such as antimetabolite drugs, or conditionally cytotoxic, dependent on the interplay of other, cytotoxic or non-cytotoxic factors.
  • a cytotoxic generating domain is defined as a portion of a cytotoxic molecule capable of inducing or initiating cytotoxicity, such as a coding sequence of a cytotoxic gene. Cytotoxic pathways include, inter alia, apoptosis and necrosis.
  • the expression of the cytotoxic agent is directed to a subpopulation of angiogenic cells.
  • the nucleic acid construct of the present invention includes a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain which can be, for example, a cell-surface receptor domain of a receptor tyrosine kinase, a receptor serine kinase, a receptor threonine kinase, a cell adhesion molecule or a phosphatase receptor fused to an effector domain of an cytotoxic molecule such as, for example, Fas, TNFR, and TRAIL.
  • a ligand binding domain which can be, for example, a cell-surface receptor domain of a receptor tyrosine kinase, a receptor serine kinase, a receptor threonine kinase, a cell adhesion molecule or a phosphatase receptor fused to an effect
  • Such a chimeric polypeptide can include any ligand binding domain fused to any cytotoxic domain as long as activation of the ligand binding domain, i.e., via ligand binding, triggers cytotoxicity via the effector domain of the cytotoxic molecule.
  • the chimeric polypeptide when targeting specific subset of endothelial cells (e.g., proliferating endothelial cells, or endothelial cells exhibiting a tumorous phenotype), the chimeric polypeptide includes a ligand binding domain capable of binding a ligand naturally present in the environment of such endothelial cells and preferably not present in endothelial cells of other non-targeted tissues (e.g., TNF, VEGF ).
  • a ligand can be secreted by endothelial cells (autocrine), secreted by neighboring tumor cells (paracrine) or specifically targeted to these endothelial cells.
  • chimeric polypeptides are provided hereinabove, and in Examples 7 and 33-36 of the Examples section which follows.
  • the chimeric polypeptide is the Fas-c chimera which is described in detail in Examples 7-9 of the Examples section which follows, or the HSV-TK gene described in Examples 33-36.
  • Expression of the Fas-c chimera has been shown to induce apoptosis via FADD-mediated activation of the Fas death pathway.
  • Expression of the HSV-TK transgene results in hypersusceptibility of the transduced cells to drugs such as ganciclovir and aciclovir, leading to apoptosis and necrotic cell death.
  • nucleic acid constructs of the present invention including the HSV-TK gene under transcriptional control of the PPE-1 (3x) promoter element, produced superior, ganciclovir-dependent endothelial cell cytotoxicity. Cytotoxicity was restricted to angiogenic endothelial cells, producing selective apoptotic and necrotic cell death in tumors and metastases.
  • the nucleic acid construct of the present invention can be used to deliver a suicide gene, capable of converting a prodrug to a toxic compound.
  • the nucleic acid construct includes a first polynucleotide region encoding such a suicide gene, and a second polynucleotide region encoding a cis acting regulatory element capable of directing expression of the suicide gene in angiogenic cells.
  • the therapeutic nucleic acid sequence or “suicide gene” is a nucleic acid coding for a product, wherein the product causes cell death by itself or in the presence of other compounds. It will be appreciated that the above described construct represents only one example of a suicide construct. Additional examples are thymidine kinase of varicella zoster virus and the bacterial gene cytosine deaminase which can convert 5-fluorocytosine to the highly toxic compound 5-fluorouracil.
  • prodrug means any compound useful in the methods of the present invention that can be converted to a toxic product, i.e. toxic to tumor cells.
  • the prodrug is converted to a toxic product by the gene product of the therapeutic nucleic acid sequence (suicide gene) in the vector useful in the method of the present invention.
  • Representative examples of such a prodrug is ganciclovir which is converted in vivo to a toxic compound by HSV-thymidine kinase. The ganciclovir derivative subsequently is toxic to tumor cells.
  • prodrugs include aciclovir, FIAU [1-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-5-iodouracil], 6-methoxypurine arabinoside for VZV-TK, and 5-fluorocytosine for cytosine deambinase.
  • Preferred suicide gene/prodrug combinations are bacteria cytosine deaminase and 5-fluorocytosine and its derivatives, varicella zoster virus TK and 6-methylpurine arabinoside and its derivatives, HSV-TK and ganciclovir, aciclovir, FIAU or their derivatives.
  • the cis acting regulatory element is an endothelial or periendothelial specific promoter. Since transduction of cells with conditionally replicating adenoviral vectors is significantly more effective in target cell lysis and spread of viral infection, the nucleic acid construct can preferably include a conditionally replicating adenovirus.
  • CRAD constructs of the present invention are described in detail in the Examples section here which follows.
  • the nucleic acid construct of the present invention is administered to the subject via, for example, systemic administration routes or via oral, rectal, transmucosal (especially transnasal), intestinal or parenteral administration routes.
  • Systemic administration includes intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, inrtaperitoneal, intranasal, intraocular injections or intra-tumoral.
  • the subject is a mammal, more preferably, a human being, most preferably, a human being suffering from diseases characterized by excessive or abnormal neovascularization such as that characterizing tumor growth, proliferating diabetic retinopathy, arthritis and the like.
  • nucleic acid constructs of the present invention can be administered to the subject per se or as part (active ingredient) of a pharmaceutical composition.
  • a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients or agents described herein with other chemical components such as physiologically suitable carriers and excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
  • physiologically acceptable carrier and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered nucleic acid construct.
  • An adjuvant is included under these phrases.
  • excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
  • excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
  • Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, inrtaperitoneal, intranasal, or intraocular injections.
  • administration directly into tumor tissue is a relevant example of local administration.
  • compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the active ingredient of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
  • physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art.
  • Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient.
  • Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions which can be used orally include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • compositions described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative.
  • the compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.
  • a suitable vehicle e.g., sterile, pyrogen-free water based solution
  • compositions of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
  • compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (e.g. antisense oligonucleotide) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., progressive loss of bone mass) or prolong the survival of the subject being treated.
  • active ingredients e.g. antisense oligonucleotide
  • the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays.
  • a dose can be formulated in an animal model, such as the murine Src deficient model of osteopetrosis (Boyce et al. (1992) J. Clin. Invest. 90, 1622-1627; Lowe et al. (1993) Proc. Natl. Acad. Sci. USA 90, 4485-4489; Soriano et al. (1991) Cell 64, 693-702), to achieve a desired concentration or titer.
  • Such information can be used to more accurately determine useful doses in humans.
  • Toxicity, cytotoxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals.
  • the data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
  • the dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in “The Pharmacological Basis of Therapeutics”, Ch. 1 p.1).
  • Dosage amount and interval may be adjusted individually to levels of the active ingredient are sufficient to retard tumor progression (minimal effective concentration, MEC).
  • MEC minimum effective concentration
  • the MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
  • dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or diminution of the disease state is achieved.
  • compositions to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
  • compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may, for example, comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • the pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.
  • Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as if further detailed above.
  • compositions of the present invention may further include any additional ingredients which may improve the uptake of the nucleic acid construct by the cells, expression of the chimeric polypeptide or suicide gene encoded by the nucleic acid construct in the cells, or the activity of the expressed chimeric polypeptide or suicide gene product.
  • adenoviral vectors into EC cells can be enhanced by treating the vectors with engineered antibodies or small peptides.
  • Such “adenobody” treatment was shown effective in directing adenovirus constructs to EGF receptors on cells (Watkins et al 1997, Gene Therapy 4:1004-1012).
  • Nicklin et al have shown that a small peptide, isolated via phage display, increased specificity and efficiency of vectors in endothelial cells and decreased the expression in liver cells in culture (Nicklin et al 2000, Circulation 102:231-237).
  • an FGF retargeted adenoviral vector reduced the toxicity of tk in mice (Printz et al 2000, Human Gene Therapy 11:191-204).
  • Low dose radiation has been shown to cause breaks in DNA strands primarily in the G2/M phase, cell membrane damage enhancing the bystander effect, and thus may potentiate other cytotoxic and anti-neoplastic therapies, when administered in combination.
  • Vascular endothelial cells may be particularly suitable to such combination, or adjunct, therapies, since it has been demonstrated that low dose radiation specifically targets the apoptotic system of the microvascular endothelial cells (Kolesnick et al., Oncogene 2003; 22:5897-906).
  • Angiostatin has been shown to potentiate the therapeutic effects of low dose radiation (Gorski et al. Can Res 1998;58:5686-89).
  • low dose radiation treatment has a clear synergistic effect on the anti-tumor and anti metastatic effectiveness of nucleic acid constructs including TK under control of PPE-1 (3x) and ganciclovir administration (Examples 35 and 36 FIGS. 79-86 ).
  • This is of specific relevance in the context of the present invention, since it has been demonstrated that such low dose radiation can activate TK expression and therapeutic effect, can specifically potentiate doxorubicin chemotherapeutic effect, and is known to activate the FADD/MORT-1 apoptotic pathway (Kim et al, JBC 2002;277:38855-62).
  • nucleic acid constructs and the pharmaceutical compositions comprising same of the present invention can be used to treat diseases or conditions associated with aberrant angiogenesis alone or in combination with one or more other established or experimental therapeutic regimen for such disorders.
  • Therapeutic regimen for treatment of cancer suitable for combination with the nucleic acid constructs of the present invention or polynucleotide encoding same include, but are not limited to chemotherapy, radiotherapy, phototherapy and photodynamic therapy, surgery, nutritional therapy, ablative therapy, combined radiotherapy and chemotherapy, brachiotherapy, proton beam therapy, immunotherapy, cellular therapy and photon beam radiosurgical therapy.
  • Anti-cancer drugs that can be co-administered with the compounds of the invention include, but are not limited to Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adriamycin; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefm
  • Additional antineoplastic agents include those disclosed in Chapter 52, Antineoplastic Agents (Paul Calabresi and Bruce A. Chabner), and the introduction thereto, 1202-1263, of Goodman and Gilman's “The Pharmacological Basis of Therapeutics”, Eighth Edition, 1990, McGraw-Hill, Inc. (Health Professions Division).
  • the present invention also envisages expression of the nucleic acid construct of the present invention in cells which are not exposed to, or naturally affected by the ligand or cytotoxic prodrug.
  • the method of the present invention includes the step of administering such a ligand, or prodrug, to the cells transformed.
  • administration can be effected by using any of the above described administration methods.
  • the ligand or prodrug is administrated in a cell targeted manner, using for example antibody conjugated targeting, such that activation of cytotoxicity is highly specific. This approach of cytotoxic or apoptotic activation is described in more detail in the Examples section which follows.
  • the present invention provides nucleic acid constructs, pharmaceutical compositions including such constructs and methods of utilizing such constructs for down-regulating angiogenesis in tissue regions characterized by excessive or abnormal angiogenesis.
  • the present invention enables targeted expression in specific cell subsets, it can also be modified and used in for treating various tumors.
  • the method according to this aspect of the present invention is effected by expressing in tumor cells the chimeric polypeptide or suicide gene described above.
  • expression of the polypeptide chimera or suicide gene is directed by a tumor specific element, such as, but not limited to, the gastrin-releasing peptide (GRP) promoter [AF293321S3; Morimoto E Anticancer Res 2001 January-February;21(1A):329-31], the hTERT promoter [AH007699; Gu J , Gene Ther 2002 January;9 (1):30-7], the Hexokinase type II promoter [AF148512; Katabi M M, Hum Gene Ther. 1999 Jan. 20;10(2):155-64.], or the L-plastin promoter [L05490, AH002870, MMU82611; Peng X Y, Cancer Res. Jun. 1, 2001;61(11):4405-13].
  • GRP gastrin-releasing peptide
  • polypeptide chimera e.g., Fas-c
  • suicide gene in tumor cells activates cytotoxicity and/or apoptosis in these cells and thus leads to cell death, which in turn causes tumor growth slowdown or arrest, and possibly tumor shrinkage.
  • Lewis Lung Carcinoma—(D122-96), Human Embryonic Kidney (293) and HeLa cells were grown in 4.5 gr/l DMEM, supplemented with 10% fetal calf serum (FCS), 50 U/ml penicillin, 50 ⁇ g/ml streptomycin and 2 mM glutamine (Biological industries, Beit-Haemek, Israel).
  • FCS fetal calf serum
  • penicillin 50 ⁇ g/ml streptomycin
  • 2 mM glutamine Biological industries, Beit-Haemek, Israel.
  • Bovine Aortic Endothelial Cells BAEC, Normal Skin Fibroblasts—NSF, HepG2 and Human Umbilical Endothelial Cells—HUVEC-304 (ATCC, USA) were grown in 1.0 gr/l DMEM (Biological industries, Beit-Haemek, Israel), supplemented with 5% FCS, 50 U/ml penicillin, 50 ⁇ g/ml streptomycine and 2 mM glutamine. The BAEC cells were supplemented with complete fibroblast growth factor (Sigma, St. Louis. Mo.).
  • RINr1046-38 (RIN-38) were grown in 199 Earle's salts (5.5 mM glucose) medium supplemented with 5% FCS (Biological Industries, Beit-Haemek, Israel), 50 U penicillin/ml, 50 ⁇ g streptomycine/ml and 2 mM glutamine.
  • HepG2 as used herein refers to ATCC-HB-8065.
  • HeLa as used herein refers to ATCC-CCL-2.
  • Human Bronchial Epithelial cells and “B2B” as used herein refers to ATCC-CRL-9609.
  • VEC Human Umbilical Vein Endothelial Cells
  • Luciferase gene expression system kit was employed (Promega Corp., Madison, Wis.). Forty eight hours post transfection or transduction the cells were washed and 200 ⁇ l lysis buffer was added for 15 minutes. Cells lysates were collected and centrifuged for 15 minutes (14,000 rpm) at 4° C. Subsequently, 10 ⁇ l of the supernatant was added to 50 ⁇ l Luciferase assay buffer. The activity was measured in Luminometer over a 20 second period.
  • Luciferase activity in solid tissue a 20 mg sample was excised and homogenized in 1 ml of the homogenization solution and centrifuged for 15 minutes (14,000 rpm) at 4° C., and 10 ml of the supernatant were assayed for Luciferase activity, as described above. Results were expressed as Luciferase light units per 1 ⁇ g protein. Protein was measured using the Bradford assay with bovine serum albumin (BSA) as a standard.
  • BSA bovine serum albumin
  • tissues were fixed in freshly made 4% paraformaldehyde in 0.1 M phosphate buffer for 6 hours at 4° C., soaked overnight in 30% sucrose at 4° C. and frozen in OCT compound (Sakura, USA).
  • OCT compound Sakura, USA.
  • the tissue blocks were sliced by a cryostat at 10 ⁇ m thickness and observed directly under fluorescence microscopy (FITC filter).
  • proliferating cells growing and infecting in 10% FCS media.
  • quiescent cells growing and infected in serum free media started in 72 hours prior to the transduction.
  • Several recombinant replication deficient adenoviruses (type 5) were constructed.
  • the GFP gene (originated from pEGFP, GenBank accession number AAB02572) was ligated to the PPE-1 promoter at the NotI restriction site.
  • Ad5PPE-1Luc or Ad5PPE-1GFP The replication deficient recombinant adenoviruses termed Ad5PPE-1Luc or Ad5PPE-1GFP were prepared by co-transfection of pPACPPE-1Luc or Ad5PPE-1GFP with adenovirus plasmid pJM17 as described by Becker, T. C. et al. (Methods Cell biol. 43, Roth M. (ed). New York. Academic Press, 1994, pp. 161-189) followed by harvest of recombinant virions.
  • Viruses were prepared for large-scale production.
  • the viral stocks were stored at 4° C. at concentration of 10 9 -10 12 plaque-forming units/ml (pfu/ml).
  • the viruses Ad5CMV-Luc and Ad5CMV-GFP (Quantum biotechnologies, Carlsbad, Canada) containing the cytomegalovirus (CMV) immediate early promoter (GenBank Accession number U47119) were prepared for large scale preparation as described for the PPE-1 viral vectors and were used as a non-tissue specific control.
  • CMV cytomegalovirus immediate early promoter
  • the modified murine PPE-1 promoter was developed by inserting three copies of the positive transcription element discovered by Bu et al (J. Biol Chem. (1997) 272(19): 32613-32622) into the NheI restriction enzyme site located downstream ( ⁇ 286 bp) to the 43 base pairs endogenous positive element ( ⁇ 364 to ⁇ 320 bp).
  • the enhancer fragment termed herein “3X” is a triplicate copy of an endogenous sequence element (nucleotide coordinates 407-452 of SEQ ID NO:1) present in the murine PPE-1 promoter. It has been previously shown that induction of PPE-1 promoter activity in vascular endothelial cells depends on the presence of this element Bu et al (J. Biol Chem. (1997) 272(19): 32613-32622). The 3X fragment was synthesized by using two complementary single stranded DNA strands 96 base pares in length (BioTechnology industries; Nes Tziona, Israel), (SEQ ID NO: 2 and 3). The two single stranded DNA fragment were annealed and filled using Klenow fragment (NEB); the resulting double stranded DNA was 145 base pairs long and included Nhe-1 restriction sites (SEQ ID NO: 4).
  • the 3X fragment was ligated into the murine PPE-1 promoter down stream of endogenous Nhe-1 site using T4 Ligase.
  • the resulting construct was propagated in DH5 alpha compatent cells and a large-scale plasmid preparation was produced using the maxi-prep Qiagene kit.
  • the PPE-1-Luciferase cassette (5249 bp) containing 1.4 kb of the murine preproendothelin-1 (PPE-1) promoter, the Luciferase gene with an SV40 polyA signal (GenBank Accession number X 65323) site and the first intron of the murine ET-1 gene is originated from the pEL8 plasmid (8848 bp) used by Harats et al (J. Clin. Inv. (1995) 95: 1335-1344).
  • the PPE-1-Luciferase cassette was extracted from the pEL8 plasmid by using the BamHI restriction enzyme, following by extraction of the DNA fragment from a 1% agarose gel using an extraction kit (Qiagen, Hilden, Germany).
  • the promoter-less pPAC.plpA plasmid (7594 bp) containing sequences of the adenovirus type 5 was originated from the pPACCMV.pLpA (8800 bp).
  • the CMV promoter, the multiple cloning site and the SV40 polyadenylation site (1206 bp) were eliminated by NotI restriction enzyme,
  • the fragmented DNA was extracted from 1% agarose gel.
  • the linear plasmid (7594 bp) was filled-in by Klenow fragment and BamHI linker was ligated by rapid DNA ligation kit to both cohesive ends.
  • the linear plasmid was re-ligated by T4 DNA ligase and transformed into DH5 ⁇ competent cells, in order to amplify the pPAC.plpA with the BamHI restriction sites.
  • the plasmid was prepared for large-scale preparation and purified by maxi prep DNA purification kit.
  • the pPACPPE-1Luciferase plasmid was constructed by inserting the PPE-1-Luciferase cassette into the BamHI restriction site of the pPAC.plpA plasmid, by using T4 DNA ligase. The plasmid was subsequently used to transform DH5 ⁇ competent cells.
  • the plasmid (12843 bp) was prepared for large-scale preparation and purified by maxi prep DNA purification kit.
  • the pPACPPE-1GFP plasmid was constructed by sub-cloning the GFP gene (originated from pEGFP, GenBank accession number AAB02572) downstream to the PPE-1 promoter into the NotI restriction site, by T4 DNA ligase.
  • the plasmid was subsequently used to transform DH5 ⁇ competent cells.
  • the plasmid (11,801 bp) was prepared for large-scale preparation and purified by maxi prep DNA purification kit.
  • the pPACPPE-1-3XLuciferase and pPACPPE-1-3XGFP were constructed by inserting the PPE-1-3XLuc or PPE-1-3XGFP cassette digested by BamHI restriction enzyme from pEL8-3X ( FIG. 26B ) containing Luc or GFP into the BamHI restriction site of the pPAC.plpA plasmid.
  • pEL8-3X contains the modified murine PPE-1 promoter (1.55 kb) (red)—located between BamHI and NotI that contains the triplicate endothelial specific enhancer 3X (as set forth in SEQ ID NO.: 7) located between two NheI site.
  • the promoter, the Luciferase or GFP gene, the SV40 poly A sites and the first intron of the endothelin-1 gene, all termed the PPE-1 modified promoter cassette was digested and extracted by BamHI restriction enzyme as described in materials and methods.
  • the plasmids (12843 bp) were prepared for large-scale preparation and purified by maxi prep DNA purification kit.
  • MOI multiplicity of infection
  • mice Male and female 6 month old ApoE gene deficient mice hybrids of C57BL/6xSJ129 mice (Plump A S. et al. Cell (1991) 71:343-353).
  • mice All mice were grown in the Lipids and Atherosclerosis Research Institute.
  • Ad5PPE1Luc or Ad5CMVLuc were suspended in 100 ⁇ l of physiological saline and injected into the tail vein of mice as described hereinabove. Luciferase activity was assayed 1, 5, 14, 30 and 90 days post-injection.
  • Ad5PPE-1GFP or Ad5CMVGFP (10 10 pfu/ml in 100 ⁇ l physiological saline) were injected into the tail vein of normal 3 month old, male C57BL/6 mice. GFP expression was detected five days post-injection. All mice appeared healthy and no toxicity or inflammation was noted in the liver or other tissue.
  • tissue samples from injected mice were fixed in freshly made 4% paraformaldehyde in 0.1 M phosphate buffer for 6 hours at 4° C., soaked overnight in 30% sucrose at 4° C. and frozen in OCT compound (Sakura, Calif., USA).
  • OCT compound Sakura, Calif., USA.
  • the tissue blocks were sliced at 10 ⁇ m thickness and observed directly under fluorescence microscopy (FITC filter).
  • LLC Lewis Lung Carcinoma cells
  • the tumor tissue reached a size of 0.7 mm in diameter, the foot pad (with the primary tumor) was resected under anaesthetic and sterile conditions.
  • the viruses Ad5PPE-1, Ad5PPE-1GFP, Ad5CMVLuc or Ad5CMVGFP were injected to the mouse tail vein.
  • mice were sacrificed 5 days post viral injection, their tissues were excised and tested for Luciferase or GFP activities.
  • mice Male 3 month old C57BL/6 mice were anaesthetized by subcutaneous injection of sodium pentobarbital (6 mg/kg). Their backs were shaved and 5 cm of straight incisions was made. The incisions were immediately sutured by 4/0 sterile silk thread. The angiogenic process in the healing wound was examined every two days by H&E and anti von-Willebrand antibody immunohistochemistry staining.
  • Plasmids and adenoviral vectors for VEGF and PDGF-B transgenic expression were constructed as described in Varda-Bloom, N. et al. [Tissue-specific gene therapy directed to tumor angiogenesis. (2001) Gene Ther 8, 819-27]. Briefly, pACCMV.pLpA plasmid was modified to include either the cDNA for murine VEGF 165 (GenBank Accession number M95200) or rat PDGF-B (GenBank Accession number AF162784), under the regulation of the cytomegalovirus (CMV) immediate early promoter.
  • CMV cytomegalovirus
  • the pACPPE-1-3X plasmids in which the CMV promoter was replaced by the modified murine preproendothelin-1 (PPE-1-3X) promoter, were constructed with the same cDNA sequences. Each of the plasmids was co-transfected with pJM17 plasmid into HEK293 cells, to generate the various recombinant adenoviruses. The viruses were propagated in HEK293 cells and reduced to a concentration of 10 10 PFUs/ml. Control vectors were generated similarly.
  • Ultrasonic imaging Ultrasonic imaging was performed at 7 days intervals following ligation using Synergy ultrasound system (General Electric, USA) at 7.5 MHz in angiographic mode. Animals were awake and restrained while imaging. Animals were accommodated under conventional conditions for up to 90 days.
  • In-situ hybridization 5 ⁇ m skeletal muscle sections were prepared from both hind limbs of ischemic animals. In-situ hybridization with either sense or antisense DIG-labeled probes to VEGF 165 or PDGF-B was performed, and digoxigenin (DIG) was detected by anti-DIG-AP conjugate (Roche Molecular Biochemicals, Mannheim, Germany). Background was stained with methyl green.
  • DIG digoxigenin
  • Image processing Ultrasonic images were processed using the Image-Pro Plus software tools (Media Cybernetics, Silver Spring, Md.). Number of colored pixels indicating the most intensive perfusion was calculated for each image.
  • pro-apoptotic genes including MORT1 (FADD—Fas associated death domain protein, GenBank Accession number NM — 003824), RIP (receptor-interacting-protein, GenBank Accession number U25995), CASH (c-FLIP, GenBank Accession number AF010127), MACH (caspase 8 GenBank Accession number X98172), CPP32 (caspase 3, GenBank Accession number U13737), caspase 9 (U60521) and Fas-chimera (Fas-c), a previously described fusion of two “death receptors”, constructed from the extracellular region of TNFR1 and the trans-membrane and intracellular regions of Fas [Boldin M P et al.
  • MORT1 FADD—Fas associated death domain protein, GenBank Accession number NM — 003824
  • RIP receptor-interacting-protein, GenBank Accession number U25995
  • CASH c-FLIP, GenBank Accession number AF0
  • pro-apoptotic gene constructs were co-expressed along with pGFP in BAEC (Bovine Aortic Endothelial Cells) and 293 cells, which were used as non-endothelial control cells. 24 hours post transfection, cells were analyzed using fluorescent microscopy. Apoptotic cells were identified based on typical morphology, (i.e., small and round shape) using fluorescence microscopy ( FIGS. 2 a - b ). Further assessment of the apoptotic phenotype was effected using electron microscopy ( FIGS. 3 a - f ).
  • Fas-chimera (Fas-c) gene was selected for the generation of an adenoviral-vector to be used in anti-angiogenic therapy.
  • a cDNA encoding a full length Fas-chimera was subcloned into the plasmid pPACPPE1-3x containing the modified pre-proendothelin1 promoter (see FIG. 1 b ).
  • Recombinant adenoviruses were produced by co-transfection of this plasmid with pJM17 plasmid into human embryonic kidney 293 cells. Successful viral cloning was verified via PCR amplification ( FIG. 5 a ).
  • endothelial BAEC cells were transduced with the indicated titer of Ad-PPE-1(3x)-Fas-c.
  • 72h post transduction cells were lysed and cellular proteins resolved using a non-reducing SDS-PAGE gel.
  • Western blot analysis was performed using anti-TNFR1 antibody (Sc-7895, Santa-Cruz Biotech).
  • a prominent band migrating at 45 kD was clearly evident and its expression was dose-dependent, suggesting correct folding and expression of the chimeric protein.
  • no corresponding bands were evident in non-transduced endothelial cells or in cells transduced with control empty viral vector.
  • Ad-PPE-1(3x)-Fas-c Expression Induces Apoptosis in Endothelial Cells
  • Ad-PPE-1(3x)-Fas chimera The ability of Ad-PPE-1(3x)-Fas chimera to induce apoptosis of endothelial cells was determined. As shown in FIGS. 6 a - b , pre-proendothelin directed, adenovirus-mediated transduction of endothelial cells resulted in an evident and massive cell death; HUVEC and BAEC infected with Ad-PPE-1(3x)-Fas-c (10 3 MOI) had morphological features of adherent cells undergoing apoptosis including membrane blebbing, rounding and shrinking and detachment from the culture dish. In contrast, cells infected with control viruses at the same MOI, maintained normal appearance and growth rate. Cells transduced with 100 MOI presented only a minimal degree of cell death (data not shown).
  • Ad-PPE-1(3x)-Fas-c Further assessment of the cytotoxic properties of Ad-PPE-1(3x)-Fas-c was effected by expressing this virus in cells expressing the reporter gene GFP under the control of the PPE-1 promoter. As is evident from FIGS. 6 c - d , most of the transduced cells acquired a typical apoptotic appearance 72 hours following transduction, whereas cells co-transduced with control virus and Ad-PPE-GFP appeared normal.
  • the cytotoxic effect of Fas-c was quantified using crystal violet staining. As shown in FIG. 7 , infection of BAEC and HUVEC with Ad-PPE-Fas-c resulted in mortality rates of 57% and 65%, respectively, while the control virus did not affect cell viability.
  • Ad-PPE-Fas- The endothelial cell specificity of the pro-apoptotic vector Ad-PPE-Fas- was demonstrated by infecting NSF (normal skin fibroblasts) with this vector. These cells, which express low levels of PPE-1 [Varda-Bloom, N. et al. Gene Ther 8, 819-27. (2001)] were not affected by infection with Ad-PPE-Fas-c. In contrast, the recombinant vector Ad-CMV-Fas-c induced apoptotic in these cells.
  • TNF ⁇ The ability of TNF ⁇ to augment the apoptotic effect in Fas-c expressing cells was investigated.
  • Human TNF ⁇ was added to an endothelial cell culture 48 h-post virus infection with Ad-PPE-Fas-c (MOI of 100). Cell viability was assayed 24 h later.
  • TNF ⁇ (10 ng/ml) induced a 73% decrease in viabilty of Ad-PPE-1(3x)-Fas-c infected cells, whereas no significant mortality was effected by TNF ⁇ alone or in cells infected with control virus (Ad-Luc).
  • NSF normal skin fibroblasts
  • DA3 mammary adenocarcinoma
  • D122 Lewis lung carcinoma
  • B16 melanoma cells were infected with Ad-PPE-Fas-c or a control virus. 48 hours later, culture was supplemented with TNF ⁇ and cell morphology was assessed following staining with crystal violet. As shown in FIGS. 9 a - e , non-endothelial cells infected with Ad-PPE-Fas-c displayed normal appearance and were not affected by TNF.
  • FIG. 10 a illustrates the TNF-dependent apoptotic effect of Ad-CMV-Fas-c on endothelial cells. Viability of BAEC cells infected with the indicated MOI of Ad-CMV-Fas-chimera was determined following incubation with TNF.
  • Ad-PPE1(3x)-Fas-c Induces In-vivo Growth Retardation of B16 Melanoma in Mice
  • the B16 melanoma mouse model was used in order to test the anti-tumoral effect of Fas-c expressed from the PPE1-3x promoter.
  • B16 melanoma cells (8 ⁇ 10 5 ) were injected subcutaneously to the flank region of 40 C57bl/6 mice.
  • mice When the tumor was palpable ( ⁇ 5 ⁇ 5 mm), the mice were randomized into 4 groups as follows: (i) control—saline injection; (ii) control virus (Adeno virus containing luciferase controlled by PPE promoter); (iii) Ad-PPE1-3x-Fas-c-virus containing the Fas-TNF receptor chimeric gene controlled by the preproendothelin (PPE) promoter; and (iv) Ad-CMV-Fas-c-virus containing the Fas-TNF receptor chimeric gene controlled by the non-endothelial specific, CMV promoter.
  • control virus Ad-PPE1-3x-Fas-c-virus containing the Fas-TNF receptor chimeric gene controlled by the preproendothelin (PPE) promoter
  • PPE preproendothelin
  • Ad-CMV-Fas-c-virus containing the Fas-TNF receptor chimeric gene controlled by the non-endotheli
  • Tumor size (length and width) was measured using a hand caliper. As shown in FIG. 11 a , tumor size was lower for mice treated with Ad-PPE1-3x-Fas-c or Ad-CMV-Fas-c as compared to control mice. Tumor weights at the end of the treatment period was also lower in the Ad-PPE1-3x-Fas-c treated mice ( FIG. 11 b ). Mice injected with Ad-PPE1-3x-Fas-c showed marked necrosis of their tumor ( FIG. 11 c ).
  • Lewis Lung Carcinoma model Specificity of expression and efficacy of inhibition of tumor growth with PPE-1(3x)-Fas-c chimera was further tested in the metastatic Lewis Lung Carcinoma model.
  • Lung LLC metastases were induced in male C57BL/6J as described in detail hereinbelow, and mice were injected with the viral vectors AdPPe-1 (3x) LUC, AdPPE-1 (3x)-Fas-c, and AdCMV-Fas-c twice, at 9 day intervals (Greenberger et al, J Clin Invest 2004;1 13:1017-1024).
  • Luciferase activity in cells transfected with PPE-1 and PPE-1-3X Luciferase constructs non endothelial Luciferase activity in: endothelial cell lines cell lines Plasmid HUVAC BAEC RIN PPE-1 135.12 1121.3 0.73 PPE-1-3X 768 18331.7 0.32
  • PPE-1/Luciferase, PPE-1-3X/Luciferase, PPE-1/GFP and PPE-1-3X/GFP were also ligated into the Ad5 plasmid to produce Ad5PPE-1/Luc and Ad5PPE-1-3X/luc, Ad5PPE-1/GFP and Ad5PPE-1-3X/GFP (Varda-Bloom et al., (2001) Gene therapy 8:819-827). These constructs were assayed separately as detailed hereinbelow.
  • B2B Human bronchial epithelial
  • BAEC Bovine Aortic Endothelial Cells
  • HUVEC Human Umbilical Vein Endothelial Cells
  • FIG. 13 clearly illustrates that higher Luciferase expression was achieved in endothelial BAEC and HUVEC cell lines with the PPE-1 promoter than with the CMV promoter.
  • the CMV promoter produced more Luciferase activity than the PPE-1 promoter.
  • Ad5PPE-3X/Luciferase and Ad5PPE-3X/GFP constructs were used to transfect the cell lines described hereinabove in Example 7 in order to ascertain the impact of the 3X element on specificity and expression levels.
  • Ad5CMVLuc was used as a non-endothelial-specific control.
  • Higher Luciferase expression in BAEC and HUVEC cell lines was detected under the control of the PPE-3X promoter as compared to the CMV promoter.
  • FIG. 14A is a photomicrograph illustrating GFP expression under the control of Ad5PPE-1-3X in the BAEC cell line.
  • FIG. 14B is a photomicrograph illustrating GFP expression of Ad5CMV in the BAEC line.
  • the PPE-1-3X promoter is more active in endothelial cells. These results clearly indicate that the 3X element does not detract from the endothelial specificity of the PPE-1 promoter. Relative activities of the PPE-1 and PPE-1-3X promoters in cell culture are presented in Example 11 hereinbelow.
  • Hypoxia Responsive Element can Enhance Target Gene Expression in Hypoxic Sensitive Endothelial Cells
  • hypoxia is an important regulator of blood vessels' tone and structure. It has also been shown to be a potent stimulus of angiogenesis (in both ischemic heart diseases and cancer (Semenza, G. L. et al. (2000) Adv Exp Med Biol.; 475:123-30; Williams, K. J. (2001) Breast Cancer Res. 2001: 3;328-31 and Shimo, T. (2001) Cancer Lett. 174;57-64). Further, hypoxia has been reported to regulate the expression of many genes including erythropoietin, VEGF, glycolytic enzymes and ET-1. These genes are controlled by a common oxygen-sensing pathway, an inducible transcription complex termed hypoxia inducible factor-1 (HIF-1).
  • HIF-1 hypoxia inducible factor-1
  • the HIF-1 complex mediates transcriptional responses to hypoxia by binding the cis acting hypoxia responsive element (HRE) of target genes.
  • HRE hypoxia responsive element
  • the HRE is a conserved sequence located in the promoters of few genes that respond to hypoxia including: VEGF, Nitric Oxide Syntase-2, erythropoietin and others including endothelin-1, ET-1.
  • the ET-1 promoter contains an inverted hypoxia response element at position ⁇ 118 bp upstream of the transcription start site, the element contain 7 base pairs and is located between the GATA-2 and AP1 sites 5′ GCACGTT 3′-50 base-pairs. (SEQ ID NO: 5.)
  • the preproendothelin-1 (PPE-1) promoter contains an hypoxia responsive element (HRE) that has the potential to increase its expression in the hypoxic microenvironment of tumor or ischemic tissues, thus making it “tumoral tissue specific” and/or “ischemic tissue specific”.
  • HRE hypoxia responsive element
  • assays of the PPE-1 promoter and PPE-1-3X promoter in conjunction with a Luciferase or GFP reporter gene and delivered by an adenoviral vector were undertaken.
  • Luciferase activity under the control of the PPE-1 promoter or the PPE-1-3X promoter was compared in BAEC cells under normoxic and hypoxic conditions (0.5% O 2 for 16 h).
  • the Luciferase activity under the control of PPE-1 promoter was 5 times higher when exposed to hypoxia ( FIGS. 16 and 17 ).
  • the Luciferase activity under the control of PPE-1-3X promoter was 2.5 times higher under hypoxic conditions.
  • introduction of the 3X element into the PPE 1 promoter is till capable of increasing expression levels of a downstream gene in response to hypoxia, even though the normoxic levels of expression with the PPE-1-3X gene are higher than those observed with the unmodified PPE-1 promoter.
  • FIG. 18 summarizes the results from B2B, HUVEC and BAEC transfection experiments using pPPE-1/Luciferase and pPPE-1-3X/Luciferase.
  • Higher Luciferase expression (30, 8.5 and 1.5 times more) was observed under the control of the PPE-1-3X promoter than under the PPE-1 promoter in B2B, HUVEC and BAEC, respectively.
  • Ad5PPE-1/Luciferase construct was injected into C57BL/6 mice as described hereinabove in “Tissue gene expression in normal mice”. As in the in-vitro studies, Ad5CMV/Luciferase was employed as a negative control.
  • Luciferase activity was found in the liver. Luciferase activity controlled by the PPE-1 promoter was lower in the liver (37-54% of the total body expression).
  • the PPE-1 derived expression was much higher in the aorta (23-33% of the total body expression 5 and 14 days post injection, respectively), compared to Ad5CMV/Luciferase. treated mice (up to 1.8% of total body expression; Table 2). These results confirm the endothelial specificity observed in cell culture. It should be remembered that the liver is a highly vascularized organ. Therefore examination of cellular expression within organs was undertaken, as detailed hereinbelow.
  • the results in the aorta represent the promoters (PPE-1 or CMV) activity mostly in endothelial cells, while the results in the livers represent their activity mostly in hepatocytes.
  • tissue specificity of the PPE-1 promoter is sufficiently strong to effectively eliminate hepatocyte expression, despite preferential uptake of injected DNA by hepatocytes.
  • GFP Green Fluorescent Protein
  • Ad5PPE-1 and Ad5PPE-1-3X In order to determine the relative efficacy of Ad5PPE-1 and Ad5PPE-1-3X in driving expression of the reporter genes Luciferase and green fluorescent protein (GFP) in cells, specific activity in endothelial cells was tested in-vitro using cell lines described hereinabove. Ad5CMVLuc and Ad5CMVGFP were employed as non-tissue specific controls. Ad5PPE-1Luc and Ad5PPE-1GFP were employed to ascertain the relative change in expression level caused by addition of the 3X sequence.
  • Results summarized in FIGS. 21 and 22 , indicate that Luciferase activities under the control of the PPE-1-3X promoter were 5-10 times higher in EC lines (Bovine Aortic Endothelial Cells—BAEC) compared to activity in non-endothelial cells—Rat Insulinoma—RIN, HeLA, HePG2 and normal skin fibroblasts (NSF) ( FIGS. 21 and 22 ).
  • BAEC Bovine Aortic Endothelial Cells
  • NSF normal skin fibroblasts
  • FIG. 21 shows Luciferase activity as light units/ ⁇ g protein in B2B, BAEC and RIN cells transduced by Ad5PPE-1Luc, Ad5PPE-1-3XLuc, and Ad5CMVLuc Highest Luciferase expression was observed in RIN cells transduced by Ad5CMVLuc, however this construct was poorly expressed in BAEC and B2B cells. The next highest level of Luciferase expression was observed in BAEC cells transduced by Ad5PPE-1-3XLuc. Ad5PPE-1Luc was expressed at lower levels in BAEC cells. In the B2B cell line Ad5PPE-1Luc and Ad5PPE-1-3XLuc were expressed at nearly identical levels.
  • FIG. 22 shows Luciferase activity as light units/ ⁇ g protein in HeLA, HepG2, NSF and BAEC cells transduced by Ad5PPE-1Luc, Ad5PPE-1-3XLuc and Ad5CMVLuc. Transduction with Ad5CMVLuc caused high levels of Luciferase expression in HeLA, HepG2 and NSF cells. These cell lines failed to express Luciferase under the control of PPE-1 and expressed Luciferase at low levels with the PPE-1-3X promoter. As expected, BAEC cells transduced with Ad5PPE-1Luc or Ad5PPE-1-3XLuc exhibited high Luciferase expression.
  • panel A indicates Ad5PPE-1-3XGFP transduced cells
  • panel B indicates Ad5PPE-1GFP transduced cells
  • panel C indicates Ad5CMVGFP.
  • Ad5PPE-1-3X-GFP and Ad5PPE-1GFP transduction resulted in no GFP expression in non-endothelial cells SMC, HeLa, HePG2 and normal skin fibroblasts (NSF) compared to the high expression under the CMV promoter as summarized in FIGS. 24-27 .
  • FIG. 25 shows results of a similar experiment conducted in HeLa cells.
  • panel A indicates cells transduced with Ad5PPE-1-3XGFP and panel B indicates cells transduced with Ad5CMVGFP.
  • panel B indicates cells transduced with Ad5CMVGFP.
  • FIG. 26 shows results of a similar experiment conducted in HepG2 cells.
  • panel A indicates cells transduced with Ad5PPE-1(3X)GFP and panel B indicates cells transduced with Ad5CMVGFP.
  • panel B indicates cells transduced with Ad5CMVGFP.
  • FIG. 27 shows results of a similar experiment conducted in NSF cells.
  • panel A indicates cells transduced with Ad5PPE-1-3XGFP and panel B indicates cells transduced with Ad5CMVGFP.
  • panel B indicates cells transduced with Ad5CMVGFP.
  • Ad5PPE-1-3XGFP and Ad5PPE-1GFP were injected into mice as described hereinabove. Five days post-intravenous injection, the mice were sacrificed and their tissues were analyzed by a fluorescent microscopy.
  • FIGS. 28 A-B show representative results.
  • FIG. 28A shows low level GFP expression in endothelial cells lining a blood vessel of a mouse injected with the Ad5PPE-1GFP.
  • FIG. 28B shows the much higher level of GFP expression resulting from addition of the 3 X sequence to the construct.
  • FIGS. 18 and 19 Despite the high expression in the lining of the blood vessels, no expression was detected in the hepatocytes, glomeruli, epithelial cells and splenocytes ( FIGS. 18 and 19 ).
  • FIG. 29 shows representative results from kidney tissue of injected mice.
  • Ad5CMVGFP injected mice FIG. 29A
  • Ad5PPE-1GFP FIG. 29 b
  • Ad5PPE-1-3 ⁇ GFP FIG. 29C
  • FIG. 29B slightly higher GFP expression is visible in the blood vessel wall (indicated by arrow).
  • FIG. 30 shows representative results from spleen tissue of injected mice.
  • Ad5CMVGFP injected mice (FIG. 30A), Ad5PPE-1GFP injected mice ( FIG. 30B ) and Ad5PPE-1-3 ⁇ GFP injected mice ( FIG. 30C ) all exhibited low level GFP activity in cells of the spleen. Higher GFP activity is visible in the blood vessels of Ad5PPE-1-3 ⁇ GFP injected mice (indicated by arrow).
  • both the PPE-1 and the PPE-1-3 ⁇ promoter are endothelial cell specific in-vivo. They further suggest that activity of both promoters was limited in non-proliferating endothelial tissue (i.e. blood vessels of healthy organs. Therefore, assays in a tumor angiogenic model were undertaken.
  • Luciferase expression in tumor neovascularization was tested five days post systemic injections of Ad5PPE-1Luc or Ad5CMVLuc (10 10 pfu/ml each).
  • the Luciferase expression in non-metastatic tissues such as the liver, kidney, heart and pancreas was minimal.
  • the expression level in the aorta was about 30% of the levels in the metastatic lungs.
  • Ad5PPE-1GFP and Ad5CMVGFP constructs were employed to localize reporter gene expression in the primary tumor and metastatic lungs.
  • Ad5PPE-1GFP injected mice showed high levels of GFP specific expression in the blood vessels of the primary tumor ( FIG. 47C ), although no expression was detected in the tumor cells themselves. This observation is consistent with the results of the LLC cell culture model presented in example 20.
  • high levels of GFP expression were detected in both big arteries and small angiogenic vessels of the metastatic foci ( FIG. 47A ). No expression was detected in the normal lung tissue.
  • the endothelial cell localization was demonstrated by co-localization of the GFP expression ( FIG. 47A ) and the CD31 antibody immunostaining ( FIG. 47B ).
  • Ad5CMVGFP injected mice no GFP activity was detectable in both the primary tumor and lung metastasis.
  • FIG. 47C illustrates GFP expression in blood vessels of a primary tumor following intra tumoral injection of Ad5PPE-1GFP.
  • FIG. 47D is a phase contrast image of the same filed as panel C illustrating the tumor and its blood vessels.
  • LLC Lewis Lung Carcinoma
  • FIGS. 31A-D summarize the GFP expression in metastatic lungs of control mice injected with Saline ( FIG. 31A ), mice injected with Ad5CMVGFP ( FIG. 31 B), mice injected with Ad5PPE-1GFP ( FIG. 31C ) and mice injected with Ad5PPE-1-3 ⁇ GFP ( FIG. 31D ).
  • Anti-CD31 immunostaining (FIGS. 31 C′ to 20 D′) confirm the location of the GFP expression in each metastatic tissue. The results show that while no GFP expression was detected in control—saline injected mice ( FIG. 31A ), there was a slight expression around the epithelial bronchi of the CMV injected mice, but not in the angiogenic blood vessels of the metastatic lung of these mice ( FIG.
  • the LLC metastases model was employed. Five days post i.v. injection of 10 10 pfu/ml of Ad5PPE-1Luc, Ad5PPE-1-3 ⁇ Luc, Ad5CMVLuc, Ad5PPE-1GFP, Ad5PPE-1-3 ⁇ -GFP or Ad5CMVGFP, the mice were sacrificed and their tissues were analyzed for Luciferase or GFP expression as described hereinabove.
  • Luciferase expression under the control of the PPE-1-3 ⁇ promoter was 35 fold greater in the metastatic lungs relative to its activity in normal lungs and 3.5 fold higher than expression driven by the PPE-1 promoter without the 3 ⁇ element (p ⁇ 0.001). Very low Luciferase activity was detected in other tissues of mice injected with Ad5PPE-1-3 ⁇ Luc. Calculating the Luciferase expression in the lungs as percentage from the liver of each injected animal revealed that the activity increased 10 fold in the metastatic lung compared to the activity in normal lung ( FIG. 49 ).
  • FIG. 50A-B show the GFP expression ( FIG. 50A ) in metastatic lungs of Ad5PPE-1-3 ⁇ GFP injected mice. Immunostaining by CD31 antibody ( FIG. 50B ) confirm the location of the GFP expression in the new blood vessels. No GFP expression was detected in control—saline injected mice. Low level expression around the epithelial bronchi of the CMV injected mice, but not in the angiogenic-blood vessels of the metastatic lung. In summary, these results indicate that large increases in expression level resulted from introduction of a 3 ⁇ element into Ad5PPE-1 constructs and that this increased expression was specific to the angiogenic blood vessels of tumors. Potentially, the observed effect may be coupled with the hypoxia response described hereinabove to further boost expression levels of a sequence of interest.
  • bovine aortic endothelial cells were transfected by a DNA plasmid (pEL8; FIG. 37A ).
  • the pEL8 plasmid contains the murine PPE-1 promoter (1.4 kb) (red), the luciferase gene (1842 bp), the SV40 poly A sites and the first intron of the endothelin-1 gene, all termed the PPE-1 promoter cassette was digested and extracted by BamHI restriction enzyme as described in material and methods. Following transfection, cells were subjected to hypoxic conditions.
  • Luciferase expression in transfected BAEC subjected to 18 hours of hypoxia (0.5% O2) was eight times higher than Luciferase expression in cells grown in a normoxic environment ( FIG. 32 ).
  • FIG. 32 shows that Luciferase activity (light units/g protein) in BAEC transfected by a plasmid containing the murine PPE-1 promoter was significantly higher when transfected cells were incubated in a hypoxic environment. Equivalent transfection efficiencies were confirmed by co-transfection with a ⁇ -galactosidase reporter vector and assays of LacZ activity.
  • mice In order to examine the murine PPE-1 promoter activity in tissues subjected to regional hypoxia/ischemia, mPPE-1-Luc transgenic mice, described hereinabove in materials and methods, were employed. The mice were induced to regional hind limb ischemia as previously described (Couffinhal T. et al. (1998) Am. J. Pathol. 152;1667-1679). In brief, animals were anesthetized with pentobarbital sodium (40 mg/kg, IP). Unilateral ischemia of the hind limb was induced by ligation of the right femoral artery, approx. 2 mm proximal to the bifurcation of the saphenous and popliteal arteries.
  • Luciferase expression was assayed 2, 5, 10 and 18 days post ligation in the ischemic muscle, in the normal non-ligated muscle, in the liver, lung, and aorta.
  • Luciferase in other non-ischemic tissues including liver, lungs and aorta of the transgenic mice subjected to regional ischemia revealed no significant changes within 18 days post ischemic induction in the Luciferase expression in these tissues ( FIG. 52 ).
  • BAEC endothelial cells
  • Luciferase expression under the control of PPE-1 promoter (open bars; FIG. 28 ) was 4 times higher in normal proliferating BAEC than in quiescent cells, and 25 times higher in normal proliferating BAEC than Luciferase expression under control of the CMV promoter (Black bars; FIG. 28 ). Further, in proliferating cells, the activity under the control of PPE-1 promoter was 10 times higher than that under the CMV promoter control.
  • Ad5PPE-1Luc activity was tested in BAEC induced to rapid proliferation by addition of 40 ng/ml vascular endothelial growth factor (VEGF). Activity under these conditions was compared activity in normal proliferating cells and quiescent cells as described hereinabove. Luciferase expression in BAEC induced to cell proliferation with VEGF was 44 times higher than in normal proliferating cells, and 83 times higher than in quiescent cells ( FIG. 40 ).
  • VEGF vascular endothelial growth factor
  • FIG. 43 is a picture of an aorta dissected from an ApoE deficient mouse colored by Sudan-IV. Note that the thoracic aorta contains less red stained atherosclerotic lesions while the abdominal region is highly atherosclerotic. ( FIG. 43 adapted from Imaging of Aortic atherosclerotic lesions by 1251-HDL and 1251-BSA. A. Shaish et al, Pathobiology-Pathobiol 2001;69:225-9).
  • Luciferase expression controlled by the PPE-1 promoter was 6 fold higher in the highly atherosclerotic abdominal, and 1.6 fold higher in the slightly atherosclerotic thoracic aorta as compared to expression under the control CMV promoter.
  • CMV constitutive promoter
  • Ad5CMVLuc was used as a non-tissue specific control. Luciferase activity under the PPE-1 promoter ( FIG. 45 ; open bars) control was higher both in the normal (6.8 ⁇ 3.2) and in healing wound region (5 ⁇ 1.6) compared to the activity observed under the CMV control ( FIG. 45 ; black bars).
  • the modified preproendothelin-1 promoter, PPE-1-3 ⁇ was used to express in the endothelium of ischemic limb muscles either VEGF or PDGF-B, an endothelial secreted factor which recruits smooth muscle cells towards the origin of secretion thereby preventing hyper permeability of newly formed vessels.
  • VEGF and PDGF-B in-situ hybridization was performed. As shown in FIGS. 54A-C , while a significant expression of VEGF mRNA could be detected in ischemic muscle sections from Ad5PPE-1-3 ⁇ VEGF treated mice, essentially no signal could be seen in muscle sections of Ad5CMVVEGF or saline-treated mice. Similarly, the presence of mRNA of PDGF-B was detected in ischemic limb muscles of mice treated with Ad5PPE-1-3 ⁇ PDGF-B, but not in Ad5CMVPDGF-B or saline-treated mice ( FIGS. 54E-G ). Interestingly, the pattern of the signal in FIGS.
  • FIGS. 54D and 54H representative liver sections from the various treatment groups demonstrated massive expression of VEGF or PDGF-B in Ad5CMV treated animals ( FIGS. 54D and 54H ), while no expression was detected in the livers of Ad5PPE-1-3 ⁇ vectors treated mice (data not shown).
  • the assay indicates that the Ad5PPE-1-3 ⁇ vectors mediate measurable expression of angiogenic factors in a target organ, while the constitutive Ad5CMV vectors expressed their transgene almost exclusively in hepatic tissues.
  • Ad5PPE-1-3 ⁇ VEGF The therapeutic effect of Ad5PPE-1-3 ⁇ VEGF was compared to that of previously reported Ad5CMVVEGF.
  • 10 9 PFUs of either therapeutic vectors, as well as reporter vector Ad5CMVluciferase and equivalent volume of saline as control were systemically administered to mice, 5 days following femoral artery ligation.
  • Ultrasonic (US) images of the medial aspect of both limbs were taken in angiographic mode. As shown in FIGS. 38A-D , 21 days following ligation, the signal of perfusion was diminished and truncated in the control animals; however, continuous, enhanced signal was seen in the US images of both Ad5PPE-1-3 ⁇ VEGF and Ad5CMVVEGF treated mice.
  • the mean intensity of perfusion on the 21 st day in the two VEGF treatment groups was over 3 times higher than that of the control group (p ⁇ 0.01), and similar to that recorded from the normal, contralateral limbs of the animals ( FIG. 38E ).
  • Tissue specific expression versus constitutive expression of pro-angiogenic factors was addressed with respect to the induction of angiogenesis.
  • the effects of PPE-regulated and CMV-regulated VEGF expression on perfusion and angiogenesis were tested in 70 days long experiments. Mice with ischemic limb were treated as above (see Example 28). US imaging revealed significant improvement in perfusion in both treatment groups beginning 1-2 weeks following virus administration, while minor changes were detected in the control group (data not shown).
  • the long-term effect of the Ad5PPE-1-3 ⁇ VEGF treatment was detected 50 and 60 days following femoral artery ligation. Perfusion was significantly increased in the Ad5PPE-1-3 ⁇ VEGF treated mice, as compared to Ad5CMVVEGF or saline-treated mice.
  • PDGF-B is a paracrine endothelial secreted factor, which has been shown to be involved in vessel maturation by recruitment of smooth muscle cells, and probably also in angiogenesis [Edelberg, J. M. et al. Circulation 105, 608-13. (2002); Hsu et al. J Cell Physiol 165, 239-45. (1995); Koyama, N. et al. J Cell Physiol 158, 1-6. (1994)]. It has also been shown that PDGF-B is involved in intimal thickening [Sano, H. et al. Circulation 103, 2955-60. (2001); Kaiser, M., et al. Arthritis Rheum 41, 623-33.
  • Ad5PPE-1-3 ⁇ PDGF-B vector induced angiogenic changes in endothelial cells in-vitro like Ad5PPE-1-3 ⁇ VEGF (data not shown).
  • Transduction of endothelial cells cultured on fibrin coated cultureware with 10 MOI of Ad5PPE-1-3 ⁇ PDGF-B resulted in the formation of 2-dimensional circular structures and fibrin degradation.
  • mice were systemically treated with 10 9 PFUs of Ad5PPE-1-3 ⁇ PDGF-B, 5 days following femoral artery ligation. 30 days following ligation the mean intensity of perfusion in the Ad5PPE-1-3 ⁇ PDGF-B treated mice was about 90% higher than that in the control group ( FIG. 56A ). 80 days following ligation the intensity of perfusion in the Ad5PPE-1-3 ⁇ PDGF-B treated group was 60% higher than in the control group ( FIG. 56B )
  • Capillary density was measured 35 and 90 days following ligation.
  • the mean capillary density in ischemic muscle sections of the Ad5PPE-1-3 ⁇ PDGF-B treated mice was 516 CD31+ cells/mm 2 , while in the saline-treated group it was 439 ( FIG. 56C ).
  • 90 days following ligation the mean capillary density in Ad5PPE-1-3 ⁇ PDGF-B treated mice increased slightly to 566 CD31+ cells/mm 2 , while a moderate decrease was detected in the control group (378 CD31+ cells/mm 2 , FIG. 56D )
  • Ad5PPE-1-3 ⁇ PDGF-B vector by itself is a potent angiogenic treatment, which not only induces angiogenesis in the short term following administration, but is capable of retaining a therapeutic effect for a long period of time. No chronic changes were detected in the livers of the mice treated with Ad5PPE-1-3 ⁇ PDGF-B.
  • the HSV-TK/GCV is the most widely studied and implemented cytoreductive gene-drug combination.
  • Cells transfected with an HSV-TK-containing plasmid or transduced with an HSV-TK containing vector are made sensitive to the drug super-family including aciclovir, ganciclovir (GCV), valciclovir and famciclovir.
  • the guanosine analog GCV is the most active drug in combination with TK.
  • HSV-TK positive cells produce a viral TK, which is three orders of magnitude more efficient in phosphorylating GCV into GCV monophosphate (GCV-MP) than the human TK.
  • GCV-MP is subsequently phosphorylated by the native thymidine kinase into GCV diphosphate and finally to GCV triphosphate (GCV-TP).
  • One plasmid contains the HSV-TK gene controlled by the modified murine pre-proendothelin-1 (PPE-13 ⁇ ) promoter and was prepared in order to test the efficacy of the gene controlled by the PPE-1(3 ⁇ ) promoter in vitro.
  • a larger plasmid containing the HSV-TK gene controlled by the PPE-1(3 ⁇ ) promoter as well as adenoviral sequences was prepared for virus vector preparation by homologous recombination.
  • the HSV-TK gene (1190 bp) was digested from the 4348 bp plasmid pORF-HSV1TK by two restriction enzymes.
  • the SalI restriction site was positioned against the 5′ end of the HSV-TK gene and the EcoRI site was positioned against the 3′ end.
  • the HSV-TK gene was ligated to the multiple cloning site of the 3400 bp plasmid pBluescript-SK that contains a NotI restriction site upstream to the inserted gene (against the 3′ end of the HSV-TK gene).
  • the SalI site underwent the Klenow procedure and the NotI linker was ligated to the 5′ end of the HSV-TK gene.
  • HSV-TK gene (now outflanked by two NotI restriction sites) was ligated into the NotI restriction site of two plasmids, pEL8(3 ⁇ )-Luc and pACPPE-1(3 ⁇ )-GFP, described hereinabove:
  • the 8600 bp plasmid designated pEL8(3 ⁇ )-Luc, instead of the 1842 bp luciferase gene, flanked by two NotI restriction sites.
  • the pEL8(3 ⁇ )-TK plasmid contains the PPE-1(3 ⁇ ) promoter, the HSV-TK gene, an SV-40 poly-adenylation site and the first intron of the murine endothelin-1 gene ( FIG. 60 a ).
  • AdPPE-1(3 ⁇ )-TK The replication-deficient vector, designated AdPPE-1(3 ⁇ )-TK, was constructed on the basis of a first generation (E1 gene deleted, E3 incomplete) adenovirus-5 vector.
  • the recombinant vector was prepared by co-transfection of the plasmids pACPPE-1(3 ⁇ )-TK and pJM-17 (40.3 kb) in human embryonal kidney-293 (HEK-293) using well-known conventional cloning techniques.
  • the pJM-17 plasmid contains the entire adenovirus-5 genome except for the E1 gene.
  • the HEK-293 cell line substitutes the E1 deletions, since they contain an E1 gene in trans.
  • One out of 40 homologous recombinations induced the vector AdPPE-1 (3 ⁇ )-TK.
  • the virus was further purified in HEK-293 cells in order to isolate a single viral clone.
  • the primers designated 2(SEQ ID NO:11) and 3(SEQ ID NO:12) were used, since no product was obtained by the primers 1(SEQ ID NO:9) and 3(SEQ ID NO:10) alone.
  • the result exhibited 99% identity to the Mus musculus Balb/c pre-proendothelin-1 gene, promoter region gi
  • the sequence of AdPPE-1(3 ⁇ ) is detailed in FIG. 92 .
  • the 3 ⁇ sequence ( FIG. 93 ) contains an additional triplicate repeat of the endothelial specific positive transcription elements.
  • this 145 bp sequence there are two complete endothelial specific positive transcription elements and one sequence cut into two fragments in opposite order, as described hereinabove.
  • the vector AdCMV-TK (used as a non tissue-specific promoter control) contains the HSV-TK gene controlled by the early cytomegalovirus (CMV) promoter ( FIG. 62 c .
  • the vector AdPPE-1(3 ⁇ )-Luc contains the luciferase (Luc) gene controlled by the modified murine pre-proendothelin-1 promoter ( FIG. 62 b ).
  • the viruses were grown in scaled up batches and stored at ⁇ 20° C. at a concentration of 10 9 -10 12 particles/ml.
  • AdPPE-1(3 ⁇ )-TK Specific endothelial cell-targeted cytotoxicity of AdPPE-1(3 ⁇ )-TK was assessed in-vitro in endothelial cell lines by comparison to control vectors AdCMV-TK and AdPPE-1 (3 ⁇ )-Luc.
  • AdPPE-1(3 ⁇ )-TK+GCV is cytotoxic at low multiplicity of infection (moi): Bovine aorta endothelial cells (BAECs) were transduced with AdPPE-1(3 ⁇ )-TK, AdCMV-TK and AdPPE-1(3 ⁇ )-Luc multiplicity of infections (m.o.i.) of 0.1, 1, 10, 100, and 1000. GCV (1 ⁇ g/ml) was added four hours post-transduction. Controls were cells transduced with the vectors without GCV, or GCV without vectors. Both controls did not induce cell death (data not shown).
  • AdPPE-1(3 ⁇ )-TK+GCV is cytotoxic at low concentrations of GCV: Bovine aorta endothelial cells (BAECs) were transduced with AdPPE-1(3 ⁇ )-TK, AdCMV-TK and AdPPE-1(3 ⁇ )-Luc, as described hereinabove, at multiplicity of infection (m.o.i.) of 10, and exposed to increasing concentrations of GCV (0.001-10 ⁇ g/ml, as indicated), added four hours post-transduction. Control cells transduced with the vectors without GCV, or receiving GCV without vectors show no indication of cell death (data not shown) at any concentrations.
  • BAECs Bovine aorta endothelial cells
  • AdPPE-1(3 ⁇ )-TK+GCV cytotoxicity is specific for endothelial cells:
  • endothelial Bovine aortic endothelial cells (BAEC), Human umbilical vein endothelial cells (HUVEC)] and non-endothelial [Human hepatoma cells (HepG-2), Human normal skin fibroblasts (NSF)] cells were transduced with AdPPE-1(3 ⁇ )-TK, AdPPE-1(3 ⁇ )-Luc or AdCMV-TK at m.o.i.
  • AdPPE-1(3 ⁇ )-Luc+GCV were nontoxic to all cell types ( FIG. 67 ). Assessment of cell viability, determined by staining with crystal violet ( FIG.
  • AdCMV-TK+GCV strong constitutive CMV promoter
  • AdPPE-1(3 ⁇ )-TK When non-endothelial NSF cells were transduced with AdPPE-1(3 ⁇ )-TK, AdPPE-1(3 ⁇ )-Luc or AdCMV-TK, at the higher m.o.i. of 100, followed by the administration of 1 ⁇ g/ml GCV four hours post-transduction, no effect of AdPPE-1(3 ⁇ )-TK+GCV on cell morphology was observed ( FIG. 69 ). In contrast, cells treated with TK under control of the strong constitutive CMV promoter (AdCMV-TK+GCV) showed strong non-specific cytotoxicity, confirming the endothelial selective cytotoxicity of TK under control of the PPE-1 (3 ⁇ ) promoter and ganciclovir administration, even at extreme multiplicity of infection.
  • AdPPE-1(3 ⁇ )-TK The therapeutic efficacy of the specific endothelial cell-targeted cytotoxicity of AdPPE-1(3 ⁇ )-TK was assessed in-vivo by comparison to systemic administration of GCV and control vectors AdCMV-TK and AdPPE-1(3 ⁇ )-Luc, in animal models of cancer tumorigenesis and metastatic growth.
  • Lewis Lung Carcinoma Synergic suppression of metastatic growth in Lewis Lung Carcinoma (LLC) by in viva expression of TK under control of the PPE-1 (3 ⁇ ) promoter and ganciclovir (GCV) administration: Lewis Lung Carcinoma is a well-characterized animal model of severely aggressive, malignant cancer with high metastatic potential.
  • Adenovirus vectors [AdPPE-1(3 ⁇ )-TK+GCV; AdCMV-TK+GCV; AdPPE-1(3 ⁇ )-TK without GCV] were administered intravenously five days post primary tumor removal followed by daily intraperitoneal GCV administration for 14 days.
  • mice exclusion was as follows: 22 mice were excluded since no primary tumor developed, one mouse was excluded due to vector injection failure, 8 mice died without any traces of lung metastasis. Of the excluded mice, 18 mice were excluded before enrollment, 6 were excluded from group 1(AdPPE-1(3 ⁇ )-TK+GCV), 2 from group 2(AdCMV-TK+GCV), 3 from group 3(AdPPE-1(3 ⁇ )-TK without GCV) and 2 from group 4 (Saline+GCV). The mice were sacrificed on the 24 h day post vector injection. On that day 25% of the mice in the control groups (saline+GCV and AdPPE-1(3 ⁇ )-TK without GCV) had died from the spread of lung metastases. FIG.
  • 70 shows representative lung tissue from treated and control groups, showing the significantly reduced extent of metastatic spread in the lungs of AdPPE-1 (3 ⁇ ) -TK+GCV treated mice, compared to those from mice treated with AdCMV-TK+GCV, AdPPE-1 (3 ⁇ )-TK without GCV and GCV without adenovirus.
  • the mean weight (an indication of extent of metastatic disease) of the metastases of mice treated with AdPPE-1(3 ⁇ )-TK+GCV was 3.3 times lower than that of mice treated with AdPPE-1(3 ⁇ )-TK without GCV (mean ⁇ SE: 0.3g ⁇ 0.04 vs. 0.8g ⁇ 0.2, respectively; p ⁇ 0.05).
  • the mean weight of the metastases of mice treated with AdCMV-TK+GCV or with saline+GCV was not statistically different from that of the other groups ( FIG. 71 ).
  • Cytotoxic effect of in vivo expression of TK under control of the PPE-1 (3 ⁇ ) promoter and ganciclovir (GCV) on metastatic lung tissue In order to determine the mechanism of the effect of AdPPE-1(3 ⁇ ) and GCV administration on LLC metastatic growth, hematoxylin and eosin staining was performed on lung tissue from metastatic lungs ( FIGS. 72 a - 72 c ). Mild peripheral necrosis was detected in lung metastases taken from mice treated with AdPPE-1(3 ⁇ )-TK without GCV or saline+GCV ( FIG. 72 a ).
  • Lung tissue taken from mice treated with AdPPE-1(3 ⁇ )-TK+GCV demonstrated alveolar and peribronchial mononuclear infiltrates, while no infiltrates were detected in lungs taken from mice treated with AdPPE-1(3 ⁇ )-TK without GCV or saline+GCV.
  • Lung metastases taken from mice treated with AdPPE-1(3 ⁇ )-TK+GCV demonstrated clusters of mononuclear infiltrates compared to metastases taken from mice treated with AdPPE-1(3 ⁇ )-TK without GCV or saline+GCV ( FIG. 72 b,c ).
  • CD-31 is a characteristic endothelial cell marker of angiogenesis. Anti CD-31 staining was performed on metastatic lung tissue in order to determine the involvement of endothelial cells in the anti-metastatic effects of systemic AdPPE-1(3 ⁇ )+GCV.
  • FIGS. 75 a - 75 d reveal that angiogenic vessels in lung metastases from AdPPE-1(3 ⁇ )-TK+GCV treated mice were short, without continuity or branching and with indistinct borders ( FIGS. 75 a - 75 c ).
  • Angiogenic blood vessels in lung metastases from mice treated with AdPPE-1(3 ⁇ )-TK without GCV or saline+GCV demonstrated long blood vessels with abundant branching and distinct borders ( FIG. 75 a ).
  • the specificity of this anti-angiogeneic effect for proliferating endothelial tissue is shown by the absence of effect on hepatic blood vessels ( FIG. 75 c ).
  • Systemic AdCMV-TK+GCV administration induces hepatotoxicity in mice bearing LLC lung metastases. Since one of the major side effects of systemic administration of adenovirus vectors is liver toxicity, liver morphology was assayed in C57Bl/6 mice with induced LLC tumors.
  • livers from treated mice treated with TK under control of the constitutive promoter AdCMV-TK+GCV exhibited portal and periportal mononuclear infiltrates and small confluent necrotic areas, whereas livers from mice treated with AdPPE-1(3 ⁇ )-TK+GCV, and control groups, exhibited only minimal mononuclear infiltrates and hepatocyte nuclear enlargement ( FIG. 76 ).
  • the results demonstrate that while constitutive expression of TK under control of the CMV promoter is clearly hepatotoxic, no adverse side effects on liver morphology were observed with the angiogenesis-specific AdPPE-1(3 ⁇ )-TK+GCV treatment.
  • mice Nine C57BL/6 male mice aged 15 weeks were enrolled. LLC lung metastases were induced by inoculation of the left foot with tumor cells and foot amputation as soon as the primary tumor developed. Adenovirus vectors (AdPPE-1(3 ⁇ )-TK and AdCMV-TK) or saline were delivered intravenously 14 days post primary tumor removal. The mice were sacrificed 6 days post vector injection and RNA was extracted from the harvested organs, as described. Reverse transcriptase-PCR was performed on RNA followed by PCR using HSV-TK and ⁇ -actin primers. Positive HSV-TK expression was detected in the lungs of mice treated with AdPPE-1(3 ⁇ )-TK, while no HSV-TK expression was detected in the liver.
  • AdPPE-1(3 ⁇ )-TK AdCMV-TK
  • HSV-TK expression was detected in the livers of mice treated with AdCMV-TK and no expression was detected in the lungs ( FIG. 77 ).
  • Computer based densitometery (Optiquant, Packard-Instruments), corrected for ⁇ -actin, demonstrated lung/liver expression ratio of 11.3 in the AdPPE-1(3 ⁇ )-TK treated mice, compared with the liver/lung expression ratio of 5.8 in the AdCMV-TK treated mice.
  • AdCMV-TK treated mice expression of TK under control of the CMV promoter was prominent in Coxsackie adenovirus receptor-rich organs, such as the liver ( FIG. 77 ). Strong positive HSV-TK expression was also detected in testis of AdPPE-1(3 ⁇ )-TK treated mice. While not wishing to be limited by a single hypothesis, it will be appreciated that the positive expression in the AdPPE-1(3 ⁇ )-TK treated mouse is likely explained by a high expression of endothelin promoter in the gonads. The positive expression in the AdCMV-TK treated mouse is explained by the relatively high RNA elution, as mirrored by the highly positive ⁇ -actin band.
  • Multiple modality anticancer therapies provide significant advantages over individual therapies, both in terms of reduction in required dosages and duration of treatment, leading to a reduction in undesirable side effects, and in terms of greater efficacy of treatment arising from synergic convergence of different therapeutic mechanisms (for a recent review, see Fang et al, Curr Opin Mol Ther 2003; 5:475-82).
  • AdPPE-1(3 ⁇ )-TK+GCV administration in multimodality therapy, the effect of systemic AdPPE-1 (3 ⁇ )-TK+GCV administration on a slow growing primary CT-26 colon carcinoma in Balb/C mice, and metastatic Lewis Lung Carcinoma in C57Bl/6 mice, combined with single-dose radiotherapy was assessed.
  • V ganciclovir
  • AdPPE-1(3 ⁇ )-TK+GCV+radiotherapy suppressed tumor progression compared to the other treatment regimens.
  • the duration of mean tumor suppression was approximately 2 weeks, which is compatible with the duration of adenovirus activity.
  • Radiotherapy significantly potentiated only the angiogenic endothelial cell transcription-targeted vector, AdPPE-1(3 ⁇ )-TK, compared to the non-targeted vector, AdCMV-TK (p 0.04) ( FIG. 79 c - f ). Treatment regimens with all virus vectors were ineffective without radiotherapy.
  • AdPPE-1(3 ⁇ )-TK+GCV combined with radiotherapy induces massive tumor necrosis:
  • hematoxylin and eosin staining was performed on tumor tissue. Tumor tissue was hypercellular, condensed and with a high mitotic index. Two elements were detected in all groups: necrosis and granulation tissue within the necrotic area. Tumors taken from mice treated with regimens that included radiation exhibited larger necrotic areas and granulated tissue than tumors taken from non-irradiated mice. In these groups, necrosis ( FIG. 80 a ) and granulation tissue ( FIG.
  • mice treated with AdPPE-1(3 ⁇ )-TK+GCV combined with radiotherapy exhibited the most extensive necrosis and granulation tissue ( FIG. 80 a and 80 b ), estimated at approximately 55%-80% of the specimen area ( FIG. 80 ).
  • Tumors taken from mice treated with AdPPE-1(3 ⁇ )-TK+GCV without radiotherapy exhibited a relatively larger necrotic area than the other non-irradiated groups (data not shown). The results suggest that AdPPE-1(3 ⁇ )-TK+GCV+radiotherapy induce massive central tumor necrosis, which is partially replaced by granulation tissue.
  • AdPPE-1(3 ⁇ )-TK+GCV combined with radiotherapy induce endothelial cell and massive tumor apoptosis:
  • TUNEL and anti-caspase-3 staining were performed on tumor tissues in order to demonstrate apoptotic cells.
  • TUNEL staining demonstrated apoptotic tumor cells surrounding a central necrotic area in irradiated groups. More apoptotic tumor cells were detected in tumors taken from mice treated with AdPPE-1(3 ⁇ )-TK+GCV combined with radiotherapy than in any other group ( FIG. 30 a ).
  • necrotic areas surrounded by apoptotic tumor cells had a serpentine shape and were unique in containing an increased vascular density ( FIG. 81 b ).
  • Endothelial cells of blood vessels within apoptotic areas exhibited positive anti-caspase-3 staining ( FIG. 82 ).
  • AdPPE-1(3 ⁇ )-TK+GCV combined with radiotherapy induces massive tumor cell apoptosis surrounding a necrotic area in colon cancer tumors.
  • the increased angiogenic vessel density within tumor apoptotic areas, the shape of the necrosis and apoptotic areas and the existence of endothelial cell apoptosis indicate perivascular necrosis secondary to angiogenic tissue damage.
  • CD-31 is a characteristic endothelial cell marker of angiogenesis.
  • Anti CD-31 immuno-staining was performed on tumor tissues in order to demonstrate direct effects of the combined therapy on endothelial cells.
  • Angiogenic vessels in sections of tumors taken from mice treated with a regimen that includes irradiation alone were short, without continuity or branching and with indistinct borders.
  • Administration of vector alone, without GCV, caused no abnormalities FIG. 83 a ), while AdPPE-1(3 ⁇ )-TK+GCV combined with radiotherapy demonstrated the most extensive vascular abnormalities ( FIG. 32 a ).
  • Hepatic blood vessels were not affected ( FIG. 83 b )
  • the results indicate that administration of AdPP1(3 ⁇ )-TK+GCV, combined with radiotherapy induces extensive vascular disruption in angiogenic vessels.
  • hepatic endothelial cells were not affected by the vector AdPPE-1(3 ⁇ )-TK+GCV combined with radiotherapy ( FIG. 84 , right panel).
  • the results demonstrate that the adenovirus vector expressing HSV-TK controlled by the CMV promoter is relatively hepatotoxic.
  • AdPPE-1(3 ⁇ )-TK+GCV is safe for intravenous administration.
  • the vector efficiently suppresses slow growing primary tumor progression only in combination with non-toxic, locally-delivered radiotherapy is added. Without wishing to be limited to a single hypothesis, it seems likely that specific suppression of tumor angiogenesis, via apoptosis, appears to be the mechanism for tumor suppression.
  • the cytotoxic activity of the AdPPE-1(3 ⁇ )-TK vector is dependent upon administration of GCV and radiotherapy.
  • Radiotherapy is non-toxic and sub-therapeutic to C57Bl/6 mice bearing Lewis Lung Carcinoma metastases: 35 C57BL/6 male mice aged 8 weeks were inoculated with LLC cells into the left footpad. The foot was amputated under general anesthesia as soon as the primary tumor developed. 8 days post foot amputation a single dose of radiotherapy aimed at the mouse's chest wall was administered under general anesthesia. Five radiation doses were examined: 0, 2, 50, 10 and 15 Gy. 3-4 weeks post primary tumor removal the non-irradiated mice began to loose weight, which is a sign of metastatic disease. Mouse sacrifice was therefore scheduled for the 28 th day post primary tumor removal. Mouse well-being was monitored daily by observation and weighing.
  • mice treated with 15 Gy died within 5 days post-irradiation, without any signs of lung metastasis.
  • mice were divided into 6 groups: 1. Ad5PPE-1(3 ⁇ )-TK+GCV. 2. Ad5CMV-TK+GCV, 3. saline+GCV, 4. Ad5PPE-1(3 ⁇ )-TK+GCV+radiotherapy, 5. Ad5CMV-TK+GCV+radiotherapy, and 6. saline+GCV+radiotherapy.
  • Mouse exclusion Four mice died soon after leg amputation, four mice were excluded since primary tumor development, 12 mice died without any trace of lung metastasis, 1 mouse was excluded because of bilateral eye discharge. Of the excluded mice, 14 were excluded before enrollment, 2 were excluded from group 1, 2 from group 2, 2 from group 3, 4 from group 4, 3 from group 5 and 1 from group 6.
  • radiotherapy significantly potentiated only the angiogenic endothelial cell transcription-targeted vector, AdPPE-1(3 ⁇ )-TK, compared to the non-targeted vector, AdCMV-TK (p 0.04) ( FIG. 86 b - d ).
  • the results show that combined treatment of systemically administered AdPPE-1(3 ⁇ )-TK vector+GCV+single dose radiotherapy synergically prolongs survival in metastatic disease.
  • AdPPE-1 (3 ⁇ )-Fas-c having a PPE-1(3 ⁇ ) promoter in combination with Fas-chimera (Fas-c, see detailed description hereinabove) was administered to BAEcells alone, and in combination with the anthracycline glycoside doxorubicin (DOX).
  • DOX anthracycline glycoside doxorubicin
  • Apoptosis as measured by cell survival (% viability, assessed by crystal violet staining) of BAE cells, was significantly greater in mice treated with AdPPE-1 (3 ⁇ ) -Fas-c+DOX than with either AdPPE-1 (3 ⁇ )-Fas-c or DOX alone ( FIG. 91 ).
  • Bovine Aortic Endothelial cells BAEC
  • Human Normal skin fibroblasts NSF cell-lines are cultured in low glucose DMEM containing 10% heat inactivated FCS, 100 ⁇ g/ml penicillin and 100 ⁇ g/ml streptomycin.
  • HeLa Human cervix epithelial adenocarcinoma
  • Lewis Lung Carcinoma cells D122-96
  • 293 human embryonic kidney cell-lines are cultured in high glucose DMEM containing 10% heat inactivated FCS, 100 ⁇ g/ml penicillin, 100 ⁇ g/ml streptomycin.
  • Human Umbilical Endothelial Cells (Cambrex Bio Science Walkersville, Inc.) are cultured in EGM-2 Bullet kit (Clonetics, Bio-Whittaker, Inc., MD, USA).
  • Human lung carcinoma cell line (A549) are cultured in MEM containing 10% heat inactivated FCS, 100 ⁇ g/ml penicillin and 100 ⁇ g/ml streptomycin. All cells are grown in 37° C., 5% CO 2 , humidified atmosphere.
  • Plasmid cloning The cDNA of firefly luciferase was sub-cloned into the multiple cloning site of pcDNAIII expression plasmid (containing CMV promoter region, Invitrogen), and into pPACPPE-1.plpA, which contains PPE1-3 ⁇ promoter and parts of the adenovirus-5 DNA sequence. A third plasmid was cloned by deleting the first intron of PPE-1 promoter from pPACPPE-1.plpA plasmid. The three plasmids were previously cloned in our lab and were used in cell culture transfections.
  • Replication deficient vectors cloning The cDNA of FAS-chimera was sub-cloned into pPACPPE-1.plpA and pPACCMV.plpA plasmids. These plasmids were co-transfected with pJM17 that contains most of the adenovirus-5 genome and were co-transfected with calcium phosphate method into 293 human embryonic kidney cell-line (ATCC). This cell-line was designed to include the E1 gene that is necessary for viral replication but is not included in the pPAC.plpA or pJM17 plasmids.
  • the plasmids undergo homologous recombination within the cells, and after approximately two weeks recombinant viruses are formed and start to replicate and finally cause cell lysis. Viral colonies are separated and propagated and their accurate insert orientation is verified by PCR.
  • the replication deficient vectors were previously prepared by conventional prior art cloning techniques.
  • CRAD Conditionally replicating adenovirus construction: The CRADs were constructed using the AdEasy method (Stratagene, LaJolla Calif.). PShuttle-MK, a plasmid containing parts of the adenovirus-5 DNA sequence, has been modified as follows: the multiple cloning site and right arm in pShuttle (Stratagene, La Jolla, Calif.) were replaced by Midkine (mk) promoter and the consecutive adenoviral E1 region. Later, the MK promoter was replaced by PPE1-3 ⁇ without intron.
  • AdEasy method (Stratagene, LaJolla Calif.).
  • PShuttle-MK a plasmid containing parts of the adenovirus-5 DNA sequence, has been modified as follows: the multiple cloning site and right arm in pShuttle (Stratagene, La Jolla, Calif.) were replaced by Midkine (mk) promoter and the consecutive adenoviral
  • a second plasmid was constructed by subcloning IRES sequence (from p IRES-EYFP plasmid, BD Biosciences) and FAS-chimera cDNA between the promoter and E1. IRES permits translation of two proteins from the same transcript.
  • the resultant two shuttles were linearized with Pmel digestion and subsequently transformed into Escherichia coli BJ5183ADEASY-1 (Stratagene). This type of bacteria has already been transformed with pADEASY-1 plasmid, which contains most of the adenovirus-5 sequence, except E1 and E3 gene regions.
  • the plasmids undergo homologous recombination within the bacteria (between pShuttle and pADEASY-1), thus creating the complete vector genome.
  • the recombinants were later PacI digested and transfected with calcium phosphate method into 293 human embryonic kidney cell-line (ATCC). The rest of the procedure is as described for the replication deficient vectors.
  • the positive control virus CMV-E1 was constructed by subcloning the general promoter CMV (cytomegalovirus) before the E1 gene.
  • CMV-E1 virus is ubiquitious and has no specificity to endothelial cells.
  • PPE-1(3 ⁇ )-FAS CMV-FAS
  • CMV-LUC abbreviation for firefly luciferase reporter gene
  • Transfection experiments BAEC and HeLa cells were cultured in 24-wells plates to 60-70% confluence. Cotransfection was done using 0.4 ⁇ g/well of expression construct and 0.04 ⁇ g/well of pEGFP-Cl vector (CLONTECH, Palo Alto, Calif.) as a control for transfection efficiency. Lipofectamine and Lipofectamine plus (Invitrogen, Carlsbad, Calif.) were used for transfection. After 3 hours of incubation at 37° c., transfection mixture was replaced with growth medium.
  • Vectors (PPE-FAS, CMV-FAS, CMV-LUC, PPE-LUC) were diluted with the infection growth media (Contains 2% FCS instead of 10% in normal growth media) in order to reach to multiplicity of infection (moi) of 10,100,1000,10000.
  • the multiplicity of infection was calculated as the number of viruses per target cell.
  • Target cells (BAEC and 293) had been seeded 24 hours before transduction.
  • cell's growth media was replaced with solution containing the viruses in the desired moi's mixed in 0.1 or 2 ml infection media for 96 wells plate or 60 mm plate, respectively. The cells were incubated for 4 hours, followed by the addition of fresh medium to the transduced cells.
  • PFU Proliferative Forming Unit assay
  • the viral stocks were titered and stored at ⁇ 80° C.
  • Sub-confluent (80%) culture of 293 cells was infected for 2 hours by the viral vector diluted with the infection media for serial dilutions (10 ⁇ 2 -10 ⁇ 13 ). After two hours the medium was washed by PBS and was replaced by agar overlay. The highest dilution in which plaques are apparent after approximately 2 weeks, is considered the concentration in units of PFU/ml (PFU—plaque forming units).
  • Cytotoxic gene expression enhances Adenovirus replication In order to test the influence of apoptotic induction on viral replication, CMV-FAS replication was tested in the 293 (human embryonic kidney) cell-line. In this cell-line the virus can induce apoptosis by FAS-c or cell lysis as a result of its replication. Early (a few hours after viral infection) apoptosis might interfere with viral replication, while late apoptosis (a few days after viral infection) might enhance viral spread.
  • CMV-FAS In order to test the ability of CMV-FAS to induce apoptosis, BAEC were transduced, and cell apoptosis was evaluated by ELISA-crystal violet assay of viability ( FIG. 89 ).
  • CMV-FAS at higher concentration (10000 moi) induced apoptosis without the activating ligand (TNF- ⁇ ), while in lower concentrations there was a need for addition of the ligand in order to induce apoptosis.
  • CMV-FAS spread from cell to cell was assayed by plaque development in 293 cells. Plaque development occurred at a higher rate with the CMV-FAS vector, compared to a non-apoptosis inducing vector—CMV-LUC, as observed ( FIGS. 88 and 89 ) according to the rate of plaque development and size of plaques.
  • CMV-LUC non-apoptosis inducing vector
  • adenovirus vectors such as the angiogenic, endothelial-specific viral construct AdPPE-1(3 ⁇ ) described hereinabove, bearing apoptosis-inducing “killer” genes such as FAS, can be enhanced by the additional apoptotic lysis of the host cells.
  • FIG. 91 a shows that infection of the cells with Ad5PPEC-1-3 ⁇ VEGF has an inductive effect on number and size of vessels-like structures formed in the engineered constructs.
  • Constructs were grown with or without VEGF supplementation to the medium (50 ng/ml).
  • Parallel constructs were infected with Ad5PPEC-1-3 ⁇ VEGF viruses or control GFP adenoviruses (for 4 hours). Following 2 weeks in culture the constructs were fixed, embedded, sectioned and stained.
  • constructs were permeated with host blood vessels.
  • Constructs infected with Ad5PPEC-1-3 ⁇ VEGF virus showed an increase in vessel structures compared to control constructs.
  • the in vivo imaging system works by detecting light generated by the interaction of systemically administered luciferin with locally produced luciferase.
  • Constructs were infected with Adeno Associated Virus (AAV) vector encoding luciferase for 48 hours prior to transplantation.
  • AAV-Luciferase was injected into the left lower extremity of each mouse at the time of surgery to serve as a positive control.
  • the mice received luciferin to assess perfusion to the tissue-engineered construct.
  • a common response of many tissues to repression of angiogenesis is the upregulation of endogenous angiogenic pathways, in response to complex signaling generated by the auto-regulated autocrine feedback loops governing vascular homeostasis (see Hahn et al, Am J Med 1993, 94:13S -19S, and Schramek et al, Senim Nephrol 1995;15:195-204).
  • Bosentan is a dual endothelin receptor (ETA and ETB) antagonist presently clinically approved for a variety of indications, most importantly pulmonary arterial hypertension and pulmonary fibrosis.
  • Transgenic mice bearing the PPE-1(3 ⁇ )-LUC construct of the present invention were produced by cloning methods well known in the art, as described in detail hereinabove.
  • Mice were sacrificed on the last day of treatment and organs, the organs of the mice removed for measurement of luminescence intensity, as described in the Methods section hereinabove.
  • FIG. 94 shows that the PPE-1 (3 ⁇ ) promoter confers tissue specific over-expression of the recombinant gene in the transgenic mice.
  • endothelin receptor antagonists in particular, and inhibitors of angiogenesis in general, can activate the endothelial specific promoters of the present invention, and induce further enhancement of expression of transgenes under PPE-1 (3 ⁇ ) transcriptional control, in a tissue specific manner.
  • transgenic protein As described hereinabove, gene therapy, as other long-term therapeutic modalities, is often complicated by endogenous host immune reaction to continued exposure to expressed transgenic protein. Immune stimulation by the transgenic protein can cause reduced efficacy of treatment, inflammation, and sometimes severe side effects.
  • antibody titers against adenoviral hexone and TNF-R1 were assayed in mice bearing LLC micrometastases, and treated with vectors bearing the Fas-TNF-R1 chimera (Ad5PPE-1(3 ⁇ ) Fas-c and Ad5CMV Fas-c), or the LUC reporter gene (Ad5PPE-1(3 ⁇ ) Luc) (6 mice per group). Control mice were treated with saline.
  • Vectors were injected 3 times, at an interval of 5 days between injection. Mice were sacrificed 10 days after last vector injection, for determination of levels of antibodies against the adenovirus and against human TNF-R1, the protein expressed by the transgene inserted, using an ELISA assay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
US10/988,487 2000-11-17 2004-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis Expired - Fee Related US8071740B2 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
US10/988,487 US8071740B2 (en) 2000-11-17 2004-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
KR1020077013464A KR101313257B1 (ko) 2004-11-14 2005-11-14 내피 세포 특이성을 나타내는 프로모터 및 이를 이용하여혈관신생을 조절하는 방법
MX2007005783A MX2007005783A (es) 2004-11-14 2005-11-14 Promotores que exhiben especificidad celular endotelial y metodo para usarlos para la regulacion de angiogenesis.
EP10185195A EP2301586B1 (en) 2004-11-14 2005-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
CN201210086460.1A CN102698287B (zh) 2004-11-14 2005-11-14 表现出内皮细胞特异性的启动子和使用其调节血管生成的方法
EP09168899A EP2174668B1 (en) 2004-11-14 2005-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2005303385A AU2005303385B2 (en) 2004-11-14 2005-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
EP10184033.8A EP2301585B1 (en) 2004-11-14 2005-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
PCT/IL2005/001195 WO2006051545A2 (en) 2004-11-14 2005-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
CA2913047A CA2913047A1 (en) 2004-11-14 2005-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
JP2007540833A JP2008519596A (ja) 2004-11-14 2005-11-14 内皮細胞特異性を示すプロモーター及びそのプロモーターを使って血管形成を制御する方法
CNA2005800464128A CN101098882A (zh) 2004-11-14 2005-11-14 表现出内皮细胞特异性的启动子和使用其调节血管生成的方法
NZ580289A NZ580289A (en) 2004-11-14 2005-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
NZ555612A NZ555612A (en) 2004-11-14 2005-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AT09168899T ATE531392T1 (de) 2004-11-14 2005-11-14 Promotoren mit endothelzellenspezifität und verfahren zu deren anwendung zur steuerung der angiogenese
EP05806361A EP1814897A4 (en) 2004-11-14 2005-11-14 PROMOTERS HAVING ENDOTHELIAL CELLULAR SPECIFICITY AND METHODS OF USE FOR REGULATING ANGIOGENESIS
CA2587469A CA2587469C (en) 2004-11-14 2005-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
KR1020137013132A KR101396454B1 (ko) 2004-11-14 2005-11-14 내피 세포 특이성을 나타내는 프로모터 및 이를 이용하여 혈관신생을 조절하는 방법
KR1020137031896A KR101522309B1 (ko) 2004-11-14 2005-11-14 내피 세포 특이성을 나타내는 프로모터 및 이를 이용하여 혈관신생을 조절하는 방법
SG201102612-7A SG171581A1 (en) 2004-11-14 2005-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US11/359,513 US8039261B2 (en) 2000-11-17 2006-05-23 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US12/224,178 US20100282634A1 (en) 2000-11-17 2007-02-22 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US11/790,992 US20070286845A1 (en) 2000-11-17 2007-04-30 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
IL183187A IL183187A (en) 2004-11-14 2007-05-14 Nucleic acid constructs and preparations for inhibiting angiogenesis
ZA200704687A ZA200704687B (en) 2004-11-14 2007-06-05 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US12/591,252 US20100081193A1 (en) 2000-11-17 2009-11-13 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
HK10109638.7A HK1143078B (en) 2004-11-14 2010-10-12 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
IL209034A IL209034A (en) 2004-11-14 2010-10-31 Promoters with endothelial cell specificity and methods for their use in angiogenesis control
US13/018,447 US8206743B2 (en) 2000-11-17 2011-02-01 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
IL211489A IL211489A (en) 2004-11-14 2011-02-28 Vectors and pharmaceutical compounds for inhibiting angiogenesis
US13/098,512 US20110207985A1 (en) 2000-11-17 2011-05-02 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
JP2011191492A JP5728337B2 (ja) 2004-11-14 2011-09-02 内皮細胞特異性を示すプロモーター及びそのプロモーターを使って血管形成を制御する方法
US13/549,355 US8835398B2 (en) 2000-11-17 2012-07-13 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US14/059,426 US20140155467A1 (en) 2000-11-17 2013-10-21 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
JP2014205463A JP2015057057A (ja) 2004-11-14 2014-10-06 内皮細胞特異性を示すプロモーター及びそのプロモーターを使って血管形成を制御する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24858200P 2000-11-17 2000-11-17
US33011801P 2001-10-19 2001-10-19
PCT/IL2001/001059 WO2002040629A2 (en) 2000-11-17 2001-11-15 Promoters exhibiting endothelial cell specificity and methods of using same
US10/135,447 US7067649B2 (en) 2000-11-17 2002-05-01 Promoters exhibiting endothelial cell specificity and methods of using same
PCT/IL2002/000339 WO2003033514A1 (en) 2001-10-19 2002-05-01 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US10/490,746 US7585666B2 (en) 2001-10-19 2002-05-01 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US10/988,487 US8071740B2 (en) 2000-11-17 2004-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
US10490746 Continuation-In-Part 2002-05-01
US10/490,746 Continuation-In-Part US7585666B2 (en) 2000-11-17 2002-05-01 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
PCT/IL2002/000339 Continuation-In-Part WO2003033514A1 (en) 2000-11-17 2002-05-01 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US10/135,447 Continuation-In-Part US7067649B2 (en) 2000-11-17 2002-05-01 Promoters exhibiting endothelial cell specificity and methods of using same

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US10/135,447 Continuation-In-Part US7067649B2 (en) 2000-11-17 2002-05-01 Promoters exhibiting endothelial cell specificity and methods of using same
US11/359,513 Continuation-In-Part US8039261B2 (en) 2000-11-17 2006-05-23 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US12/591,252 Division US20100081193A1 (en) 2000-11-17 2009-11-13 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US13/018,447 Division US8206743B2 (en) 2000-11-17 2011-02-01 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Publications (2)

Publication Number Publication Date
US20050186179A1 US20050186179A1 (en) 2005-08-25
US8071740B2 true US8071740B2 (en) 2011-12-06

Family

ID=36336885

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/988,487 Expired - Fee Related US8071740B2 (en) 2000-11-17 2004-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US12/591,252 Abandoned US20100081193A1 (en) 2000-11-17 2009-11-13 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US13/018,447 Expired - Fee Related US8206743B2 (en) 2000-11-17 2011-02-01 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US13/098,512 Abandoned US20110207985A1 (en) 2000-11-17 2011-05-02 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US13/549,355 Expired - Fee Related US8835398B2 (en) 2000-11-17 2012-07-13 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/591,252 Abandoned US20100081193A1 (en) 2000-11-17 2009-11-13 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US13/018,447 Expired - Fee Related US8206743B2 (en) 2000-11-17 2011-02-01 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US13/098,512 Abandoned US20110207985A1 (en) 2000-11-17 2011-05-02 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US13/549,355 Expired - Fee Related US8835398B2 (en) 2000-11-17 2012-07-13 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Country Status (14)

Country Link
US (5) US8071740B2 (enExample)
EP (4) EP2174668B1 (enExample)
JP (3) JP2008519596A (enExample)
KR (3) KR101522309B1 (enExample)
CN (2) CN101098882A (enExample)
AT (1) ATE531392T1 (enExample)
AU (1) AU2005303385B2 (enExample)
CA (2) CA2913047A1 (enExample)
IL (1) IL211489A (enExample)
MX (1) MX2007005783A (enExample)
NZ (2) NZ580289A (enExample)
SG (1) SG171581A1 (enExample)
WO (1) WO2006051545A2 (enExample)
ZA (1) ZA200704687B (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090326052A1 (en) * 2000-11-17 2009-12-31 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100081193A1 (en) * 2000-11-17 2010-04-01 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
WO2014118643A2 (en) 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
US8916378B2 (en) 2001-10-19 2014-12-23 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy
US9200056B2 (en) 2012-10-17 2015-12-01 Vascular Biogenics Ltd. FAS-chimera adenovirus vector
US9567605B2 (en) 2010-01-05 2017-02-14 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
WO2019077593A1 (en) 2017-10-20 2019-04-25 Vascular Biogenics Ltd. DIAGNOSTIC METHODS FOR ANTI-ANGIOGENIC AGENT TREATMENT
US10369196B2 (en) 2010-01-05 2019-08-06 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
WO2020183424A1 (en) 2019-03-13 2020-09-17 Vascular Biogenics Ltd. Methods of anti-tumor therapy
WO2020208612A1 (en) 2019-04-12 2020-10-15 Vascular Biogenics Ltd. Methods of anti-tumor therapy

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US8236772B2 (en) * 2005-09-16 2012-08-07 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis and screening compounds for activity in modulating angiogenesis
US20100316609A1 (en) * 2006-10-18 2010-12-16 University Of Rochester Conditionally Replicating Viruses for Cancer Therapy
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
AU2013205004B2 (en) * 2008-06-30 2015-08-27 Tocagen Inc. Formulations of 5-fluorocytosine and Uses Thereof
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
BR112012021451B8 (pt) * 2010-02-25 2021-05-25 Abt Holding Co uso de células que apresentam uma eficiência desejada para a expressão e/ou secreção dos fatores pró-angiogênicos vegf, cxcl5 e il8, métodos para construir um banco de células, para desenvolver fármaco, e para aumentar a expressão de um ou mais fatores pró-angiogênicos em uma célula realizado in vitro, e, composição
US8785192B2 (en) 2010-07-07 2014-07-22 Cellular Dynamics International, Inc. Endothelial cell production by programming
US10080784B2 (en) * 2011-02-18 2018-09-25 Southern Research Institute Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase prodrug
TWI486446B (zh) * 2011-06-02 2015-06-01 Taipei Veterans General Hospital 治療感染性與惡性疾病的標靶化學治療藥物的形成方法
IN2014DN06898A (enExample) * 2012-03-14 2015-05-15 Salk Inst For Biological Studi
CN110237447B (zh) 2013-09-27 2021-11-02 梅维昂医疗系统股份有限公司 粒子治疗系统
US9962560B2 (en) 2013-12-20 2018-05-08 Mevion Medical Systems, Inc. Collimator and energy degrader
US10675487B2 (en) 2013-12-20 2020-06-09 Mevion Medical Systems, Inc. Energy degrader enabling high-speed energy switching
US9661736B2 (en) 2014-02-20 2017-05-23 Mevion Medical Systems, Inc. Scanning system for a particle therapy system
JP6879486B2 (ja) * 2015-03-17 2021-06-02 フリーイェ・ユニヴェルシテイト・ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｅｉｔ Ｂｒｕｓｓｅｌ Ｆｖｉｉｉおよびｆｉｘ用の最適化された肝臓特異的発現系
US10786689B2 (en) 2015-11-10 2020-09-29 Mevion Medical Systems, Inc. Adaptive aperture
JP7059245B2 (ja) 2016-07-08 2022-04-25 メビオン・メディカル・システムズ・インコーポレーテッド 治療計画の決定
US11103730B2 (en) 2017-02-23 2021-08-31 Mevion Medical Systems, Inc. Automated treatment in particle therapy
EP3645111B1 (en) 2017-06-30 2025-04-23 Mevion Medical Systems, Inc. Configurable collimator controlled using linear motors
US11674141B2 (en) * 2018-02-28 2023-06-13 National University Corporation Tokyo Medical And Dental University Ischemic-lesion-site-specific gene therapy
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7311620B2 (ja) 2019-03-08 2023-07-19 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのコリメータおよびエネルギーデグレーダ
CN110714028B (zh) * 2019-11-04 2021-08-31 中国人民解放军第四军医大学 可控性上调Ang-(1-7)靶向性防治低氧性肺动脉高压的表达载体
BR112023001418A2 (pt) * 2020-08-05 2023-03-07 Spacecraft Seven Llc Vetor viral adeno-associado para expressão de glut1 e seus usos

Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5635385A (en) 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US5686281A (en) 1995-02-03 1997-11-11 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
WO1998000013A1 (en) 1996-06-28 1998-01-08 The Regents Of The University Of California Enhancement of cancer cell death
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5747340A (en) 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1998037901A1 (en) 1997-02-28 1998-09-03 Boehringer Ingelheim Pharmaceuticals, Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
US5830880A (en) 1994-08-26 1998-11-03 Hoechst Aktiengesellschaft Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound
US5882893A (en) 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor
US5906827A (en) 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
US5916763A (en) 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
WO2000006759A2 (en) 1998-07-27 2000-02-10 Valentis, Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
DE19838837A1 (de) 1998-08-27 2000-03-02 Boehringer Ingelheim Int Zellspezifische Promoter des Entkopplungsproteins 3
US6110480A (en) 1997-10-16 2000-08-29 Development Center For Biotechnology Method for preparing an environmentally compatable porous material comprising beneficial nematodes and the biotic preparations produced therefrom
US6180355B1 (en) 1998-05-07 2001-01-30 University Of Maryland, Baltimore Method for diagnosing and treating chronic pelvic pain syndrome
US6183737B1 (en) 1997-10-30 2001-02-06 The General Hospital Corporation Bonding of cartilage pieces using isolated chondrocytes and a biological gel
US6200751B1 (en) 1996-11-08 2001-03-13 Oklahoma Medical Research Foundation Endothelial specific expression regulated by EPCR control elements
US6206917B1 (en) 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
US6239151B1 (en) 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
US6265216B1 (en) 2000-01-20 2001-07-24 Isis Pharmaceuticals, Inc. Antisense modulation of cot oncogene expression
US6300127B1 (en) 1997-07-30 2001-10-09 Emory University Bone mineralization proteins, DNA, vectors, expression systems
US6300490B1 (en) * 1989-08-30 2001-10-09 Glaxo Wellcome Inc. Molecular constructs comprising a carcinoembryonic antigen (CEA) transcriptional regulatory region
US6348209B2 (en) 1996-12-30 2002-02-19 Battelle Pulmonary Therapeutics, Inc. Formulation and method for treating neoplasms by inhalation
US6376244B1 (en) 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
WO2002040629A2 (en) * 2000-11-17 2002-05-23 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US6438802B1 (en) 2001-06-07 2002-08-27 Randolph Scott Beeman Locking mechanism and method for securely fastening resilient cords and tubing
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6503886B1 (en) 1994-03-15 2003-01-07 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
WO2003033514A1 (en) 2001-10-19 2003-04-24 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6579697B1 (en) 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US20030124100A1 (en) 2000-11-17 2003-07-03 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US6627189B1 (en) 1991-03-06 2003-09-30 Board Of Regents, The University Of Texas Systems Inhibition of cellular proliferation using ras antisense molecules
US6652583B2 (en) 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
US20040224389A1 (en) 1994-05-27 2004-11-11 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
WO2004113497A2 (en) 2003-06-09 2004-12-29 University Of Florida Gene delivery to tumors
US6866864B2 (en) 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
US20050112110A1 (en) 2000-11-17 2005-05-26 Dror Harats Promoters exhibiting endothelial cell specificity and methods of using same
US20050186179A1 (en) 2000-11-17 2005-08-25 Dror Harats Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20060204478A1 (en) 2000-11-17 2006-09-14 Dror Harats Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7625558B2 (en) 1998-03-04 2009-12-01 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4410237A (en) * 1980-09-26 1983-10-18 Massachusetts Institute Of Technology Method and apparatus for shaping electromagnetic beams
DE3307925A1 (de) 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4614796A (en) * 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (ja) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4710579A (en) 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
US4827011A (en) * 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
DE3687030T2 (de) 1985-03-15 1993-03-11 Eugene Stirchak Stereoregulare polynukleotiden bindende polymere.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4711512A (en) * 1985-07-12 1987-12-08 Environmental Research Institute Of Michigan Compact head-up display
CA1293663C (en) * 1986-01-06 1991-12-31 David Christopher Auth Transluminal microdissection device
JPH01502584A (ja) * 1986-03-24 1989-09-07 ザ ユニバーシティー オブ シドニー 抗原性物質
US5314407A (en) * 1986-11-14 1994-05-24 Heart Technology, Inc. Clinically practical rotational angioplasty system
DE3807123A1 (de) 1988-03-04 1989-09-14 Boehringer Mannheim Gmbh Substrate fuer phospholipasen
DE8904026U1 (de) * 1988-04-20 1989-05-24 Schneider (Europe) AG, Zürich Katheter zum Rekanalisieren von verengten Gefäßen
DE3821544C2 (de) * 1988-06-25 1994-04-28 H Prof Dr Med Just Dilatationskatheter
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5087244A (en) * 1989-01-31 1992-02-11 C. R. Bard, Inc. Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen
US4994033A (en) * 1989-05-25 1991-02-19 Schneider (Usa) Inc. Intravascular drug delivery dilatation catheter
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5237451A (en) * 1989-11-17 1993-08-17 Minnesota Mining And Manufacturing Company Beam shaping system using diffraction
US5082629A (en) * 1989-12-29 1992-01-21 The Board Of The University Of Washington Thin-film spectroscopic sensor
US5049132A (en) * 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US5053041A (en) * 1990-03-12 1991-10-01 Ansari Shapoor S Vessel holder
ES2019552A6 (es) 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
US5364393A (en) * 1990-07-02 1994-11-15 Heart Technology, Inc. Tissue dissipative recanalization catheter
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5213576A (en) * 1991-06-11 1993-05-25 Cordis Corporation Therapeutic porous balloon catheter
US5766151A (en) * 1991-07-16 1998-06-16 Heartport, Inc. Endovascular system for arresting the heart
US5224198A (en) * 1991-09-30 1993-06-29 Motorola, Inc. Waveguide virtual image display
US5306250A (en) * 1992-04-02 1994-04-26 Indiana University Foundation Method and apparatus for intravascular drug delivery
US5368566A (en) * 1992-04-29 1994-11-29 Cardiovascular Dynamics, Inc. Delivery and temporary stent catheter having a reinforced perfusion lumen
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5447497A (en) * 1992-08-06 1995-09-05 Scimed Life Systems, Inc Balloon catheter having nonlinear compliance curve and method of using
US5569189A (en) * 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5336178A (en) * 1992-11-02 1994-08-09 Localmed, Inc. Intravascular catheter with infusion array
US5614502A (en) * 1993-01-15 1997-03-25 The General Hospital Corporation High-pressure impulse transient drug delivery for the treatment of proliferative diseases
WO1994021320A1 (en) * 1993-03-15 1994-09-29 Advanced Cardiovascular Systems, Inc. Fluid delivery catheter
JP3623250B2 (ja) * 1993-06-23 2005-02-23 オリンパス株式会社 映像表示装置
DE4324218A1 (de) * 1993-07-19 1995-01-26 Bavaria Med Tech Manschettenkatheter
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
JPH07326065A (ja) 1994-05-27 1995-12-12 Hitachi Ltd 光情報処理装置
EP1852121A3 (en) * 1994-08-29 2007-11-21 Wake Forest University Lipid analogs for treating viral infections
US5506929A (en) * 1994-10-19 1996-04-09 Clio Technologies, Inc. Light expanding system for producing a linear or planar light beam from a point-like light source
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5660855A (en) * 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US5730723A (en) * 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US5746716A (en) * 1995-07-10 1998-05-05 Interventional Technologies Inc. Catheter for injecting fluid medication into an arterial wall
MXPA98002791A (es) * 1995-10-11 2004-09-07 Esperion Luv Dev Inc Composiciones liposomales y metodos para usarlas.
US5761477A (en) * 1995-12-04 1998-06-02 Microsoft Corporation Methods for safe and efficient implementations of virtual machines
US6825980B2 (en) * 1995-12-18 2004-11-30 Metrologic Instruments, Inc. DOE-based systems and devices for producing laser beams having modified beam characteristics
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
US6027514A (en) * 1997-12-17 2000-02-22 Fox Hollow Technologies, Inc. Apparatus and method for removing occluding material from body lumens
US6699231B1 (en) * 1997-12-31 2004-03-02 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
AU3052499A (en) * 1998-04-02 1999-10-25 Elop Electro-Optics Industries Ltd. Holographic optical devices
US6364856B1 (en) * 1998-04-14 2002-04-02 Boston Scientific Corporation Medical device with sponge coating for controlled drug release
US6206283B1 (en) * 1998-12-23 2001-03-27 At&T Corp. Method and apparatus for transferring money via a telephone call
US6280411B1 (en) * 1998-05-18 2001-08-28 Scimed Life Systems, Inc. Localized delivery of drug agents
US20030060876A1 (en) * 2000-09-28 2003-03-27 Amir Loshakove Graft delivery system
US6036700A (en) * 1998-07-14 2000-03-14 Ethicon Endo-Surgery, Inc. Surgical anastomosis instrument
US6280414B1 (en) * 1998-09-30 2001-08-28 Medtronic Ave, Inc. Method and apparatus for local delivery of therapeutic agent
JP3622556B2 (ja) 1999-02-23 2005-02-23 セイコーエプソン株式会社 照明光学系および投写型表示装置
US6743196B2 (en) * 1999-03-01 2004-06-01 Coaxia, Inc. Partial aortic occlusion devices and methods for cerebral perfusion augmentation
WO2000074629A2 (fr) * 1999-06-08 2000-12-14 Transgene S.A. Composition destinee a la mise en oeuvre d'un traitement cytotoxique, notamment antitumoral ou antiviral, chez un mammifere
IL130608A0 (en) * 1999-06-23 2000-06-01 Compugen Ltd Novel nucleic and amino acid sequence
US6299622B1 (en) * 1999-08-19 2001-10-09 Fox Hollow Technologies, Inc. Atherectomy catheter with aligned imager
US6447525B2 (en) * 1999-08-19 2002-09-10 Fox Hollow Technologies, Inc. Apparatus and methods for removing material from a body lumen
US6638233B2 (en) * 1999-08-19 2003-10-28 Fox Hollow Technologies, Inc. Apparatus and methods for material capture and removal
US6348583B1 (en) * 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
US6733513B2 (en) * 1999-11-04 2004-05-11 Advanced Bioprosthetic Surfaces, Ltd. Balloon catheter having metal balloon and method of making same
ATE287700T1 (de) 1999-11-30 2005-02-15 Univ Arizona Strahlung-sensitive liposomen
US6344027B1 (en) * 1999-12-08 2002-02-05 Scimed Life Systems, Inc. Needle-less injection apparatus and method
US6629953B1 (en) * 2000-02-18 2003-10-07 Fox Hollow Technologies, Inc. Methods and devices for removing material from a vascular site
EP1272615A2 (en) * 2000-03-21 2003-01-08 The University Of Virginia Patent Foundation Osteocalcin promoter directed adenovirus replicaton for therapy
US6716190B1 (en) * 2000-04-19 2004-04-06 Scimed Life Systems, Inc. Device and methods for the delivery and injection of therapeutic and diagnostic agents to a target site within a body
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
SE0001894D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab Medical device
EP1301612A2 (en) * 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
US7030099B2 (en) * 2000-07-21 2006-04-18 Research Corporation Technologies, Inc. Tumor specific promoters of the midkine gene that allow for selective expression in P53-inactivated cells
IL138766A0 (en) * 2000-09-28 2001-10-31 Cyclo Science Ltd Constant pressure apparatus for the administration of fluids intravenously
JP2002122783A (ja) * 2000-10-13 2002-04-26 Olympus Optical Co Ltd 観察光学系及び撮像光学系及びそれを用いた装置
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6623452B2 (en) * 2000-12-19 2003-09-23 Scimed Life Systems, Inc. Drug delivery catheter having a highly compliant balloon with infusion holes
US6544223B1 (en) * 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Balloon catheter for delivering therapeutic agents
JP4542311B2 (ja) 2001-01-29 2010-09-15 バイオ−ラッド ラボラトリーズ インコーポレイテッド 核酸誘導体
US20020107504A1 (en) * 2001-02-06 2002-08-08 Gordon Lucas S. Apparatus for local drug delivery in limb
NZ528035A (en) 2001-02-14 2005-07-29 Robert J Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
KR20020083737A (ko) * 2001-04-30 2002-11-04 삼성전자 주식회사 착용형 디스플레이 시스템
CA2489420A1 (en) * 2001-06-25 2003-01-03 Buadbo Aps Oncology drug innovation
CN1195056C (zh) * 2001-07-12 2005-03-30 钱其军 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
AU2002355419A1 (en) * 2001-08-06 2003-02-24 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
US6833955B2 (en) * 2001-10-09 2004-12-21 Planop Planar Optics Ltd. Compact two-plane optical device
US20040044403A1 (en) 2001-10-30 2004-03-04 Joyce Bischoff Tissue-engineered vascular structures
NZ533164A (en) * 2001-11-01 2008-09-26 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
EP1446171A1 (en) 2001-11-16 2004-08-18 Children's Medical Center Corporation Augmentation of organ function
KR100450815B1 (ko) 2002-02-01 2004-10-01 삼성전자주식회사 조명계 및 이를 채용한 프로젝션 디스플레이 장치
US20030180268A1 (en) 2002-02-05 2003-09-25 Anthony Atala Tissue engineered construct for supplementing or replacing a damaged organ
US7247477B2 (en) 2002-04-16 2007-07-24 Technion Research & Development Foundation Ltd. Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
US6757105B2 (en) * 2002-04-25 2004-06-29 Planop Planar Optics Ltd. Optical device having a wide field-of-view for multicolor images
US7023622B2 (en) * 2002-08-06 2006-04-04 Dmetrix, Inc. Miniature microscope objective lens
US6805490B2 (en) * 2002-09-30 2004-10-19 Nokia Corporation Method and system for beam expansion in a display device
US20060099709A1 (en) 2002-10-01 2006-05-11 Chuan-Yuan Li Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
US8951772B2 (en) * 2002-10-15 2015-02-10 Per Sonne Holm Adenoviruses, nucleic acids coding therefor, and use thereof
CN100424547C (zh) 2002-12-26 2008-10-08 三洋电机株式会社 投影式视频显示器
WO2004061458A2 (en) * 2003-01-03 2004-07-22 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7184617B2 (en) * 2004-03-12 2007-02-27 Matsushita Electric Industrial Co., Ltd. Portable device
WO2006006169A2 (en) * 2004-07-14 2006-01-19 By-Pass, Inc. Material delivery system
US20080063656A1 (en) * 2004-08-09 2008-03-13 Emini Emilio A Adenoviral Vector Compositions
US20060056028A1 (en) * 2004-09-13 2006-03-16 Wildnauer Kenneth R Apodized diffraction grating with improved dynamic range
US20060194765A1 (en) 2004-11-16 2006-08-31 Garcia Joe G N Methods and compositions using oxidized phospholipids
US7206107B2 (en) * 2004-12-13 2007-04-17 Nokia Corporation Method and system for beam expansion in a display device
EP1844069A4 (en) * 2005-01-28 2009-05-20 Apollo Life Sciences Ltd MOLECULES AND CHIMESE MOLECULES THEREOF
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
CA2658972C (en) * 2006-07-31 2019-11-26 Vascular Biogenics Ltd. Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
US20080140001A1 (en) * 2006-12-12 2008-06-12 By-Pass Inc. Fluid Delivery Apparatus And Methods
WO2008152639A2 (en) * 2007-06-12 2008-12-18 Bypass, Inc. Pressure pulse actuating device for delivery systems
KR20090011223A (ko) 2007-07-25 2009-02-02 삼성전자주식회사 방송처리장치 및 그 제어방법
EP2111105A4 (en) * 2007-11-28 2011-05-04 METHOD FOR DELAYING THE BEGINNING OF A CLINICALLY DEFINED CLINIC SCLEROSIS
TW200935607A (en) * 2008-02-05 2009-08-16 Univ Yuan Ze Ceramic MESFET device and a manufacturing method therefor
US20110083464A1 (en) * 2009-10-12 2011-04-14 Craig Kettles Refrigerator with a Pullout Refrigerator Compartment
CA2786377C (en) * 2010-01-05 2018-02-27 Vascular Biogenics Ltd. Compositions and methods for treating malignant gliomas employing viral vectors encoding a fas-chimera
DK2521776T3 (en) * 2010-01-05 2017-02-13 Vascular Biogenics Ltd METHODS FOR USING A SPECIFIC ANTI-ANGIOGENT ADENOVIRAL AGENT
WO2011086509A1 (en) * 2010-01-12 2011-07-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells

Patent Citations (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6300490B1 (en) * 1989-08-30 2001-10-09 Glaxo Wellcome Inc. Molecular constructs comprising a carcinoembryonic antigen (CEA) transcriptional regulatory region
US6627189B1 (en) 1991-03-06 2003-09-30 Board Of Regents, The University Of Texas Systems Inhibition of cellular proliferation using ras antisense molecules
US5635385A (en) 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US6503886B1 (en) 1994-03-15 2003-01-07 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US20040224389A1 (en) 1994-05-27 2004-11-11 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US5747340A (en) 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
US5906827A (en) 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
US6027743A (en) 1994-06-03 2000-02-22 Stryker Corporation Manufacture of autogenous replacement body parts
US5830880A (en) 1994-08-26 1998-11-03 Hoechst Aktiengesellschaft Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5686281A (en) 1995-02-03 1997-11-11 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6579697B1 (en) 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US5916763A (en) 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
WO1998000013A1 (en) 1996-06-28 1998-01-08 The Regents Of The University Of California Enhancement of cancer cell death
US6200751B1 (en) 1996-11-08 2001-03-13 Oklahoma Medical Research Foundation Endothelial specific expression regulated by EPCR control elements
US6348209B2 (en) 1996-12-30 2002-02-19 Battelle Pulmonary Therapeutics, Inc. Formulation and method for treating neoplasms by inhalation
WO1998037901A1 (en) 1997-02-28 1998-09-03 Boehringer Ingelheim Pharmaceuticals, Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
US6206917B1 (en) 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
US6497725B2 (en) 1997-05-02 2002-12-24 St. Jude Medical, Inc. Differential treatment of prosthetic devices
US6521750B2 (en) 1997-07-30 2003-02-18 Univ Emory Bone mineralization proteins, DNA, vectors, expression systems
US6444803B1 (en) 1997-07-30 2002-09-03 Emory University Bone mineralization proteins, DNA, vectors, expression systems
US6300127B1 (en) 1997-07-30 2001-10-09 Emory University Bone mineralization proteins, DNA, vectors, expression systems
US6110480A (en) 1997-10-16 2000-08-29 Development Center For Biotechnology Method for preparing an environmentally compatable porous material comprising beneficial nematodes and the biotic preparations produced therefrom
US6183737B1 (en) 1997-10-30 2001-02-06 The General Hospital Corporation Bonding of cartilage pieces using isolated chondrocytes and a biological gel
US5882893A (en) 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor
US7625558B2 (en) 1998-03-04 2009-12-01 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6180355B1 (en) 1998-05-07 2001-01-30 University Of Maryland, Baltimore Method for diagnosing and treating chronic pelvic pain syndrome
US6239151B1 (en) 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
WO2000006759A2 (en) 1998-07-27 2000-02-10 Valentis, Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
DE19838837A1 (de) 1998-08-27 2000-03-02 Boehringer Ingelheim Int Zellspezifische Promoter des Entkopplungsproteins 3
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6783776B2 (en) 1999-12-22 2004-08-31 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6376244B1 (en) 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US6265216B1 (en) 2000-01-20 2001-07-24 Isis Pharmaceuticals, Inc. Antisense modulation of cot oncogene expression
US6866864B2 (en) 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
US6652583B2 (en) 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
US20040048280A1 (en) 2000-11-17 2004-03-11 Dror Harats Promoters exhibiting endothelial cell specificity and methods of using same
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20030124100A1 (en) 2000-11-17 2003-07-03 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
WO2002040629A2 (en) * 2000-11-17 2002-05-23 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20090326052A1 (en) 2000-11-17 2009-12-31 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20060204478A1 (en) 2000-11-17 2006-09-14 Dror Harats Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20050112110A1 (en) 2000-11-17 2005-05-26 Dror Harats Promoters exhibiting endothelial cell specificity and methods of using same
US20050186179A1 (en) 2000-11-17 2005-08-25 Dror Harats Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US6438802B1 (en) 2001-06-07 2002-08-27 Randolph Scott Beeman Locking mechanism and method for securely fastening resilient cords and tubing
US7585666B2 (en) 2001-10-19 2009-09-08 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
WO2003033514A1 (en) 2001-10-19 2003-04-24 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US20040197860A1 (en) 2001-10-19 2004-10-07 Dror Harats Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US20080305088A1 (en) 2001-10-19 2008-12-11 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
WO2003093409A2 (en) 2002-05-01 2003-11-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
WO2004113497A2 (en) 2003-06-09 2004-12-29 University Of Florida Gene delivery to tumors
WO2006051545A2 (en) 2004-11-14 2006-05-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
WO2007096882A2 (en) 2006-02-23 2007-08-30 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
WO2008132729A2 (en) 2007-04-30 2008-11-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Non-Patent Citations (286)

* Cited by examiner, † Cited by third party
Title
Aird et al. "Human von Willebrand Factor Gene Sequences Target Expression to A Subpopulation of Endothelial Cells in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 92: 4567-4571, 1995.
Aoki et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides Into the Myocardium Using HVJ-Liposome Method", Biochemical and Biophysical Research Communications, 231: 540-545, 1997.
Araki et al. "Ninjurin2, A Novel Homophilic Adhesion Molecule, Is Expressed in Mature Sensory and Enteric Neurons and Promotes Neurite Outgrowth", The Journal of Neuroscience, 20(1): 187-195, 2000.
Arap et al. "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in A Mouse Model", Science, New Series, 279(5349): 377-380, 1998.
Ausprunk et al. "Migration and Proliferation of Endothelial Cells in Preformed and Newly Formed Blood Vessels During Tumor Angiogenesis", Microvascular Research, 14: 53-65, 1977.
Bangari et al. "Current Strategies and Future Directions for Eluding Adenoviral Vector Immunity", Current Gene Therapy, 6(2): 215-226, Apr. 2006.
Barcelos et al. "Impaired Inflammatory Angiogenesis, But Not Leukocyte Influx, in Mice Lacking TNFR1", Journal of Leukocyte Biology, 78: 352-358, Aug. 2005.
Bobek et al. "Gene Therapy of the Ischemic Lower Limb-Therapeutic Angiogenesis", Vascular Pharmacology, 44: 395-405, 2006.
Boldin et al. "A Novel Protein That Interacts With the Death Domain of Fas/APO1 Contains A Sequence Motif Related to the Death Domain", The Journal of Biological Chemistry, 270(14): 7795-7798, 1995.
Boldin et al. "A Novel Protein That Interacts With the Death Domain of Fas/APOI Contains A Sequence Motif Related to the Death Domain", The Journal of Biological Chemistry, XP002035462, 270(14): 7795-7798, Apr. 7, 1995.
Brown et al. "Neovascularisation and Its Role in the Osteoarthritic Process", Annals of the Rheumatic Diseases, 47: 881-885, 1988.
Bu et al. "Identification of an Endothelial Cell-Specific Regulatory Region in the Murine Endothelin-1 Gene", Journal of Biological Chemistry, 272(51): 32613-32622, 1997.
Bu et al. "Identification of An Endothelial Cell-Specific Regulatory Region in the Murine Endothelin-1 Gene", The Journal of Biological Chemistry, 272(51): 32613-32611, 1997, Fig. 5A.
Carmeliet et al. "Growing Better Blood Vessels", Nature Biotechnology, 19: 1019-1020, 2001.
Chen et al. "Upstream Stimulatory Factors Regulate Aortic Preferentially Expressed Gene-1 Expression in Vascular Smooth Muscle Cells", The Journal of Biological Chemistry, 276(50): 47658-47663, 2001.
Cho et al. "Development of an Efficient Endothelial Cell Specific Vector Using Promoter and 5′ Untranslated Sequences From the Human Proproendothelin-1 Gene", Experimental and Molecular Medicine, 35(4): 269-274, 2003.
Collins et al. "Molecular Cloning of the Human Gene for Von Willebrand Factor and Identification of the Transcription Initiation Site", Proc. Natl. Acad. Sci. USA, 84: 4393-4397, 1987.
Collins et al. "Strucutre and Chromosomal Location of the Gene for Endothelial-Leukocyte Adhesion Molecule 1", The Journal of Biological Chemistry, 266(4): 2466-2473, 1991.
Communication Pursuant to Article 94(3) EPC Dated Apr. 27, 2007 From the European Patent Office Re.: Application No. 01996590.4.
Communication Pursuant to Article 94(3) EPC Dated Feb. 10, 2009 From the European Patent Office Re.: Application No. 02801473.6.
Communication Pursuant to Article 94(3) EPC Dated Feb. 16, 2009 From the European Patent Office Re.: Application No. 05806361.1.
Communication Pursuant to Article 94(3) EPC Dated Jan. 25, 2011 From the European Patent Office Re. Application No. 09168899.4.
Communication Pursuant to Article 94(3) EPC Dated May 29, 2008 From the European Patent Office Re.: Application No. 05806361.1 Mailed by Associate on Jun. 16, 2008.
Communication Pursuant to Article 96(2) EPC Dated Apr. 17, 2007 From the European Patent Office Re.: Application No. EP 02801473.6.
Communication Pursuant to Article 96(2) EPC Dated Apr. 27, 2007 From the European Patent Office Re.: Application No. EP 01996590.4. Mailed by Associate on May 31, 2007.
Communication Pursuant to Article 96(2) EPC Dated Dec. 21, 2006 From the European Patent Office Re.: Application No. 01996590.4.
Communication Pursuant to Article 96(2) EPC Dated Jul. 31, 2006 From the European Patent Office Re.: Application No. EP 03717516.3. Mailed by Associate on Aug. 17, 2006.
Communication Pursuant to Article 96(2) EPC Dated May 3, 2006 From the European Patent Office Re.: Application No. EP 01996590.4.
Communication Pursuant to Rules 70(2) and 70a (2) EPC and Reference to Rule 39(1) EPC Dated Feb. 21, 2011 From the European Patent Office Re. Application No. 10177257.2.
Communication Pursuant to Rules 70(2) and 70a(2) EPC and Reference to Rule 39(1) EPC Dated Apr. 4, 2011 From the European Patent Office Re. Application No. 10184033.8.
Communication Pursuant to Rules 70(2) and 70a(2) EPC and Reference to Rule 39(1) EPC Dated Apr. 4, 2011 From the European Patent Office Re. Application No. 10185195.4.
Communication Pursuant to Rules 70(2) and 70a(2) EPC and Reference to Rule 39(1) EPC Dated Jun. 21, 2010 From the European Patent Office Re. Application No. 09168899.4.
Communication Relating to the Results of the Extended International Search Dated Apr. 8, 2010 From the European Patent Office Re.: Application No. 09174998.6.
Dancer et al. "Expression of Thymidine Kinase Driven by An Endothelial-Specific Promoter Inhibits Tumor Growth of Lewis Lung Carcinoma Cells in Transgenic Mice", Gene Therapy, XP002522579, 10(14): 1170-1178, Jul. 2003.
Davis "The Many Faces of Epidermal Growth Factor Repeats", The New Biologist, 2(5): 410-419, May 1990.
Deonarain "Ligand-Targeted Receptor-Mediated Vectors for Gene Delivery", Expert Opinion on Therapeutic Patents, 8(1): 53-69, 1998.
Dor et al. "Induction of Vascular Networks in Adult Organs: Implications to Proangiogenic Therapy", Annals of the NY Academy of Sciences, 995: 208-216, 2003.
Eck et al. "Gene-Based Therapy", Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Section I(Chap.5): 77-101, 1996.
Edelberg et al. "Platelet-Derived Growth Factor-AB Limits the Extent of Myocardial Infarction in a Rat Model: Feasibility of Restoring Impaired Angiogenic Capacity in the Aging Heart", Circulation, 105: 608-613, 2002.
Epstein et al. "Therapeutic Interventions for Enhancing Collateral Development by Administration of Growth Factors: Basic Principles, Early Results and Potential Hazards", Cardiovascular Research, 49: 532-542, 2001. *
European Search Report and the European Search Opinion Dated Feb. 22, 2011 From the European Patent Office Re. Application No. 10185195.4.
European Search Report and the European Search Opinion Dated Feb. 24, 2011 From the European Patent Office Re. Application No. 10184033.8.
European Search Report and the European Search Opinion Dated Jan. 19, 2011 From the European Patent Office Re. Application No. 10177257.2.
European Search Report and the European Search Opinion Dated Jul. 29, 2010 From the European Patent Office Re. Application No. 09176343.3.
European Search Report and the European Search Opinion Dated May 17, 2010 From the European Patent Office Re. Application No. 09168899.4.
Examination Report Dated Apr. 13, 2006 From the Government of India, Patent Office Re.: Application No. 743/CHENP/2003—in English only. Mailed by the Associate on Jun. 2, 2006.
Examination Report Dated Apr. 3, 2009 From the Intellectual Property Office of New Zealand Re.: Application No. 555612.
Examination Report Dated Aug. 3, 2006 From the Intellectual Property Office of New Zealand Re.: Application No. 536578. Mailed by Associate Aug. 6, 2006.
Examination Report Dated Aug. 6, 2009 From the Intellectual Property Office of New Zealand Re.: Application No. 555612.
Examination Report Dated Jan. 26, 2011 From the Instituto Mexicano de la Propiedad Industrial Re. Application No. PA/a/2004/010711. Eng. Clms 1-13 consider only.
Examination Report Dated Jul. 12, 2007 From the Government of India, Patent Office Re.: Application No. 801/CHENP/2004. Mailed by the Associate on Aug. 31, 2007.
Examination Report Dated Jun. 20, 2007 From the Government of India, Patent Office Re.: Application No. 2679/CHENP/2004.
Examination Report Dated Oct. 1, 2010 From the Intellectual Property Office of New Zealand Re. Application No. 581511.
Examination Report Dated Oct. 16, 2009 From the Intellectual Property Office of New Zealand Re.: Application No. 580289.
Examination Report Dated Sep. 5, 2005 from the Intellectual Property Office of New Zealand Re.: Application 536578 Mailed by Associate Oct. 12, 2005.
Examination Report Dated Sep. 5, 2005 From the Intellectual Property Office of New Zealand Re.: Application 536578. Mailed by Associate Oct. 12, 2005.
Examiner's Report Dated Dec. 10, 2008 From the Australian Government, IP Australia Re.: Application No. 2003222427.
Faries et al. "Assessing the Role of Gene Therapy in the Treatment of Vascular Disease", Annals of Vascular Surgery, 14(2): 181-188, 2000. *
Feldman et al. "Progress in Antiangiogenic Gene Therapy of Cancer", Cancer, 89: 1181-1194, 2000. *
Folkman "Angiogenesis and Apoptosis", Seminars in Cancer Biology, 13: 159-167, 2003.
Folkman "How Is Blood Vessel Growth Regulated in Normal and Neoplastic Tissue?-G.H.A. Clowes Memorial Award Lecture", Cancer Research, 46: 467-473, 1986. *
French Anderson "Human Gene Therapy", Nature, 392: 25-30, 1998. *
Garlanda et al. "Heterogeneity of Endothelial Cells. Specific Markers", Arteriosclerosis, Thrombosis, and Vascular Biology, 17(7): 1193-1202, 1997. *
Goldman et al. "Influence of Pressure on Permeability of Normal and Diseased Muscular Arteries to Horseradish Peroxidase. A New Catheter Approach", Atherosclerosis, 65: 215-225, 1987. *
Goltsev et al. "CASH, A Novel Caspase Homologue With Death Effector Domains", The Journal of Biological Chemistry, 272(32): 19641-19644, Aug. 8, 1997.
Górecki "‘Dressed-Up’ Naked Plasmids: Emerging Vectors for Non-Viral Gene Therapy", Discovery Medicine, 6(35): 191-197, Jul. 28, 2008.
Gorecki "‘Dressed-Up’ Naked Plasmids: Emerging Vectors for Non-Viral Gene Therapy", Discovery Medicine, 6(35): 191-197, Jul. 28, 2009.
Gorecki "Prospects and Problems of Gene Therapy: An Update", Expert Opinion on Emerging Drugs, 6(2): 187-198, 2001.
Górecki "Prospects and Problems of Gene Therapy: An Update", Expert Opinion on Emerging Drugs, 6(2): 187-198, 2001.
Gorski et al. "Potentiation of the Antitumor Effect of Ionizing Radiation by Brief Concomitant Exposures to Angiostatin", Cancer Research, 58(24): 5686-5689, Dec. 15, 1998.
Gorski et al. "Potentiation of the Antitumor Effect of Ionizing Radiation by Brief Concomitant Exposures to Angiostatin", Cancer Research, 58: 5686-5689, 1998. *
Gray et al. "Cloning of Human Tumor Necrosis Factor (TNF) Receptor cDNA and Expression of Recombinant Soluble TNF-Binding Protein", Proc. Natl. Acad. Sci. USA, 87: 7380-7384, Oct. 1990.
Greenberger et al. "Transcription-Controlled Gene Therapy Against Tumor Angiogenesis", The Journal of Clinical Investigation, XP002349281, 113(7): 1017-1024, Apr. 1, 2004, Abstract, P1018, P.1019, LLC Model, Fig. 2A.
Greenberger et al. "Transcription-Controlled Gene Therapy Against Tumor Angiogenesis", The Journal of Clinical Investigations, 113(7): 1017-1024, 2004.
Gu et al. "HTERT Promoter Induces Tumor-Specific Bax Gene Expression and Cell Killing in Syngenic Mouse Tumor Model and Prevents Systemic Toxicity", Gene Therapy, 9: 30-37, 2002. *
Harada et al. "Basic Fibroblast Growth Factor Improves Myocardial Function in Chronically Ischemic Porcine Hearts", Journal of Clinical Investigation, 94: 623-630, 1994. *
Harats et al. "Targeting Gene Expression to the Vascular Wall in Transgenic Mice Using the Murine Preproendothelin-1 Promoter", Journal of Clinical Investigation, 95(3): 1335-1344, 1995. see esp. p. 1336, Fig. 1.
Hoefer et al. "Direct Evidence for Tumor Necrosis Factor-? Signaling in Arteriogenesis", Circulation, 105: 1639-1641, Apr. 9, 2002.
Hoefer et al. "Direct Evidence for Tumor Necrosis Factor-alpha Signaling in Arteriogenesis", Circulation, 105: 1639-1641, Apr. 9, 2002. *
Hoefer et al. "Direct Evidence for Tumor Necrosis Factor-α Signaling in Arteriogenesis", Circulation, 105: 1639-1641, Apr. 9, 2002. *
Hu et al. "Hypoxia Regulates Expression of the Endothelial-1 Gene Through A Proximal-Inducible Factor-1 Binding Site on the Antisence Strand", Biochemical and Biophysical Research Communication, 245: 894-899, 1998.
International Preliminary Examination Report Dated Jan. 28, 2005 From the International Preliminary Examining Authority Re.: Application No. PCT/IL01/01059.
International Preliminary Examination Report Dated Jan. 5, 2005 From the International Preliminary Examining Authority Re.: Application No. PCT/IL02/00339.
International Preliminary Examination Report Dated May 26, 2005 From the International Preliminary Examining Authority Re.: Application No. PCT/IL03/00347.
International Preliminary Report on Patentability Dated Jan. 22, 2009 From the International Bureau of WIPO Re.: Application No. PCT/IL2007/000242.
International Preliminary Report on Patentability Dated May 24, 2007 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/001195.
International Preliminary Report on Patentability Dated Nov. 12, 2009 From the International Bureau of WIPO Re.: Application No. PCT/IL2008/000543.
International Search Report Dated Apr. 29, 2009 From the International Searching Authority Re.: Application No. PCT/IL08/00543.
International Search Report Dated Aug. 4, 2006 From the International Searching Authority Re.: Application No. PCT/IL05/01195.
International Search Report Dated Dec. 2, 2002 From the International Searching Authority Re.: Application No. PCT/IL02/00339.
International Search Report Dated May 4, 2004 From the International Searching Authority Re.: Application No. PCT/IL01/01059.
International Search Report Dated Sep. 18, 2008 From the International Searching Authority Re.: Application No. PCT/IL07/00242.
International Search Report or the Declaration Dated Jan. 28, 2005 From the International Searching Authority Re: Application No. PCT/IL03/00347.
Invitation to Pay Additional Fees Dated Jun. 1, 2006 From the International Searching Authority Re.: Application No. PCT/IL05/01195.
Invitation to Remedy Deficiencies Prusuant to Rule 30(3) EPC/Rule 163(3) EPC Dated Apr. 11, 2011 From the European Patent Office Re: Application No. 10185193.9.
Invitation to Remedy Deficiencies Pursuant to Rule 30(3) EPC/Rule 163(3) EPC Dated Mar. 16, 2010 From the European Patent Office Re.: Application No. 09176343.3.
Iris et al. "Dense Alu Clustering and A Potential New Member of the NFkappaB Family Within A 90 Kilobase HLA Class III Segment", Nature Genetics, 3: 137-145, 1993. *
Iris et al. "Dense Alu Clustering and A Potential New Member of the NFκB Family Within A 90 Kilobase HLA Class III Segment", Nature Genetics, 3: 137-145, 1993. *
Itasaka et al. "Endostatin Blocks Endothelial Repopulation After Radiation Therapy", Proceedings of the American Association for Cancer Research, 44: 26, Abstract #115, Mar. 2003. Abstract.
Jäger et al. "Endothelial Cell-Specific Transcriptional Targeting From A Hybrid Long Terminal Repeat Retrovirus Vector Containing Human Prepro-Endothelin-1 Promoter Sequences", Journal of Virology, 73(12): 9702-9709, 1999. *
Jager et al. "Endothelial Cell-Specific Transcriptional Targeting From A Hybrid Long Terminal Repeat Retrovirus Vector Containing Human Prepro-Endothelin-I Promoter Sequences", Journal of Virology, 73(12): 9702-9709, 1999.
Jones et al. "A Portable Regulatory Element Directs Specific Expression of the Caenorhabditis Elegans Ubiquitin Gene UBQ-2 in the Somatic Gonad", Developmental Biology, 171: 60-72, 1995.
Joshi et al. "Endothelial Cells Adhere to the RGD Domain and the Fibrinogen-Like Terminal Knob of Tenascin", Journal of Cell Science, 106: 389-400, 1993.
Juengst "What Next for Human Gene Therapy? Fene Transfer Often Has Multiple and Unpredictable Effects on Cells", BMJ, 326: 1410-1411, Jun. 28, 2003.
Jurnot et al. "N-Acetylsyteine Augments Adenovirus-Mediated Gene Expression in Human Endothelial Cells by Enhancing Tansgen Transcription and Virus Entry", The Journal of Gene Medicine, 4: 54-65, 2002.
Kaiser et al. "Platelet-Derived Growth Factor, Intimal Hyperplasia, and Ischemic Complications in Giant Cell Arteritis", Arthritis & Rheumatism, 41(4): 623-633, 1998.
Kaito et al. "Potentiation of the Activity of Bone Morphogenetic Protein-2 in Bone Regeneration by A PLA-PEG/Hydroxyapatite Composite", Biomaterials, 26: 73-79, 2005.
Kaplan et al. "Fas Ligand (CD95 Ligand) Controls Angiogenesis Beneath the Retina", Nature Medicine, 5(3): 292-297, Mar. 1999.
Kay et al. "Viral Vectors for Gene Therapy: The Art of Turning Infectious Agents Into Vehicles of Therapeutics", Nature Medicine, 7(1): 33-40, Jan. 2001.
Kaye et al. "A Single Amino Acid Substitution Results in A Retinoblastoma Protein Defective in Phosphorylation and Oncoprotein Binding", Proc. Natl. Acad. Sci. USA, 87: 6922-6926, Sep. 1990.
Khan et al. "Gene Therapy Progeress and Prospects: Therapeutic Angiogenesis for Limb and Myocardial Ischemia", Gene Therapy, 10: 285-291, 2003.
Kolesnick et al. "Radiation and Ceramide-Induced Apoptosis", Oncogene, 22(37): 5897-5906, Sep. 1, 2003.
Kolesnick et al. "Radiation and Ceramide-Induced Apoptosis", Oncogene, 22: 5897-5906, 2003.
Kong et al. "Gene Therapy Strategies for Tumor Antiangiogenesis", Journal of the National Cancer Institute, 90(4): 273-286, 1998.
Korhonen et al. "Endothelial-Specific Gene Expression Directed by the TIE Gene Promoter in Vivo", Blood, 86(5): 1828-1835, 1995.
Koshikawa et al (2000, Cancer Research, vol. 60, pp. 2936-2941). *
Koshikawa et al. "Therapeutic Efficacy of the Suicide Gene Driven by the Promoter of Vascular Endothelial Growth Factor Gene Against Hypoxic Tumor Cells", Cancer Research, XP001024127, 60(11): 2936-2941, 2000.
Koyama et al. "Migratory and Proliferative Effect of Platelet-Derived Growth Factor in Rabbit Retinal Endothelial Cells: Evidence of an Autocrine Pathway of Platelet-Derived Growth Factor", Journal of Cellular Physiology, 158: 1-6, 1994.
Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset", Blood, 91(3): 852-862, 1998.
Lahav et al. "Endothelin Receptor B Inhibition Triggers Apoptosis and Enhances Angiogenesis in Melanomas", Cancer Research, 64:8945-8953, Dec. 16, 2004.
Lavigne et al. "Enhanced Antisense Inhibition of Human Immunodeficiency Virus Type 1 in Cell Cultures by DLS Delivery System", Biochemical and Biophysical Research Communications, 237: 566-571, 1997.
Layne et al. "Characterization of the Mouse Aortic Carboxypeptidase-Like Protein Promoter Reveals Activity in Differentiated and Dedifferentiatid Vascular Smooth Muscle Cells", Circulation Research, 90: 728-736, 2002.
Lebedeva et al. "Restoring Apoptosis as A Strategy for Cancer Gene Therapy: Focus on P53 and MDA-7", Seminars in Cancer Biology, 13: 169-178, 2003.
Lee et al. "Functional Analysis of the Endothelin-1 Gene Promoter", Journal of Biological Chemistry, 265(18): 10446-10450, 1990. Fig.1, wherein Nucleotides—124 to—118 Are Identical to SEQ ID No. 5.
Li et al. "Transcriptional Regulation of Fas Gene Expression by GA-Binding Protein and AP-1 in T Cells Antigen Receptor CD3 Complex-Stimulated T Cells", The Journal of Biological Chemistry, 274(49): 35203-35210, Dec. 3, 1999.
Liu et al. "Restenosis After Coronary Angioplasty. Potential Biologic Determinants and Role of Intimal Hyperplasia", Circulation, 79: 1374-1387, 1989.
Lowe et al. "Osteopetrosis in Src-Deficient Mice Is Due to An Autonomous Defect of Osteoclasts", Proc. Natl. Acad. Sci. USA, 90: 4485-4489, 1993.
Luft "Making Sense Out of Antisense Oligodeoxynucleotide Delivery: Getting There Is Half the Fun", Journal of Molecular Medicine, 76: 75-76, 1998.
Lyden "Impaired Recruitment of Bone-Marrow-Derived Endothelial and Hematopoietic Precursor Cells Blocks Tumor Angiogenesis and Growth", Nature Medicine, 7(11): 1194-1201, 2001.
Micheau et al. "STAT-1-Independent Upregulation of FADD and Procaspase-3 and -8 in Cancer Cells Treated With Cytotoxic Drugs", Biochemical and Biophysical Research Communications, 256(3): 603-607, Mar. 24, 1999.
Micheau et al. "STAT-1-Independent Upregulation of FADD and Procaspase-3 and -8 in Cancer Cells Treated With Cytotoxic Drugs", Biochemical and Biophysical Research Communications, 256: 603-607, 1999.
Minchenko et al. "Regulation of Endothelin-1 Gene Expression in Human Microvascular Endothelial Cells by Hypoxia and Cobalt: Role of Hypoxia Responsive Element", Molecular and Cellular Biochemistry, 208(1-2): 53-62, 2000. p. 57, l-h col., § 2, p. 57, r-h col., Last §, Fig.2.
Minchenko et al. Regulation Of endothelin-1 Gene Expression In Human Microvascular Endothelial Cells By Hypoxia and Cobalt: Role Of Hypoxia Responsive Element, 2000.
Minchenko et al. Regulation Of endothelin-1 Gene Expression in Human Microvascular Endothelial Cells by Hypoxia and Cobalt: Role of Hypoxia Responsive Element.
Modlich et al. "Increasing Endothelial Cell Specific Expression by the Use of Heterologous Hypoxic and Cytokine-Iducible Enhancers", Gene Therapy, 7: 896-902, 2000.
Morishita et al. "A Novel Promoter for Vascular Endothelial Growth Factor Receptor (Flt-1) That Confers Endothelial-Specific Gene Expression", The Journal of Biological Chemistry, 270(46): 27948-27953, 1995.
Nayak et al. "Progress and Prospects: Immune Responses to Viral Vectors", Gene Therapy, Advance Online Publication on Nov. 12, 2009. Abstract.
Newman et al. "PECAM-1 (CD31) Cloning and Relation to Adhesion Molecules of the Immunoglobulin Gene Superfamily", Science, New Series, 247(4947): 1219-1222, 1990.
Nicklin et al. "Selective Targeting of Gene Transfer to Vascular Endothelial Cells by Use of Peptides Isolated by Phage Display", Circulation, 102: 231-237, 2000.
Notice of Allowance Dated Aug. 14, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/075,619.
Notice of Allowance Dated Jun. 11, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Notice of Grant of the Patent Application Dated Aug. 31, 2010 From the Instituto Mexicano de la Propiedad Industrial Re.: Application No. PA/a/2004/003514.
Office Action Dated Apr. 27, 2008 From the Korean Intellectual Property Office Re.: Application No. 2004-7005720 and its translation in English. Mailed by Associate May 23, 2008.
Office Action Dated Dec. 29, 2009 From the Israel Patent Office Re.: Application No. 183187 and Its Translation Into English.
Office Action Dated Jan. 10, 2008 From the Israeli Patent Office Re.: Application No. 155940.
Office Action Dated Jul. 31, 2007 From the Japanese Patent Office Re.: Application No. 2002-543626 Mailed by Associate Aug. 23, 2007.
Office Action Dated Jul. 31, 2007 From the Japanese Patent Office Re.: Application No. 2004-501545. Mailed by the Associate on Aug. 8, 2007.
Office Action Dated Oct. 13, 2006 From the Patent Office of the People's Republic of China Re.: Application No. CN 03815262.2—English Translation only. (mailed by Associate only on Nov. 13, 2006.
Office Action Dated Oct. 31, 2010 From the Israel Patent Office Re.: Application No. 183187 and Its Translation Into English.
Office Action Dated Sep. 20, 2007, From the Israeli Patent Office Re.: Application No. 155940.
Official Action Dated Apr. 10, 2008 From US Patent and Trademark Office Re.: U.S. Appl. No. 10/975,619.
Official Action Dated Apr. 6, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/975,619.
Official Action Dated Apr. 9, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Official Action Dated Apr. 9, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/940,746.
Official Action Dated Aug. 31, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/790,992.
Official Action Dated Aug. 4, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Official Action Dated Aug. 5, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Official Action Dated Dec. 15, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/790,992.
Official Action Dated Dec. 23, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/222,439.
Official Action Dated Dec. 29, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Official Action Dated Dec. 6, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/224,178.
Official Action Dated Jan. 14, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Official Action Dated Jan. 22, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/457,200.
Official Action Dated Jan. 26, 2011 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Official Action Dated Jul. 10, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Official Action Dated Jul. 14, 2004 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/135,447.
Official Action Dated Jul. 29, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Official Action Dated Jul. 6, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/790,992.
Official Action Dated Jun. 24, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/222,439.
Official Action Dated Jun. 4, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/975,619.
Official Action Dated Jun. 4, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/457,200.
Official Action Dated May 13, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/222,439.
Official Action Dated May 28, 2008 From the Japanese Patent Office Re.: Application No. 202-543626 Mailed by Associate Jun. 9, 2008.
Official Action Dated May 6, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Official Action Dated Nov. 10, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/457,200.
Official Action Dated Nov. 14, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Official Action Dated Oct. 11, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/490,746.
Official Action Dated Oct. 13, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/222,439.
Official Action Dated Oct. 2, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Official Action Dated Oct. 7, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/224,178.
Official Communication Dated Feb. 1, 2008 From the Instituto Mexicano de la Propiedad Industrial Re.: Application No. PA/a/2004/003514 and its summary in English by Associate. Mailed by Associate May 7, 2008.
Official Communication Dated Feb. 28, 2008 From the Instituto Mexicano de la Propiedad Industrial Re.: Application No. PA/a/2003/004325, and its Summary in English by Associate. Mailed by Associate Apr. 16, 2008.
Official Communication Dated Jul. 14, 2010 From the Instituto Mexicano de la Propiedad Industrial Re.: Application No. PA/a/2004/003514 and Its Summary in English by Associate.
Official Communication Dated Jul. 18, 2007 From the Instituto Mexicano de la Propiedad Industrial Re.: Application No. PA/a/2004/010711 and its English summary by Associate. Mailed by Associate Sep. 20, 2007.
O'Reilly et al. "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth", Cell, 88: 277-285, 1997.
Ozawa et al. "Histologic Changes of Nonbiodegradable and Biodegradable Biomaterials Used to Repair Right Ventricular Heart Defects in Rats", The Journal of Thoracic and Cardiovascular Surgery, 124(6): 1157-1164, 2002.
Palu et al. "In Pursuit of New Development for Gene Therapy of Human Diseases", Journal of Biotechnology, 68: 1-13, 1999.
Palù et al. "In Pursuit of New Developments for Gene Therapy of Human Diseases", Journal of Biotechnology, 68: 1-13, 1999.
Partial European Search Report Dated Feb. 23, 2010 From the European Patent Office Re.: Application No. 09168899.4.
Patan et al. "Intussusceptive Microvascular Growth in A Human Colon Adenocarcinoma Xenograft: A Novel Mechanism of Tumor Angiogenesis", Microvascular Research, 51: 260-272, 1996.
Patil et al. "DNA-Based Therapeutics and DNA Delivery Systems: A Comprehensive Review", The AAPS Journal, 7(1): E61-E77, 2005.
Peled et al. "Systemic Administration of A Conditionally Replicating Adenovirus, Targeted to Angiogenesis, Reduced Lung Metastasis Burden in Cotton Rats", Clinical Cancer Research, 15(5): 1664-1673, Mar. 1, 2009.
Peled et al. "Systemic Administration of A Conditionally Replicating Adenovirus, Targeted to Angiogenesis, Reduced Lung Metastasis Burden in Cotton Rats", Clinical Cancer Research, XP002579967, 15(5): 1664-1673, Mar. 1, 2009.
Peng et al. "The Use of the L-Plastin Promoter for Adnoviral-Mediated, Tumor-Specific Gene Expression in Ovarian and Bladder Cancer Cell Lines", Cancer Research, 61: 4405-4413, 2001.
Percy et al. "Sequence Analysis of the 3' Hypoxia-Responsive Element of the Human Erythropoietin Gene in Patients With Erythrocytosis", Biochemical and Molecular Medicine, 62: 132-134, 1997.
Plump et al. "Severe Hypercholesterolemia and Atherosclerosis in Apolipoprotein E-Deficient Mice Created by Homologous Recombination in ES Cells", Cell, 71: 343-353, 1992.
Rajur et al. "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules", Bioconjugate Chemistry, 8: 935-940, 1997.
Requisition by the Examiner Dated Dec. 16, 2008 From the Canadian Intellectual Property Re.: 2,429,342.
Requisition by the Examiner Dated Jan. 18, 2010 From the Canadian Intellectual Property Office Re.: Application No. 2,463,816.
Requisition by the Examiner Dated May 14, 2010 From the Canadian Intellectual Property Office Re. Application No. 2,483,996.
Response Dated Apr. 14, 2010 to Official Action of Dec. 15, 2009 From the US Patent and Treademark Office Re.: U.S. Appl. No. 11/790,992.
Response Dated Apr. 14, 2011 to Official Action of Jan. 26, 2011 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Response Dated Apr. 22, 2010 to Official Action of Dec. 23, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/222,439.
Response Dated Apr. 27, 2011 to Communication Pursuant to Article 94(3) EPC of Jan. 25, 2011 From the European Patent Office Re. Application No. 09168899.4.
Response Dated Apr. 29, 2010 to Office Action of Dec. 29, 2009 From the Israel Patent Office Re.: Application No. 183187.
Response Dated Apr. 5, 2011 to Search Report and Written Opinion of Nov. 11, 2010 From the Intellectual Property Office of Singapore Issued by the Austrian Patent Office Re. Application No. 200907209.1.
Response Dated Aug. 12, 2010 to Official Action of May 13, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/222,439.
Response Dated Aug. 25, 2010 to Official Action of Jun. 4, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/457,200.
Response Dated Aug. 25, 2010 to Official Communication of Jul. 14, 2010 From the Instituto Mexicano de la Propiedad Industrial Re.: Application No. PA/a/2004/003514.
Response Dated Dec. 15, 2010 to European Search Report and the European Search Opinion of May 17, 2010 From the European Patent Office Re. Application No. 09168899.4.
Response Dated Dec. 2, 2010 to Office Action of Jul. 30, 2010 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200580046412.8.
Response Dated Dec. 31, 2010 to Office Action of Sep. 14, 2010 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200910137707.6.
Response Dated Dec. 5, 2010 to Official Action of Aug. 5, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Response Dated Feb. 15, 2011 to European Search Report and the European Search Opinion of Jul. 29, 2010 From the European Patent Office Re. Application No. 09176343.3.
Response Dated Feb. 22, 2010 to Official Action of Jan. 22, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/457,200.
Response Dated Feb. 28, 2011 to Office Action of Oct. 31, 2010 From the Israel Patent Office Re.: Application No. 183187.
Response Dated Feb. 3, 2011 to Official Action of Nov. 10, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/457,200.
Response Dated Jan. 10, 2010 to Examiner's Report of Dec. 10, 2008 From the Australian Government, IP Australia Re.: Application No. 2003222427.
Response Dated Jan. 3, 2011 to Official Action of Oct. 13, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/222,439.
Response Dated Jul. 14, 2010 to Requisition by the Examiner of Jan. 18, 2010 From the Canadian Intellectual Property Office Re.: Application No. 2,463,816.
Response Dated Mar. 15, 2011 to Examination Report of Oct. 1, 2010 From the Intellectual Property Office of New Zealand Re. Application No. 581511.
Response Dated May 12, 2010 to Invitation to Remedy Deficiencies Pursuant to Rule 30(3) EPC/Rule 163(3) EPC of Mar. 16, 2010 From the European Patent Office Re.: Application No. 09176343.3.
Response Dated May 13, 2010 to Official Action of Jan. 14, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Response Dated May 20, 2010 to Communication Relating to the Results of the Extended International Search of Apr. 8, 2010 From the European Patent Office Re.: Application No. 09174998.6.
Response Dated May 5, 2011 to Official Action of Dec. 6, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/224,178.
Response Dated Nov. 4, 2009 to Official Action of Aug. 4, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/359,513.
Response Dated Nov. 7, 2010 to Examination Report of Oct. 16, 2009 From the Intellectual Property Office of New Zealand Re.: Application No. 580289.
Response Dated Nov. 8, 2010 to Official Action of Oct. 7, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 12/224,178.
Response Dated Oct. 5, 2010 to Official Action of Jul. 6, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/790,992.
Richardson et al. "Polymeric System for Dual Growth Factor Delivery", Nature Biotechnology, 19: 1029-1034, 2001.
Risau "Mechanisms of Angiogenesis", Nature, 386: 671-674, 1997.
Ríus et al. "Cloning of the Promoter Region of Human Endoglin, the Target Gene for Hereditary Hemorrhagic Telangiectasia Type 1", Blood, 92(12): 4677-4690, 1998.
Sano et al. "Functional Blockade of Platelet-Derived Growth Factor Receptor-? But Not of Receptor-? Prevents Vascular Smooth Muscle Cell Accumulation in Fibrous Cap Lesions in Apolipoprotein E-Deficient Mice", Circulation, 103: 2955-2960, 2001.
Sano et al. "Functional Blockade of Platelet-Derived Growth Factor Receptor-beta But Not of Receptor-alpha Prevents Vascular Smooth Muscle Cell Accumulation in Fibrous Cap Lesions in Apolipoprotein E-Deficient Mice", Circulation, 103: 2955-2960, 2001.
Sano et al. "Functional Blockade of Platelet-Derived Growth Factor Receptor-β But Not of Receptor-α Prevents Vascular Smooth Muscle Cell Accumulation in Fibrous Cap Lesions in Apolipoprotein E-Deficient Mice", Circulation, 103: 2955-2960, 2001.
Sato et al. "Tie-1 and Tie-2 Define Another Class of Putative Receptor Tyrosine Kinase Genes Expressed in Early Embryonic Vascular System", Proc. Natl. Acad. Sci. USA, 90: 9355-9358, 1993.
Savontaus et al. "Transcriptional Targeting of Conditionally Replicating Adenovirus to Dividing Endothelial Cells", Gene Therapy, 9: 972-979, 2002.
Savontaus et al. "Transcriptional Targeting of Conditionally Replicating Adenovirus to Dividing Endothelial Cells", Gene Therapy, XP002579436, 9(14): 972-979, Jul. 2002. Fig.1.
Schlaeger et al. "Vascular Endothelial Cell Lineage-Specific Promoter in Transgenic Mice", Development, 121: 1089-1098, 1995.
Search Report and Written Opinion Dated Apr. 21, 2009 From the Intellectual Property Office of Singapore Issued by the Austrian Patent Office Re.: Application No. 200703466-3.
Search Report and Written Opinion Dated Oct. 7, 2010 From the Intellectual Property Office of Singapore Issued by the Austrian Patent Office Re. Application No. 200907209-1.
Shimo et al. "Connective Tissue Growth Factor as A Major Angiogenic Agent That Is Induced by Hypoxia in A Human Breast Cancer Cell Line", Cancer Letters, 174: 57-64, 2001.
Shir et al. "Gene Therapy for Glioblastoma: Future Perspective for Delivery Systems and Molecular Targets", Cellular and Molecular Neurobiology, 21(6): 645-656, 2001.
Skolnick "From Genes to Protein Stucture and Function: Novel Applications of Computational Approaches in the Genomic Era", Trends in Biotechnology, TIBTECH, 18: 34-39, Jan. 2000.
Smythe et al. "Treatment of Experimental Human Mesothelioma Using Adenovirus Transfer of the Herpes Simplex Thymidine Kinase Gene", Annals of Surgery, 222(1): 78-86, 1995.
Soriano et al. "Targeted Disruption of the C-SRC Proto-Oncogene Leads to Osteopetrosis in Mice", Cell, 64: 693-702, 1991.
Stefanidakis et al. "Identification of a Negatively Charged Peptide Motif Within the Catalytic Domain of Progelatinases That Mediates Binding to Leukocyte ?2 Integrins", the Journal of Biological Chemistry, 278(36): 34674-34684, 2003.
Stefanidakis et al. "Identification of A Negatively Charged Peptide Motif Within the Catalytic Domain of Progelatinases That Mediates Binding to Leukocyte beta2 Integrins", The Journal of Biological Chemistry, 278(36): 34674-34684, 2003.
Stefanidakis et al. "Identification of A Negatively Charged Peptide Motif Within the Catalytic Domain of Progelatinases That Mediates Binding to Leukocyte β2 Integrins", The Journal of Biological Chemistry, 278(36): 34674-34684, 2003.
Strasser et al. "Apoptosis Signaling", Annual Review of Biochemistry, 69: 217-245, 2000.
Strasser et al. "Apoptosis Signaling", Annual Review of Biochemistry, XP002283497, 69: 217-245, 2000.
Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC Dated Jul. 13, 2009 From the European Patent Office Re.: Application No. 05806361.1.
Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC Dated Sep. 14, 2009 From the European Patent Office Re.: Application No. 02801473.6.
Sun et al. "Functional Analysis of the Preproendothelin-1 Gene Promoter in Pulmonary Epithelial Cells and Monocytes", Biochemical and Biophysical Research Communications, 221(3): 647-652, 1996. p. 649, last §—p. 651, § 1.
Supplementary European Search Report and the European Search Opinion Dated Oct. 17, 2007 From the European Patent Office Re.: Application EP 05806361. Mailed Oct. 18, 2007 by Associate.
Supplementary European Search Report Dated Mar. 21, 2006 From the European Patent Office Re.: Application No. 02801473.6.
Supplementary European Search Report Dated Mar. 21, 2006 From the European Patent Office Re.: Application No. EP 02801473.6.
Supplementary European Search Report Dated Oct. 28, 2005 From the European Patent Office Re.: Application No. EP 03717516.
Supplementary Partial European Search Report Dated Nov. 15, 2004 From the European Patent Office Re. Application No. 01996590.4.
Supplementary Partial European Search Report Dated Nov. 15, 2004 From the European Patent Office Re.: Application EP 01996590.
Thomas et al. "Progress and Problems With the Use of Viral Vectors for Gene Therapy", Nature Reviews: Genetics, 4: 346-358, May 2003.
Translation of Notice of Reason for Rejection Dated May 28, 2008 From the Japanese Patent Office Re.: Application No. 202-543626 Mailed by Associate Jun. 9, 2008.
Translation of Notice of Reason for Rejection Dated Oct. 16, 2007 From the Japanese Patent Office Re.: Application No. 2003-536253 Mailed by Associate on Oct. 25, 2007.
Translation of Notice of the Reason for Rejection Dated Jan. 7, 2009 From the Korean Intellectual Property Office Re.: Application No. 2008-7018598.
Translation of Office Action Dated Jul. 30, 2010 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200580046412.8.
Translation of Office Action Dated Sep. 14, 2010 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 200910137707.6.
Triozzi et al. "A Phase I Study to Assess the Safety and Distribution of GT-111 in Patients With Advanced Metastatic Cancer", Vascular Biogenics, Ltd., Clinical Trials Identifier: NCT00559117, Jun. 9, 2009.
Van de Stolpe et al. "Intercellular Adhesion Molecule-1", Journal of Molecular Medicine, 74(1): 13-33, 1996. Abstract.
Varda-Bloom et al. "Tissue-Specific Gene Therapy Directed to Tumor Angiogenesis", Gene Therapy, 8(11): 819-827, 2001. p. 822-825.
Varda-Bloom et al. "Tissue-Specific Gene Therapy Directed to Tumor Angiogenesis", Gene Therapy, XP002349279, 8(11): 819-827, Jun. 2001. pp. 822-825.
Verma et al. "Gene Therapy-Promises, Problems and Prospects", Nature, 389: 239-242, 1997.
Wadhwa et al. "Cancer Gene Therapy: Scientific Basis", Annual Review of Medicine, XP002568022, 53: 437-453, 2002. p. 438.
Wang et al. "Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor", Science, New Series, 228(4696): 149-154, 1985.
Watkins et al. "The 'Adenobody' Approach to Viral Targeting: Specific and Enhanced Adenoviral Gene Delivery", Gene Therapy, 4: 1004-1012, 1997.
West et al. "Endothelial Cell Proliferation and Diabetic Retinopathy", The Lancet, 1: 715-716, 1988.
Whitaker et al. "Induction of Functional Neovascularization by Wisker Stimulation After Focal Ischemia", Abstract Viewer and Itinery Planner, Society for Neuroscience, 2003: Abstract No. 789.12, Nov. 2003. 33rd Annual Meeting of the Society of Neuroscience, New Orleans, LA, USA, Nov. 8-12, 2003.
Williams et al. "Hypoxia and Oxidative Stress in Breast Cancer Tumour Hypoxia-Therapeutic Considerations", Breast Cancer Research, 3: 328-331, 2001.
Wong et al. "Human GM-CSF: Molecular Cloning of the Complementary DNA and Purification of the Natural and Recombinant Proteins", Science, New Series, 228(4701): 810-815, 1985.
Written Opinion Dated Apr. 29, 2009 From the International Searching Authority Re.: Application No. PCT/IL08/00543.
Written Opinion Dated Nov. 2, 2004 From the International Preliminary Examining Authority Re.: Application PCT/IL01/01059.
Written Opinion Dated Oct. 29, 2003 From the International Preliminary Examining Authority Re.: Application No. PCT/IL02/00339.
Written Opinion Dated Sep. 18, 2008 From the International Searching Authority Re.: Application No. PCT/IL07/00242.
Written Opinion of the International Searching Authority Dated Aug. 4, 2006 From the International Searching Authority by the Patent Cooperation Treaty Re.: Application No. PCT/IL05/01195.
Wu et al. "Chimeric PSA Enhancers Exhibit Augmented Activity in Prostate Cancer Therapy Vectors", Gene Therapy, 8: 1416-1426, 2001.
Yanagisawa-Miwa et al. "Salvage of Infarcted Myocardium by Angiogenic Action of Basic Fibroblast Growth Factor", Science, New Series, 257(5075): 1401-1403, 1992.
Zou et al. "Antitumor Activity of Free and Liposome-Entrapped Annamycin, A Lipophilic Anthracycline Antibiotic With Non-Cross-Resistance Properties", Cancer Research, 54: 1479-1484, Mar. 15, 1994.

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081193A1 (en) * 2000-11-17 2010-04-01 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8835398B2 (en) 2000-11-17 2014-09-16 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8846401B2 (en) 2000-11-17 2014-09-30 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8859747B2 (en) 2000-11-17 2014-10-14 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8859745B2 (en) 2000-11-17 2014-10-14 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20090326052A1 (en) * 2000-11-17 2009-12-31 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8916378B2 (en) 2001-10-19 2014-12-23 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy
US9567605B2 (en) 2010-01-05 2017-02-14 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
US10369196B2 (en) 2010-01-05 2019-08-06 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
US9200056B2 (en) 2012-10-17 2015-12-01 Vascular Biogenics Ltd. FAS-chimera adenovirus vector
EP3441089A1 (en) 2012-10-17 2019-02-13 Vascular Biogenics Ltd. Treatment methods using adenovirus
US11311583B2 (en) 2012-10-17 2022-04-26 Vascular Biogenetics Ltd. Treatment methods using adenovirus
US9682154B2 (en) 2013-02-04 2017-06-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
WO2014118643A2 (en) 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
US10383954B2 (en) 2013-02-04 2019-08-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
US11191848B2 (en) 2013-02-04 2021-12-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
WO2019077593A1 (en) 2017-10-20 2019-04-25 Vascular Biogenics Ltd. DIAGNOSTIC METHODS FOR ANTI-ANGIOGENIC AGENT TREATMENT
WO2020183424A1 (en) 2019-03-13 2020-09-17 Vascular Biogenics Ltd. Methods of anti-tumor therapy
WO2020208612A1 (en) 2019-04-12 2020-10-15 Vascular Biogenics Ltd. Methods of anti-tumor therapy

Also Published As

Publication number Publication date
CN101098882A (zh) 2008-01-02
KR101522309B1 (ko) 2015-05-21
CN102698287A (zh) 2012-10-03
JP2012010710A (ja) 2012-01-19
AU2005303385B2 (en) 2011-08-11
EP2174668A3 (en) 2010-06-16
EP2301586A1 (en) 2011-03-30
US20130011367A1 (en) 2013-01-10
ZA200704687B (en) 2008-12-31
US20110207985A1 (en) 2011-08-25
KR20130072263A (ko) 2013-07-01
ATE531392T1 (de) 2011-11-15
WO2006051545A2 (en) 2006-05-18
WO2006051545A3 (en) 2006-09-28
CA2913047A1 (en) 2006-05-18
JP5728337B2 (ja) 2015-06-03
SG171581A1 (en) 2011-06-29
EP1814897A4 (en) 2007-11-14
EP2301585A1 (en) 2011-03-30
AU2005303385A1 (en) 2006-05-18
NZ580289A (en) 2010-12-24
KR20070086209A (ko) 2007-08-27
CA2587469A1 (en) 2006-05-18
KR101313257B1 (ko) 2013-10-16
KR101396454B1 (ko) 2014-05-20
EP1814897A2 (en) 2007-08-08
EP2174668B1 (en) 2011-11-02
JP2008519596A (ja) 2008-06-12
EP2301586B1 (en) 2012-09-26
NZ555612A (en) 2009-12-24
CA2587469C (en) 2016-02-02
KR20130137724A (ko) 2013-12-17
EP2174668A2 (en) 2010-04-14
US20110129511A1 (en) 2011-06-02
US20100081193A1 (en) 2010-04-01
CN102698287B (zh) 2017-06-13
US8835398B2 (en) 2014-09-16
MX2007005783A (es) 2007-09-11
HK1143078A1 (en) 2010-12-24
US8206743B2 (en) 2012-06-26
JP2015057057A (ja) 2015-03-26
US20050186179A1 (en) 2005-08-25
IL211489A (en) 2014-06-30
EP2301585B1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
US8206743B2 (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8039261B2 (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2008243817B2 (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
AU2011205076B2 (en) Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
HK1143078B (en) Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
IL183187A (en) Nucleic acid constructs and preparations for inhibiting angiogenesis
IL209034A (en) Promoters with endothelial cell specificity and methods for their use in angiogenesis control
IL201760A (en) Nucleic acid vectors for inhibiting angiogenesis

Legal Events

Date Code Title Description
AS Assignment

Owner name: VASCULAR BIOGENICS LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARATS, DROR;GREENBERGER, SHOSHANA;REEL/FRAME:016361/0345;SIGNING DATES FROM 20050203 TO 20050303

Owner name: VASCULAR BIOGENICS LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARATS, DROR;GREENBERGER, SHOSHANA;SIGNING DATES FROM 20050203 TO 20050303;REEL/FRAME:016361/0345

AS Assignment

Owner name: VASCULAR BIOGENICS LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BREITBART, EYAL;BANGIO, LIVNAT;REEL/FRAME:021367/0091;SIGNING DATES FROM 20080212 TO 20080213

Owner name: VASCULAR BIOGENICS LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BREITBART, EYAL;BANGIO, LIVNAT;SIGNING DATES FROM 20080212 TO 20080213;REEL/FRAME:021367/0091

ZAAA Notice of allowance and fees due

Free format text: ORIGINAL CODE: NOA

ZAAB Notice of allowance mailed

Free format text: ORIGINAL CODE: MN/=.

AS Assignment

Owner name: VASCULAR BIOGENICS LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PELED, MICHAEL;REEL/FRAME:025806/0975

Effective date: 20110118

ZAAA Notice of allowance and fees due

Free format text: ORIGINAL CODE: NOA

ZAAB Notice of allowance mailed

Free format text: ORIGINAL CODE: MN/=.

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20231206